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The bacterial cell envelope, consisting primarily of the cell membrane and the 
cell wall, is the most important physical and structural barrier. The cell wall provides 
the cell with structural strength and protects it from lysis due to the high turgor. The 
cytoplasmic membrane functions as a molecular sieve, controlling the transport of 
specific proteins, and nutrients.  Because many aspects of the cell envelope are 
specific to bacteria, it is also a prime target for antibiotics. To date, at least 17 classes 
of antibiotics are available for treatment; however, to each class bacteria have 
developed resistance. This selective pressure within bacteria not only originates from 
the widespread use of antibiotics, it is also inherent in the natural environment of 
many soil dwelling prokaryotes which evolved to produce antibiotics as signaling 
molecules or for nutrient competition. Here, we have investigated the response of the 
Gram-positive model bacterium Bacillus subtilis to commonly used cell envelope 
active antibiotics. By combining global analytical techniques, including microarray 
analyses, proteomic studies, transposon mutagenesis, whole genome sequencing, and 
fluorescence and electron microscopy, we obtained a clearer picture of the response of 
B. subtilis to daptomycin, moenomycin, ramoplanin, fosfomycin, and duramycin. In 
addition, we discuss mechanisms of resistance to these antibiotics. 
 
 iii 
BIOGRAPHICAL SKETCH 
Anna-Barbara Geertruida Hachmann, née Kleijn, was born on December 5
th
, 
1978 in Bielefeld, Germany and grew up in the town of Tecklenburg. 
 After graduating from the Graf-Adolf-Gymnasium Tecklenburg in 1998, she 
worked for one year as laboratory assistant at Wiewelhove GmbH, a pharmaceutical 
company that specializes in contract manufacturing of solid forms in Ibbenbüren, 
Germany. She was responsible for analyzing raw materials and proprietary medicinal 
products according to the Pharmacopoea Europaea in the Department of Quality 
Control. It was during this time that she decided to persue a research career with a 
pharmaceutical background. 
 In October 1999 Anna began her studies of pharmacy at the Friedrich-Schiller 
University in Jena, Germany. From October 2003 until May 2004, she joined Dr. 
Hendrik van Veen in the Department of Pharmacology at the University of 
Cambridge, UK, where she explored structure activity relationships of the ATP-
binding cassette multidrug transporter LmrA in Lactococcus lactis. She returned to 
Jena, to complete her pharmacy degree. In December 2004 she received her European 
pharmacist license.  
 Anna began her graduate studies at Cornell University in January 2005 where 
she joined Professor John D. Helmann’s group in the Department of Microbiology. 
She was fascinated about studying mechanisms of antibiotic resistance at the level of 
transcriptional regulation in the Gram-positive model bacterium Bacillus subtilis. This 
dissertation summarizes her major findings. 
 Following the completion of her PhD, she will begin post-doctoral research 
with Professor Jon Clardy and Dr. David Rudner at Harvard Medical School, Boston. 
 iv 
ACKNOWLEDGMENTS 
I am sincerely grateful to my advisor and mentor, Professor John D. Helmann, 
who has supported me throughout my graduate studies with his patience and 
knowledge while allowing me room to investigate different aspects of antibiotic 
resistance. This dissertation would not have been possible without his guidance.  
It is a pleasure to thank my committee members, Associate Professor Ruth 
Collins, Professor Tadhg Begley, and Assistant Professor Hening Lin for their support 
and helpful advice. In addition, I would like to thank Professor Esther Angert, 
Professor Joseph Peters, Dr. Qiaojuan Shi, and Professor Anthony Hay for their 
assistance with various techniques. 
During my graduate studies I was fortunate to work with a friendly and 
cheerful group of fellow students who encouraged me along the way and shared the 
excitement of “re”search. It was a privilege to work with Ahmed Gaballa, who is a 
wonderful mentor and friend, and has the ability to always put a smile on your face. I 
would like to thank the members of the Helmann lab and Winans lab, in particular 
Shawn MacLellan, Yun Luo, Veronica Guariglia-Oropeza, Tina Wecke, as well as 
Showey Yazdanian, Alex Fishman, Dominika Zgid, Paulina Gonzalez-Morelos, and 
my class mates for their friendship and many fond memories. I owe Cornell Outdoor 
Education and my climbing partners my love for climbing and the outdoors.  
All this would not have been possible without the constant support from my 
husband and my family. With this I would also like to thank Nancy and Robert Nead 
(including the Zoo) for making us feel home away from home.
 v 
TABLE OF CONTENTS 
 
BIOGRAPHICAL SKETCH           iii 
ACKNOWLEDGMENTS           iv 
TABLE OF CONTENTS            v 
LIST OF FIGURES            vi 
LIST OF TABLES          viii 
 
CHAPTER 1  
Introduction             1 
 
CHAPTER 2 
Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis                      
to Daptomycin          31 
 
CHAPTER 3 
Pgsa depletion leads to High Daptomycin Resistance in Bacillus subtilis   65 
 
CHAPTER 4 
Tn7SX Transposon Mutagenesis: a Tool to Study Antibiotic Resistance     
Mechanisms in Bacillus subtilis       99 
 
CHAPTER 5 
The Transglycosylation Inhibitors Ramoplanin and Moenomycin Induce           
Distinct Transcriptional Responses       147 
 
 vi 
LIST OF FIGURES 
 
Figure 1.1. Electron micrograph of Bacillus subtilis. 1 
Figure 1.2. Peptidoglycan crosslinking by bi-functional penicillin binding proteins. 2 
Figure 1.3. Peptidoglycan biosynthesis in B. subtilis. 3 
Figure 1.4. Structure of teichoic acids in B. subtilis. 4 
Figure 1.5. Essentiality of teichoic acids. 5 
Figure 1.6. Membrane lipid biosynthesis in B. subtilis. 7 
Figure 1.7. Cell envelope stress response systems in B. subtilis. 8 
Figure 1.8. Induction of cell envelope stress response systems in B. subtilis. 9 
Figure 1.9. Targets of antibiotic action during cell wall synthesis. 11 
Figure 1.10. Structure of the cyclic lipopeptide daptomycin. 13 
Figure 1.11. Proposed mechanism of action of daptomycin. 14 
Figure 1.12. Structure of the glycolipid moenomycin. 16 
Figure 1.13. Moenomycin interaction with transglycosylase. 17 
Figure 1.14. Imaging of peptidoglycan synthesis with fluorescent ramoplanin. 18 
Figure 1.15. Structure of the ramoplanin dimer. 19 
Figure 1.16. Antibiotic resistance profile of soil inhabiting bacteria. 20 
Figure 1.17. Resistance levels against tested antibiotics. 21 
Figure 1.18. Increase of antibiotic resistance versus decrease of new antibiotics. 21 
Figure 1.19. Part of the bacitracin stress response in B. subtilis. 22 
Figure 1.20. Mechanism of vancomycin resistance in enterococci. 23 
Figure 1.21. Inactivation of β-lactams by β-lactamase. 24 
Figure 1.22. MprF mediated resistance to cationic antimicrobial peptides. 24 
 
Figure 2.1. Daptomycin stimulon in B. subtilis. 41 
Figure 2.2. Daptomycin-BDP inserts preferentially at new division septa and in           
a spiral pattern. 51 
Figure 2.3. Daptomycin-BDP staining of stationary phase cells. 52 
Figure 2.4. Correlation between daptomycin-BDP staining and anionic      
phospholipid content and distribution. 54 
Figure 2.5. Cluster analysis of B. subtilis microarray studies with 40 different 
antimicrobial agents. 57 
 
Figure 3.1. Daptomycin-BDP inserts in a spotted pattern and at cell poles and   
division septa in Dap
R
1. 76 
Figure 3.2. Transmission electron micrographs of W168. 78 
Figure 3.3. TEM of Dap
R
1 reveal a thicker cell wall at the poles and irregular    
septum placement compared to W168. 79 
Figure 3.4. Comparison of Dap
R
1 and W168 transcriptome. 81 
Figure 3.5. Dap
R
1 and W168 gene expression ratios after daptomycin treatment. 81 
 vii 
Figure 3.6. Cytoplasmic proteome. 84 
Figure 3.7. Extracellular proteome. 85 
Figure 3.8. Cell wall proteome. 86 
Figure 3.9. Muramic acid quantification in Dap
R
1 and W168. 94 
 
Figure 4.1. The Tn7SX transposon. 101 
Figure 4.2. Synthesis of phosphatidylethanolamine. 106 
Figure 4.3. Structure and target of moenomycin. 107 
Figure 4.4. Growth inhibition of W168 and a sigM deletion by moenomycin. 108 
Figure 4.5. Distribution of moenomycin resistant Tn7SX insertions. 111 
Figure 4.6. Regular and alternative cell wall synthesis pathways in E. faecium. 120 
Figure 4.7. Putative interaction network of ybcI. 122 
Figure 4.8. Expression of the dinG ypmA ypmB aspB operon. 124 
Figure 4.9. Putative interaction network of ypmB. 125 
Figure 4.10. Tn7SX transposon insertions in ybfM and psd. 128 
Figure 4.11. Affinity of moenomycin to truncated HMW PBPs. 129 
Figure 4.12. aprE regulatory network. 131 
Figure 4.13. Structure of the NRPS produced lipopeptide plipastatin. 134 
Figure 4.14. Synthesis of the low-molecular-weight thiol bacillithiol in B. subtilis. 136 
 
Figure 5.1. Structure of the lipoglycodepsipeptide ramoplanin. 149 
Figure 5.2. Inhibition of transglycosylation by ramoplanin. 150 
Figure 5.3. Structure of a ramoplanin dimer at the membrane interface. 150 
Figure 5.4. Crystal structure of moenomycin. 151 
Figure 5.5. Ramoplanin stimulon in B. subtilis. 158 
Figure 5.6. Ramoplanin stimulon in B. subtilis liaR deletion. 159 
Figure 5.7. Ramoplanin stimulon of a liaR deletion versus wild-type CU1065. 160 
Figure 5.8. Cluster analysis of B. subtilis with 40 antibiotics. 160 
Figure 5.9. Teichoic acid and peptidoglycan synthesis. 162 
Figure 5.10. Moenomycin stimulon in B. subtilis. 164 
Figure 5.11. Overexpression of sigV in B. subtilis W168. 167 
Figure 5.12. Overexpression of sigV in B. subtilis Δ7 ECF deletion strain. 168 
Figure 5.13. Antibiotic sensitivity profile of ECF σ mutants. 169 
Figure 5.14. Promoter consensus sequence of σW, σX, and σM. 170 
Figure 5.15. Promoter consensus sequence of σM and σV. 172 
 viii 
LIST OF TABLES 
 
Table 1.1. Cell envelope active antibiotics with their respective targets. 10 
 
Table 2.1. Strains used in this study. 38 
Table 2.2. Oligonucleotides used in this study. 39 
Table 2.3. Daptomycin stimulon. 42 
Table 2.4. Minimum inhibitory concentration of B. subtilis mutants with                       
altered membrane composition, or deletion of transcriptional regulators. 46 
 
Table 3.1. Strains and oligonucleotides used in this study. 72 
Table 3.2. Minimum inhibitory concentrations of B. subtilis wild-type and Dap
R
1. 74 
Table 3.3. Minimum inhibitory concentrations of B. subtilis mutants. 74 
Table 3.4. Comparison of cell wall thickness of W168 and Dap
R
1. 77 
Table 3.5. Fold change of cytosolic protein expression of Dap
R
1 and W168. 87 
Table 3.6. Fold change of extracellular protein expression of Dap
R
1 and W168. 88 
Table 3.7. Single nucleotide polymorphisms in genes or intergenic regions. 91 
Table 3.8. Fatty acid methyl esther analysis of B. subtilis wild-type and Dap
R
1. 93 
 
Table 4.1. Strains and oligonucleotides used in this study. 102 
Table 4.2. Tn7 proteins and their roles during transposition. 104 
Table 4.3. High molecular weight penicillin binding proteins in B. subtilis. 107 
Table 4.4. Moenomycin resistant Tn7SX insertions in W168, sigM, and pbpDFG. 112 
Table 4.5. Moenomycin resistant Tn7SX insertions summary. 116 
Table 4.6. Regulon members of the YdfHI two-component regulatory system. 118 
Table 4.7. Fosfomycin sensitive Tn7SX insertions in W168. 137 
 
Table 5.1. Strains and oligonucleotides used in this study. 154 
Table 5.2. Ramoplanin stimulon. 157 
Table 5.3. Moenomycin stimulon and σV regulon. 165 
Table 5.4. σV and σM specific regulon members. 172 
 
Table S3.1. Gene expression of Dap
R
1 and W168 without daptomycin treatment. 177 
Table S3.2. Gene expression of Dap
R
1 and W168 with daptomycin treatment. 186 
 
   
 1 
CHAPTER 1  
INTRODUCTION 
 
1.1 The cell envelope of Gram-positive bacteria 
In Gram-positive bacteria, the cell is enclosed by the cytoplasmic membrane 
and the cell wall, which consists of peptidoglycan (PG) as well as wall- and lipo-
teichoic acids (Fig. 1.1, Fig. 1.2). As a three-dimensional lattice of about 50 nm 
thickness, the cell wall functions as the most important physical barrier, providing the 
cell with structural strength and protecting it from lysis due to the high turgor (2, 65). 
These properties and its specificity to bacteria also render the cell wall a prime target 
for antibiotics (61) (Fig. 1.3). 
 
Figure 1.1. Electron micrograph of Bacillus subtilis. 
The enlarged frame highlights the cytoplasmic membrane in dark gray (CM) and the 
cell wall in lighter gray (CW). Scale bar represents 0.2 µm. 
 2 
The structural strength of the cell wall is a result of the high degree of 
polymerization of sugar chains with peptide bridges. In the Gram-positive model 
bacterium, Bacillus subtilis, this is mediated by high molecular weight penicillin 
binding proteins (HMW PBPs) (31, 40). These enzymes are bifunctional, acting as 
transglycosylases and transpeptidases, polymerizing the sugar and crosslinking the 
peptide moiety of lipid II to the growing PG (Fig. 1.2). The more peptide strands are 
crosslinked, the higher the mechanical strength and protection against osmotic lysis. 
 
 
Figure 1.2. Peptidoglycan crosslinking by bi-functional penicillin binding proteins. 
Depicted are the final steps of  peptidoglycan (PG) synthesis: lipid II is anchored in 
the membrane via undecaprenyl phosphate (63). After translocation to the outside of 
the membrane, it is built into the growing glycan chain by the glycosyltransferase 
activity, and crosslinked via the transpeptidase domain of penicillin binding proteins 
(PBP)s. NAG: N-acetyl glucosamine, NAM: N-acetyl muramic acid. 
 3 
Summarized in Figure 1.3 are the different steps of PG synthesis in B. subtilis, 
with an emphasis on target sites of cell envelope active antibiotics. A central 
component during PG synthesis is lipid II. It consists of N-acetyl muramic acid 
(MurNAc) pentapeptide that is linked to N-acetyl glucosamine (GlcNAc) and 
anchored to the membrane by the released  undecaprenylphosphate. During cell wall 
synthesis, lipid II is translocated to the outside of the membrane. After crosslinking by 
the action of transglycosylases and transpeptidases the undecaprenylphosphate moiety 
is recycled to the cytoplasmic side of the membrane (Fig. 1.3).  
Daptomycin
Moenomycin
 
Figure 1.3. Peptidoglycan biosynthesis in B. subtilis. 
Illustrated are key steps during cell wall synthesis together with antibiotics that target 
the membrane (daptomycin), peptidoglycan precursors (green), or cell wall synthesis 
enzymes (red). The curved line in the membrane depicts undecaprenyl phosphate, 
ovals: amino acids. 
Adapted from (27) 
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In addition to PG, the Gram-positive cell wall contains teichoic acids (Fig. 
1.4). As a polymer of polyol phosphates, they are responsible for the overall negative 
charge of the cell wall. This also allows them to chelate cations (in particular Mg
2+
), 
and may create a pH gradient across the wall by sequestering protons that are expelled 
through the membrane (29). They serve as reservoirs of phosphates which can be 
mobilized under phosphate limiting conditions (19). Two types are present in Gram-
positives; wall teichoic acids, which are linked to the cell wall, and lipoteichoic acids, 
which are anchored to the membrane and provide the main component of the 
hydrophobicity of the cell envelope (6). The charge of the cell wall can be regulated 
by the degree of D-alanylation, the coupling of D-alanine to the teichoic acids, which 
reduces the negative charge (7) (Fig. 1.4). 
 
 
Figure 1.4. Structure of teichoic acids in B. subtilis. 
Poly(glycerol phosphate) is covalently attached to peptidoglycan via disaccharide and 
one to three glycerol phosphate monomers. Hydroxyl groups on the main chain are 
often glucosylated or D-alanylated. GroP: glycerol phosphate; GlcNAc: N-
acetylglucosamine; ManNAc: N-acetylmannosamine; Glc: glucose; MurNAc: N-
acetylmuramic acid (5).  
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Wall teichoic acids are essential under certain condition. Attempts to delete 
genes that are involved in later teichoic acid synthesis steps have failed, indicating 
their essentiality. However, early synthesis genes are dispensable (Fig. 1.5) (16). It is 
believed that the toxicity of deleting late teichoic acid synthesis genes arises from 
accumulation of toxic intermediates or sequestration of essential metabolites (like 
undecaprenylphosphate), that are also used for PG synthesis (5, 11).  
 
 
Figure 1.5. Essentiality of teichoic acids. 
Teichoic acids are not required for viability in B. subtilis when early stages of the 
pathway are disrupted. Deletions in late stages of teichoic acid production are 
deleterious (16).   
 
The B. subtilis membrane is composed of glycolipids and phospholipids (Fig. 
1.6). Depending on the growth stage and culture medium used, the contents of the 
lipids vary. During logarithmic growth in rich media, the largest part is made up by the 
zwitterionic phosphatidylethanolamine (~50% PE), followed by glycolipids (~30% 
GL), and negatively charged phosphatidylglycerol (~16% PhG). Negatively charged 
cardiolipin (~0.8% CL) and positively charged lysyl-phosphatidylglycerol (~2.4% 
 6 
LPG) are present to a smaller percentage (53).  
Contrary to the fluid-mosaic model by Singer and Nicholson (50), lipids are 
now believed to aggregate in lipid domains (52). This was shown in the example of 
the negatively charged phosphatidylglycerol (PhG) in co-localization studies with the 
cell division inhibitor MinD (3). Strains that conditionally expressed pgsA (PhG 
synthase) were labeled with the membrane dye FM4-64, which preferentially stains 
negatively charged lipids. It was demonstrated that PhG localized in a spiral pattern 
along the long axis of the cell. Upon depletion of PgsA, the staining was delocalized, 
too. In addition, Barák et al. found MinD to co-localize with PhG using MinD-GFP 
(green fluorescent protein) in fluorescence resonance energy transfer studies (3). This 
further indicates a localization of the cell wall synthesis complex in regions of 
negatively charged lipids, supporting previous observations of a helical localization of 
PBPs (46). 
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Figure 1.6. Membrane lipid biosynthesis in B. subtilis. 
Phospholipids and glycolipids are derived from the precursor phosphatidic acid (PA). 
Positively or negatively charged moieties are shown in green or red, respectively. 
Phosphatidylethanolamine (PE), glycolipids (GL), phosphatidylglycerol (PG), 
cardiolipin (CL), lysyl-phosphatidylglycerol (LPG). 
Adapted from (45) 
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1.2 Cell envelope stress response in Bacillus subtilis 
 Figure 1.7 illustrates the main cell envelope stress response (CESR) pathways 
in B. subtilis: two-component regulatory systems (TCS) and extracytoplasmic function 
(ECF) σ factors. TCS can sense perturbations to the cell envelope either through direct 
interaction with the histidine kinase (HK), or indirectly, for instance due to 
conformational changes. The HK is autophosphorylated and transfers the phosphate to 
its cognate response regulator (RR) (27). A well studied example is the LiaRS TCS 
(28). The LiaS HK is induced by a subset of antibiotics that target cell wall synthesis 
(e.g., vancomycin, bacitracin), and membrane active antibiotics (e.g., daptomycin) 
(Fig. 1.8). It then phosphorylates the RR, LiaR, which changes gene expression of a 
small regulon, including the phage shock protein A (PspA) family protein LiaH (20).   
 
differential gene expression  
 
Figure 1.7. Cell envelope stress response systems in B. subtilis. 
Extracytoplasmic Function σ factors (ECF) are shown left, two-component regulatory 
systems (TCS) right (HK = histidine kinase; RR = response regulator). Green: sensor 
protein, blue: inhibitory protein, red: transcriptional regulators; arrows signify 
activation, T-shaped lines: repression (27).  
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B. subtilis has seven known ECF σ factors, of which three are well studied; σM, 
σW, and σX (7, 8, 14, 23, 24). The analysis of σV, σY, σZ, and YlaC, however, turned 
out to be rather complex, because precise inducing conditions, and therefore most 
regulon members, are not yet known (9, 33, 34, 44, 66). Generally, when inactive, 
ECF σ factors are sequestered by their respective anti-σ factor. Under certain stress 
conditions, the anti-σ releases the σ factor by degradation through proteolytical 
cleavage, or by conformational changes (Fig. 1.7) (64). Recruitment by the RNA 
polymerase core enzyme allow it to recognize a promoter region, where the domains 2 
and 4 of the σ factor can bind to conserved -10 and -35 promoter sites and redirect 
gene expression of its regulon members (32). 
 
Figure 1.8. Induction of cell envelope stress response systems in B. subtilis. 
Induction of ECF σ factors and the LiaRS TCS by Bac: bacitracin, CAP: cationic 
antimicrobial peptides, Cep: cephalosporin C, Fos: fosfomycin, Nis: nisin, Van: 
vancomycin. Color-coding: same as in Figure 1.7. Dotted arrows indicate cross-
regulation/ regulatory overlap (27).
 10 
 
Figure 1.8 exemplifies antibiotics that can induce ECF σ factors in B. subtilis. Of note 
is a partial regulon overlap between different ECF σ factors, which is due to similarity 
between their promoter consensus sequences (33). Likewise, it can be seen that a 
particular stress or antibiotic can induce more than one σ factor (e.g., vancomycin, or 
bacitracin) (27). 
 
1.3 Overview of cell envelope active antibiotics 
Amongst the oldest classes of antibiotics are the β-lactams and glycopeptides. 
β-lactam antibiotics are comprised of penicillins, cephalosporins, and monobactams 
(Table 1.1). They owe their name to their central structural moiety, a β-lactam ring. 
The antimicrobial activity during cell wall synthesis is exerted by binding to 
transpeptidases as suicide inhibitors. Glycopeptides, like vancomycin, bind to the 
terminal, uncrosslinked D-Ala
4
-D-Ala
5
 residues of lipid II (Fig. 1.9).  
 
Table 1.1. Cell envelope active antibiotics with their respective targets.  
Compounds are grouped by decade of introduction. 
Decade Compound (compound class)
1
 Bacterial target of action 
1940s Penicillins (beta-lactams) Cell wall biosynthesis 
 Nisin (peptide lantibiotic) Cell wall/cell membrane 
 Gramicidins (cationic cyclic peptides) Cell membrane 
 Polymyxins (cationic cyclic peptides) Cell membrane 
1950s Vancomycin (glycopeptides) Cell wall biosynthesis 
1960s Cephalosporin (beta-lactams) Cell wall biosynthesis 
 Moenomycin (glycolipid) Cell wall biosynthesis 
 Tunicamycin (nucleotide sugar analog) Cell wall biosynthesis 
1980s Third generation cephalosporins Cell wall biosynthesis 
2000s Carbapenemes (beta-lactams) Cell wall biosynthesis 
 Ramoplanin (lipoglycodepsipeptide) Cell wall biosynthesis 
 Daptomycin (cyclic lipopeptide) Cell membrane 
 Telavancin (lipoglycopeptide) Cell wall/cell membrane 
1
See references for further detail (6, 36, 41, 47, 51, 59). 
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Figure 1.9. Targets of antibiotic action during cell wall synthesis. 
Fosfomycin and tunicamycin target intracellular PG synthesis steps, which are 
catalyzed by MurA-MurG (steps 1-4). Ramoplanin and moenomycin inhibit the 
transglycosylation step. Bacitracin inhibits recycling of the lipid II carrier 
undecaprenyl phosphate. Vancomycin and β-lactams inhibit the transpeptidation 
reaction (61). 
 
Here, a selection of antibiotics is discussed in more detail, with focus on cell 
envelope active antibiotics that are subject of the studies in subsequent chapters. 
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Daptomycin 
Daptomycin is the first member of a new antibiotic class, the cyclic 
lipopeptides (Fig. 1.10). It was discovered in the early 1980’s by Eli Lilly and 
Company  as fermentation product of Streptomyces roseosporus (35). Initial clinical 
studies reported skeletal muscle toxicity as side-effect, and it was not until 2003, then 
marketed by Cubist Pharmaceuticals, that it was FDA approved to treat complicated 
skin and skin structure infections (22, 56). Additional applications include right-sided 
endocarditis and bacteraemia caused by Gram-positive pathogens (1).  
A product of non-ribosomal peptide synthesis, daptomycin consists of 13 
amino acids and a decanoyl side chain. Asp 3, Asp 7, Asp 9, MeGlu 12, and Orn 6 
contribute to its overall charge of -3 (Fig. 1.10). Because of its negative net charge, the 
molecule needs to be administered with Ca
2+
-ions to exert its full activity. It acts by 
disrupting the functional integrity of the membrane of Gram-positive bacteria. NMR 
and differential scanning calorimetry studies with liposomes have shown that 
daptomycin approaches the bacterial membrane in micelles. 14-16 molecules of 
daptomycin oligomerize in a 1:1 ratio with Ca
2+ 
and orient their decanoyl side chains 
towards the center of the micelles (Fig. 1.11) (25, 48). The Ca
2+
-ions function to 
buffer the negative charge of daptomycin, thereby allowing the complex to come 
closer to the cell envelope which is usually negatively charged because of teichoic 
acids in the cell wall and phospholipids in the membrane. Subsequently, daptomycin 
insert its decanoyl side chain into the membrane, which is followed by dissipation of 
the membrane potential and extrusion of K
+
-ions. This, in turn, leads to arrest of DNA, 
RNA, and protein synthesis, and ultimately cell death, without cell lysis (Fig. 1.11) 
(49, 55). 
 13 
 
 
 
 
 
 
 
 
 
Figure 1.10. Structure of the cyclic lipopeptide daptomycin (PDB ID 1XT7). 
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Figure 1.11. Proposed mechanism of action of daptomycin. 
14-16 molecules of daptomycin oligomerize into micelles with Ca
2+
 (yellow spheres) 
in a 1:1 molar ratio. In the proximity of the bacterial membrane daptomycin molecules 
dissociate and insert into the membrane, facilitated by Ca
2+
. Modeled after (48). 
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Moenomycin 
Moenomycin is a phospho-glycolipid antibiotic produced by various strains of 
Streptomyces. It inhibits transglycosylases of Gram-positive bacteria by mimicking 
their substrate, lipid IV (lipid II with an additional disaccharide), during cell wall 
synthesis (Fig. 1.12). Also known as flavomycin or bambermycin, it is used as a 
growth promoter in animal feeding. It is not used in humans, however, because of poor 
absorption (39). In addition, it serves as a tool to study enzymes involved in cell wall 
synthesis (Fig. 1.13) (31). Structural analogs are currently being investigated by 
Walker et al. (38). 
Besides its uses as a growth additive in animals, it was shown to decrease the 
frequency of transferable drug-resistance among Gram-negative pathogens and to 
reduce shedding of pathogenic bacteria, which is surprising, as it is mainly active 
against Gram-positive organisms. Furthermore, cross-resistance with other antibiotics 
and plasmid mediated resistance to moenomycin have not been described (39). The 
latter will be subject of our studies in Chapter 4.  
 
 
 
Figure 1.12. Structure of the glycolipid moenomycin (57). 
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Figure 1.13. Moenomycin interaction with transglycosylase. 
Crystal structure of moenomycin with the bi-functional PBP2 of S. aureus (PDB ID 
2OLV, 2.80 Å, X-Ray diffraction). 
 18 
Ramoplanin 
The lipoglycodepsipeptide ramoplanin was discovered in the 1980s as part of 
an industrial drug discovery program targeted to find cell wall synthesis inhibitors. It 
is produced by non-ribosomal peptide synthesis in Actinomycetes spp., which indicates 
that it contains unusual amino acids. Here, seven out of 17 amino acids are in the D-
form (see Chapter 5, Fig. 5.1) (6). The positively charged molecule is active against 
Gram-positive organisms, where it inhibits the transglycosylase reaction during PG 
synthesis by binding to lipid II, and probably also to the reducing ends of the growing 
glycan chain (17). Initial assumptions that it inhibits MurG by binding to lipid I were 
revised, because it is unlikely that ramoplanin, large and highly water soluble, can 
diffuse easily through membranes (42). It was shown that the ramoplanin aglycon 
binds lipid II preferentially over lipid I by a factor of five. Both form complexes that 
self-assemble into fibrils, which is a reason for its hydrolytic instability, making it not 
suitable for systemic administration (17). Regarding its clinical application, 
ramoplanin is in late stages of clinical trials for treatment of Clostridium difficile 
infections and prevention of enterococcal infections (Oscient Pharmaceuticals 
Corporation, Waltham, MA). 
 
 
Figure 1.14. Imaging of peptidoglycan synthesis with fluorescent ramoplanin. 
The micrographs depict a BodipyFl-labeled ramoplanin derivative. The fluorescent 
dye visualizes the helical pattern of active cell wall synthesis sites (58).  
 19 
Hamburger et al. illustrate ramoplanin as a dimer in a 1.4 Å resolution crystal 
structure by use of detergents to mimic membrane properties (Fig. 1.15) (21). The two 
monomers are predicted to assemble as half-disks where residues 9–15 of each 
monomer interact in an antiparallel manner with six backbone-backbone hydrogen 
bonds. This structure also confirms previous assumptions that the hydrophobic 
polyprenyl chain inserts into the membrane, leaving the polar disaccharide in the 
aqueous region, and allowing the lipid II headgroup to interact with the hydrophilic 
face of the dimer (21). 
 
 
Figure 1.15. Structure of the ramoplanin dimer. 
 (A) shows a schematic view of the dimer, with one monomer blue and the other 
yellow. (B) depicts the structure of the dimer, with the peptide backbone and selected 
side chains of the blue monomer labeled. An asterisk marks the fatty acid moiety (21).  
 
 
 
 20 
1.4 Mechanisms of antibiotic resistance 
Because of its specificity to bacteria, the cell wall is a prime target for 
antibiotics. To date, at least 17 classes of antibiotics have been successfully produced 
or isolated (Table 1.1), but to each class, bacteria have developed resistance (47). This 
selective pressure within bacteria not only originates from the widespread use of 
antibiotics (in fact, 50% of current antibiotics are being used in agriculture and 
aquaculture (12)), it is also inherent in the natural environment of many prokaryotes 
(Fig. 1.16). Due to permanent competition for nutrients, many soil inhabiting bacteria 
have evolved to become prodigious antibiotic producers (26, 47).  
 
 
 
Figure 1.16. Antibiotic resistance profile of soil inhabiting bacteria. 
The diagram demonstrates the density and diversity of resistance profiles of 480 
bacterial isolates. Each of the 191 black dots corresponds to a different resistance 
profile, with each line symbolizing resistance to the antibiotic it points to (10). 
 
Of note is the high prevalence of resistance to daptomycin in these isolates 
(Fig. 1.17). However, this is most likely due to the fact that many strains isolated from 
soil are Streptomyces spp., and daptomycin is produced by S. roseosporus. Producing 
strains have naturally evolved resistance mechanisms to their antibiotics. 
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Figure 1.17. Resistance levels against tested antibiotics. 
Soil isolates were each screened with 20 µg/ml antibiotic. Reproducible growth was 
defined as resistance (10). 
 
Resistance also increased in clinical isolates. Fig. 1.18 shows increase of 
methicillin resistant Staphylococcus aureus (MRSA) in countries with extensive 
reporting (more than 250 S. aureus bacteraemias in at least three out of four years) 
(30). At the same time, the number of new antimicrobial drugs approved by the FDA 
between 1983 and 2007 decreased (18). 
 
 
Figure 1.18. Increase of antibiotic resistance versus decrease of new antibiotics. 
The percentage of S. aureus bacteraemias that are caused by MRSA increased despite 
the availability of anti-MRSA agents (30). The numbers of new, FDA approved 
antibiotics declined in the past 40 years(18). 
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Mechanisms of antibiotic resistance can generally be grouped into three 
categories. First, the antibiotic can be transported away from its site of action by 
pumps (e.g., ATP-binding cassette (ABC) transporters). Second, modification of the 
target can make it unreachable or unrecognizable for the antibiotic. Third, destruction 
or modification of the antibiotic can render the antibiotic ineffective (6, 60).  
Figure 1.19 serves as example for the first group. Bacitracin is a peptide 
antibiotic that prevents dephosphorylation of undecaprenyl pyrophosphate (UPP). This 
inhibits essential UPP recycling, and therefore also cell wall synthesis (54).  
When the BceRS two-component system (TCS) senses low concentrations of 
bacitracin, it increases expression of bceAB. BceAB is an ATP transporter that was 
shown to confer resistance to bacitracin (43). Whether it does so by exporting or 
importing the drug is still controversial (4, 13, 37). Importing would pump the 
antibiotic away from its site of action, if, in fact, bacitracin acts extracellularly. 
 
Figure 1.19. Part of the bacitracin stress response in B. subtilis.  
The BceRS TCS regulates expression of the BceAB transporter which confers 
resistance to bacitracin (43). Solid lines: signal transduction, striped lines: bacitracin 
transport, box: genes encoding known bacitracin resistance determinants. 
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An example for target modification is displayed in Figure 1.20. Vancomycin 
resistance in enterococci can be achieved by target alteration, from the amide linkage 
in UDP-MurNAc(pep)3-D-Ala-D-Ala to the ester linkage in UDP-MurNAc(pep)3-D-
Ala-D-Lac. This leads to a 1,000-fold drop in drug-binding affinity. The switch to D-
Ala-D-Lac is regulated by the vanA operon. VanX, a D,D-dipeptidase, cleaves the 
terminal D-Ala. The dehydrogenase VanH converts pyruvate to lactate, which is 
ligated to D-Ala by VanA. Cell wall synthesis is not affected, as the terminal amino 
acid is cleaved during the transpeptidation step (60, 62).  
 
 
Figure 1.20. Mechanism of vancomycin resistance in enterococci. 
Hydrogen bond formation between vancomycin and two D-alanine residues from lipid 
II (left) or D-alanine-D-lactate (right) (60). 
  
The third group, destruction of an antibiotic, is exemplified by the action of β-
lactamases (Fig. 1.21). Here, the β-lactam antibiotic penicillin is inactivated by the 
action of β-lactamases (also called penicillinases) in the periplasmic space of Gram-
negative bacteria. Ring opening leads to penicilloic acid which can not bind to its 
target, the penicillin binding proteins (60).   
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Figure 1.21. Inactivation of β-lactams by β-lactamase (penicillinase) (60).  
 
 
Figure 1.22. MprF mediated resistance to cationic antimicrobial peptides. 
Transfer of lysine to phosphatidylglycerol decreases the negative charge of the 
membrane, and thereby leads to repulsion of positively charged peptides that target the 
cell membrane (15). 
 
Last, but not least, resistance to antibiotics can also be obtained by indirect measures. 
Figure 1.22 shows how a change of the net charge of the bacterial membrane can 
affect the insertion ability of cationic antimicrobial peptides (CAMPs). The conversion 
of negatively charged phosphatidylglycerol to the positively charged lysyl-
phosphatidylglycerol via Lys-tRNA, catalyzed by MprF, leads to a more neutralized 
membrane charge, which results in increased repulsion towards CAMPs (15). 
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CHAPTER 2  
GENETIC ANALYSIS OF FACTORS AFFECTING SUSCEPTIBILITY OF 
BACILLUS SUBTILIS TO DAPTOMYCIN 
 
Daptomycin is the first of a new class of cyclic lipopeptide antibiotics used 
against multidrug-resistant Gram-positive pathogens. The proposed mechanism of 
action involves disruption of the functional integrity of the bacterial membrane in a 
Ca
2+
-dependent manner. We have used transcriptional profiling to demonstrate that 
treatment of Bacillus subtilis with daptomycin strongly induces the lia operon 
including the autoregulatory LiaRS two-component system (homologous to 
Staphylococcus aureus VraSR). The lia operon protects against daptomycin and 
deletion of liaH, encoding a phage shock protein A (PspA)-like protein, leads to 3-fold 
increased susceptibility. Since daptomycin interacts with the membrane, we tested 
mutants with altered membrane composition for effects on susceptibility. Deletion 
mutations of mprF (lacking lysyl-phosphatidylglycerol) or des (lipid desaturase) 
increased daptomycin susceptibility, whereas overexpression of MprF decreased 
susceptibility. Conversely, depletion of the cell for the anionic lipid 
phosphatidylglycerol led to increased resistance. Fluorescently-labeled daptomycin 
localized to the septa and in a helical pattern around the cell envelope and was 
delocalized upon depletion of phosphatidylglycerol. Together, these results indicate 
that the daptomycin-Ca
2+
 complex interacts preferentially with regions enriched in 
anionic phospholipids and leads to membrane stresses that can be ameliorated by 
PspA family proteins.  
The results of this study were published in A. B. Hachmann, E. R. Angert, and 
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J. D. Helmann. 2009. Antimicrob Agents Chemother 53:1598-609. 
 
2.1 Introduction 
Within the soil micro-environment bacteria compete for limiting nutrients by 
the production of antibiotics that serve to inhibit the growth of their competitors. 
Indeed, the majority of antibacterial compounds in clinical use are natural products of 
soil-dwelling organisms and, in many cases, are produced by Streptomyces spp. and 
related members of the actinomycetales (14). Many of these compounds target the 
synthesis of the peptidoglycan (PG) cell wall layer or disrupt membrane function. 
Those compounds in clinical use owe their selectivity to the fact that eukaryotic cells 
lack PG and have a different membrane lipid composition compared to most bacteria.  
Antibiotics have also proven to be useful tools for microbial cell biology and 
have allowed the visualization of the subcellular location of cell envelope biosynthetic 
processes. For example, fluorescently-labeled vancomycin and ramoplanin, antibiotics 
that bind specifically to the uncrosslinked PG precursors and/or lipid II, have served to 
confirm the helical arrangement of the lateral cell wall biosynthetic complexes (15, 
58) which was also shown in studies using green fluorescent protein (GFP)-tagged 
envelope proteins (53). 
We have used Bacillus subtilis as a model system to investigate the genetic and 
physiological responses to both antibiotics and co-culture with antibiotic-producing 
strains. To date, our studies have focused on cell envelope antibiotics (including 
vancomycin, bacitracin, and fosfomycin) and bacteriocins such as nisin, duramycin, 
and sublancin (17, 43). Exposure to these compounds activates distinct cell envelope 
stress responses (CESRs) controlled by extracytoplasmic function (ECF)  factors and 
 33 
two-component regulatory systems (TCS) (34). In most cases, the activity of ECF  
factors and TCS is controlled by transmembrane sensors (anti- factors or membrane-
bound histidine protein kinases, respectively) which thereby allow gene expression to 
be regulated in response to changes in the cell envelope. The identification of genes 
induced by a certain antibiotic stress provides insights into the nature of the 
antibiotic’s target(s) and also aids in the identification of resistance functions, many of 
which are inducible by their cognate antibiotic (30).  
Daptomycin, a cyclic lipopeptide antibiotic originally purified from 
Streptomyces roseosporus (46), is notable for its activity against methicillin-resistant 
Staphylococcus aureus (MRSA) and certain streptococci and enterococci.  The 
mechanism of action of daptomycin has been controversial. Initial studies suggested 
that daptomycin inhibited lipoteichoic acid synthesis (6). However, these findings 
could not be verified (40). The current proposed mechanism of action involves the 
insertion of its decanoyl side chain into the cytoplasmic membrane in a Ca
2+
-
dependent
 
manner. Subsequent oligomerization, followed by depolarization of the 
membrane potential and efflux of potassium ions, leads to arrest of protein, RNA, and 
DNA synthesis (56). It has been suggested that daptomycin approaches the bacterial 
membrane in the form of micelles composed of 14-16 daptomycin molecules and an 
equal number of Ca
2+
 ions which are proposed to help mask the negative charge of 
daptomycin. After insertion into the membrane, daptomycin dissipates the membrane 
potential and leads to cessation of macromolecule synthesis (24, 54, 56). Daptomycin 
treatment neither results in cell lysis nor does it enter the cytoplasm (6, 13). 
Here, we have investigated the genetic and physiological responses of B. 
subtilis to daptomycin. Using transcriptional profiling, we demonstrate that 
 34 
daptomycin strongly activated the LiaRS TCS which regulates the liaIHGFSR operon. 
Mutants defective for liaH, which encodes a phage shock protein A (PspA)-like 
membrane stress protein (35), were 3-fold more susceptible to daptomycin. This 
susceptibility was further exacerbated in cells additionally lacking the paralogous gene 
pspA. Fluorescence microscopy studies using Bodipy-FL labeled daptomycin together 
with strains having altered membrane lipid composition supports a model in which the 
daptomycin-Ca
2+
 complex interacts preferentially with regions enriched in anionic 
lipids (primarily phosphatidylglycerol (PhG) in B. subtilis) and is localized at new cell 
division septa and in a helical pattern along the long axis of the cell.  
 
2.2 Materials and Methods 
Bacterial strains and growth conditions. Strains and primers used in this 
study are listed in Tables 2.1 and 2.2. Deletion mutants were obtained by replacing 
genes with antibiotic resistance cassettes using long-flanking-homology PCR as 
described previously (43, 60) in the wild-type W168 (trpC2) or CU1065 (W168 trpC2 
attSPβ). Unless otherwise noted, bacteria were cultured in Müller Hinton broth 
supplemented with 50 mg/L Ca
2+
 at 37°C with vigorous shaking. The following 
antibiotics were used for selection when necessary: spectinomycin 100 g/mL, 
kanamycin 10 g/mL, chloramphenicol 10 µg/mL, tetracycline 20 µg/mL, and 
erythromycin 1 µg/mL with lincomycin 25 µg/mL (mls: macrolide-lincomycin-
streptogramin B resistance). Daptomycin and Bodipy-FL labeled daptomycin were 
provided by Cubist Pharmaceuticals (Lexington, MA). For microarray analyses (Table 
2.3), cells were grown to mid-log phase from a 1:1000 dilution of overnight cultures. 
To determine the minimal inhibitory concentration (MIC), overnight cultures were 
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diluted 1:100, grown to mid-log, and re-diluted to 5 x 10
5
 CFU/mL in Müller Hinton 
broth supplemented with 50 mg/L Ca
2+
. At least 10 appropriate antibiotic 
concentrations close to the predicted MIC were added to the cultures at the beginning 
of the growth curve (including a control without antibiotics) in a total inoculum of 200 
µL. Growth was measured spectrophotometrically (OD600) using a Bioscreen 
incubator (Growth Curves USA, Piscataway, NJ) at 37°C with vigorous shaking by 
monitoring the absorbance every 20 minutes for 24 hours. Inhibition was defined as a 
final OD600 < 0.05 (at the 24 hour time point). The mode of the MIC of a minimum of 
triplicate experiments is shown in Table 2.4. 
RNA preparation and microarray analyses. Cultures of W168 were grown 
to mid-log phase (OD600 of 0.4) and split into two flasks. One sample was treated with 
1 µg/mL daptomycin (1X MIC) for 20 minutes; the other sample was used as non-
treated control. Total RNA was isolated from three different biological replicas with 
the RNeasy Mini Kit (Qiagen Sciences, Maryland). After DNase treatment with 
TURBO DNA-free
TM
 (Ambion), RNA concentrations were quantified using a 
NanoDrop spectrophotometer (NanoDrop Tech. Inc., Wilmington, DE). The 
corresponding cDNA was synthesized from 20 µg total RNA and differentially labeled 
according to manufacturer’s instructions using the SuperScriptTM Plus Indirect cDNA 
labeling System (Invitrogen). Before and after indirect labeling with Alexa Fluor 555 
or Alexa Fluor 647 (at least 3 h at room temperature) cDNA was purified using the 
Qiagen PCR purification kit (Qiagen, Maryland) and quantified with NanoDrop. Both 
labeled cDNA populations were combined (approximately 100 pmoles coupled cDNA 
each), denatured, and hybridized to a microarray slide overnight at 42
o
C for 16-18 h. 
After washing, hybridized microarray slides were scanned with a GenePix
TM
 4000B 
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array scanner (Axon Instruments, Inc.). Our B. subtilis W168 microarrays, consisting 
of 4109 gene-specific antisense oligonucleotides (65-mers; Sigma-Genosys), were 
printed at the W.M. Keck Foundation Biotechnology Resource Laboratory, Yale 
University. Each slide contains 8,447 features corresponding to duplicates of each 
ORF-specific oligonucleotide, additional oligonucleotides of control genes, and 50% 
DMSO blank controls. Images were processed using the GenePix Pro 4.0 software 
package which produces (R,G) fluorescence intensity pairs for each gene. Each 
expression value is represented by at least six separate measurements (duplicate spots 
on each of three arrays). Mean values and standard deviations were calculated with 
MS Excel. The normalized microarray datasets were filtered to remove those genes 
that were not expressed at levels significantly above background in either condition 
(sum of mean fluorescence intensity <20). In addition, the mean and standard 
deviation of the fluorescence intensities were computed for each gene and those where 
the standard deviation was greater than the mean value were ignored. The fold 
induction values were calculated by using the signal intensities of daptomycin-treated 
samples divided by untreated samples. These data are available at NCBI’s Gene 
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) accessible via the 
Series accession number GSE13900. The graph in Fig.1 represents average results of 
triplicates. 
Fluorescence microscopy. Cells were either treated with the lipophilic 
membrane dye FM
®
 4-64 (Invitrogen), with Bodipy-FL labeled vancomycin 
(vancomycin-BDP) (Invitrogen), or with Bodipy-FL labeled daptomycin (daptomycin-
BDP) (Cubist Pharmaceuticals). Daptomycin-BDP is an N-BodipyFL-ornithine 
derivative of daptomycin. The activity of daptomycin-BDP was confirmed by 
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measuring the MIC of B. subtilis wild-type and a set of more susceptible mutants. In 
all cases, the MIC corresponded to about ten-fold higher MIC compared to 
daptomycin treatment. Furthermore, daptomycin-BDP was able to induce cat-lacZ 
reporter fusions to liaI independent of the solvent. 100 µl cells from exponential or 
stationary growth phases were incubated with 4 µl daptomycin-BDP 0.5 mg/mL in 
50% DMSO for 10 min, with 2 µl vancomycin-BDP mixed 1:1 with vancomycin 0.1 
mg/mL, or with 1µl FM
®
 4-64 0.5 µg/mL for 20 min. After washing in Müller Hinton 
broth the cells were mounted in the antifade reagent Citifluor (Ted Pella, inc.) on poly-
L-lysine (Sigma-Aldrich) treated slides. Nomarski differential interference contrast 
(DIC) or fluorescent images were taken with an Olympus BX61 epifluorescent 
microscope with a 100× UPlanApo (N.A 1.35) objective. The microscope is equipped 
with fluorescence filter cubes for viewing DAPI, FITC, and Cy3. Images were 
acquired using a Cooke SensiCam with a Sony Interline chip. Image acquisition and 
post-processing were performed using SlideBook Software package (Intelligent 
Imaging). 
Cluster analysis. Results of whole genome microarray analyses of B. subtilis 
with a set of antimicrobial compounds from our data and from a study by Hutter et al. 
(30) was compared by complete linkage clustering (arrangement based on treatment 
and genetic response similarity) using the Gene Cluster 3.0 software. The resulting 
cluster was visualized with Treeview 1.60 written by Michael Eisen (18). 
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strains genotype, remarks, purpose reference, construction
1
 
 
W168 trpC2 BGSC no. 1A1 
CU1065 W168 trpC2 attSPß lab stock, (59) 
HB5121 W168 liaIHGFSR::spc LFH-PCR → W168 
HB0934 CU1065 liaGFSR::kan (43) 
HB0920 CU1065 liaH::kan (43) 
HB0935 CU1065 liaIH::tet (43) 
HB0933 CU1065 liaR::kan (43) 
HB5337 CU1065 mprF::kan (52) 
HB5123 CU1065 liaIH::tet mprF::kan HB5337 chr DNA → HB0935 
HB0919 CU1065 pspA::cat (4) 
HB5124 CU1065 liaH::kan pspA::cat HB0919 chr DNA → HB0920 
HB5125 CU1065 liaIH::tet pspA::cat HB0919 chr DNA → HB0935 
HB5126 CU1065 liaIH::tet mprF::kan pspA::cat HB0919 chr DNA → HB5123 
HB0938 CU1065 yhcYZ::cat T. Mascher, unpublished 
HB5127 CU1065 liaH::kan yhcYZ::cat HB0938 chr DNA → HB0920 
HB0031 CU1065 sigM::kan    (12)   
HB0020 CU1065 sigW::mls (7)  
HB7007 CU1065 sigX::spc (27) 
HB0097 CU1065 sigX::spc sigM::kan (9) 
HB0096 CU1065 sigW::mls sigM::kan (11) 
HB0030        CU1065 sigX::spc sigW::mls M. Cao, unpublished                                                                                            
HB0982 CU1065 sigM::kan sigW::mls sigX::spc (42) 
HB5128 CU1065 liaH::kan sigW::mls HB0020 chr DNA → HB0920 
HB5129 CU1065 liaH::kan pspA::cat sigW::mls HB0020 chr DNA → HB5124 
HB5130 CU1065 sigX::spc sigM::kan liaIH::tet HB0935 chr DNA → HB0097 
HB5131 CU1065 sigM::kan sigW::mls sigX::spc liaIH::tet HB0935 chr DNA → HB0982 
HB5132 CU1065 sigW::mls pspA::cat HB0919 chr DNA → HB0020 
HB5133 CU1076 sigM::kan sigW::mls sigX::spc pspA::cat HB0919 chr DNA → HB0982 
HB5134 W168 des::spc LFH-PCR → W168 
HB5135 W168 des::spc pspA::cat HB0919 chr DNA → HB5134 
HB5346 CU1065 ugtP::mls (52) 
HB5361 CU1065 pssA::spc (52) 
HB5347 CU1065 ywnE::tet (52) 
HB5343 CU1065 psd::mls (52) 
HB5350 CU1065 mprF::kan ugtP::mls (52) 
HB5388 CU1065 mprF::kan pssA::spc (52) 
HB5344 CU1065 psd::mls mprF::kan (52) 
HB5136 CU1065 mprF::kan pspA::cat HB0919 chr DNA → HB5337 
HB5363 CU1065 PxylA-mprF at thrC locus, spc
R
 L. I. Salzberg, unpublished 
BFA2809 W168 trpC2 pgsA::pMutin4 (2) 
HB0950 CU1065 attSPß2Δ2::PliaI-cat-lacZ (44) 
HB0070 CU1065 sigM::kan SPß (PM-cat-lacZ) (9) 
HB7022 CU1065 SPß7019 (PX-cat-lacZ) (27) 
HB0050 CU1065 SPß::PsigW -cat-lacZ (28)   
HB0021 CU1065 sigW::mls SPß::PsigW -cat-lacZ (12) 
  
1Long-Flanking Homology (LFH-)PCR was applied as described previously to construct some of the deletions, 
using the primers listed in Table 2.2. 
 
Table 2.1. Strains used in this study. 
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no. name sequence
1
  
 
2443 Lia-Do-Fwd(spc) 5-CGTTACGTTATTAGCGAGCCAGTCGCGGCTGCTATTTGTTTGCGCC-3 
2444 Lia-Do-Rev 5-GGAGGGCTCTTCATCTGATCCG-3 
2445 Lia-Up-Rev(spc) 5-CAATAAACCCTTGCCCTCGCTACGAAAAACGCCATGCACGAGGC-3 
2446 Lia-Up-Fwd 5-GCTGTCACATTATGCGGCGC-3 
3197 Des-Up-Fwd 5-CCCACTTCTCAACATTTGCAA-3 
3198 Des-Up-Rev(spc) 5- CGTTACGTTATTAGCGAGCCAGTCCGACTTGCTTTGTCAGCTGT-3 
3199 Des-Do-Fwd(spc) 5-CAATAAACCCTTGCCCTCGCTACGGTTTGTGTCATT TGGGCTAT-3 
3200 Des-Do-Rev 5-CCCAAGCGTATCATGGAGAT-3   
  
1 
Sequences complementary to antibiotic resistance cassettes for LFH-PCR are underlined. 
 
Table 2.2. Oligonucleotides used in this study. 
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2.3 Results and Discussion 
Daptomycin strongly activates the LiaRS regulon in B. subtilis. 
Determination of antibiotic stimulons reveals the transcriptional responses to the 
imposed stress, and often provides clues to both the relevant mode of action and the 
induction of possible defense mechanisms (30). Here, we have used DNA-based 
microarrays to investigate the initial transcriptional responses to treatment of B. 
subtilis with daptomycin at the MIC of 1.0 µg/mL. As monitored after 20 minutes of 
exposure, daptomycin induced ~83 genes at least 2-fold and many of these are 
members of known antibiotic-responsive regulons (Fig. 1 and Table 2.3) (17, 44). 
 The strongest response to daptomycin treatment was the induction of the 
autoregulated liaIHGFSR operon which encodes the antibiotic-responsive LiaRS TCS 
(Table 2.3). Lia was named with reference to its strong induction by lipid-II-
interacting antibiotics (35, 44), although it is now clear that there is an imperfect 
correlation between lipid II binding and induction (61). The Staphylococcus aureus 
VraSR system is orthologous to the LiaRS TCS (35). It has been implicated in 
mediating antibiotic resistance (22, 38), and was also strongly induced by daptomycin 
as deduced by microarray analyses (47). 
 In addition to the liaI operon itself, daptomycin induced several other genes in 
a LiaR-dependent manner. These included the yhcYZ operon, which was previously 
shown to be a direct target of LiaR activation (35) and the yvrI and yvrL genes. The 
yvrI gene has recently been shown to be a divergent member of the 70 family of 
transcriptional regulators (41) and activates expression of oxalate decarboxylase 
(OxdC), a major cell wall protein (1). It is not yet clear if yvrI is a direct or indirect 
target of LiaR activation.   
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Figure 2.1. Daptomycin stimulon in B. subtilis. 
The scatterplot represents the average expression levels of treated versus untreated 
cultures of B. subtilis W168 (daptomycin at MIC 1 µg/mL, 20 minutes) of triplicate 
microarray analyses. The legend lists highly expressed genes as grouped by their 
corresponding transcriptional regulators. 
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Genes induced or repressed >2-fold are shown with their respective antibiotic-
responsive regulator
1
 
  Signal Intensity
2
   
Gene + DAP - DAP Fold Change Gene Function
3
 Regulon  
liaH 78930 59 1336 PspA homolog, cell membrane protection LiaRS (35) 
liaI 78935 61 1294 putative membrane protein   LiaRS (35) 
liaG 37639 133 283 putative membrane-anchored protein  LiaRS (35) 
liaF 50616 341 149 negative regulator of LiaR    LiaRS (35)  
liaS 15435 122 126 TCS histidine kinase    LiaRS (35) 
liaR 3535 47 75 TCS response regulator    LiaRS (35) 
yhcY 149 45 3.3 TCS histidine kinase   LiaRS (35) 
yhcZ 631 289 2.2 TCS response regulator   LiaRS (35) 
yvrI 2754 4.8 574  factor yvrI    YvrI (41) 
yvrL 1390 2.6 535 negative regulator of yvrI    YvrI (41) 
yqjL 303 39 7.8 hydrolase; paraquat resistance   σMW (11) 
ydaH 306 49 6.2 uncharacterized membrane protein  σM (10)  
ypbG 211 58 3.6 marker for inhibition of cell wall biosynthesis σM (10)  
yebC 155 43 3.6 hypothetical conserved    σM (29) 
ywaC 124 36 3.5 ppGpp synthase     σM (17, 48) 
bcrC 358 115 3.1 similar to bacteriocin transport permease  σM (9) 
rodA 150 56 2.7 cell-division membrane protein   σM (17) 
yhdL 208 82 2.5 ECF anti- factor    σM (17) 
maf 605 245 2.5 cell division and shape determination  σM (17) 
murG 386 163 2.4 peptidoglycan biosynthesis   σM (17) 
murB 710 353 2.0 UDP-N-acetylenolpyruvoyl glucosamine reductase σM (17) 
sigM 199 93 2.1 ECF  factor     σM (26) 
yuaF 707 148 4.8 hypothetical protein   σW (29) 
yuaG 329 168 2.0 flotillin-like protein    σW(29) 
yxjI 144 68 2.1 unknown    σW(29) 
ywrE 159 76 2.1 unknown     σW (29)  
ydjP 328 168 2.0 similar to chloroperoxydase   σW (29) 
yoeB 2855 1332 2.1 protection against autolysins   YycFG (3, 51) 
yfiC 11780 3349 3.5 similar to ABC transporter (ATP-binding protein)   
fabHA 1203 521 2.3 fatty acid biosynthesis      
fabHB 73 26 2.8 fatty acid biosynthesis     
yvcB 1214 45 27 unknown  
yvkN 302 12 26 unknown  
yvzA 424 42 10 unknown 
yvzC 261 10 26 hypothetical protein 
yvpB 257 19 14 hypothetical protein 
sdpI 2233 252 8.9 immunity protein for SdpC; signal transduction SdpR (19) 
ywdD 163 31 5.3 hypothetical protein 
ywdE 504 51 9.9 hypothetical protein 
ywfB 299 38 7.9 similar to Bacilysin biosynthesis protein 
yknU 2917 372 7.8 similar to ABC transporter (ATP-binding protein) 
hutM 126 40 3.2 histidine permease 
ypeB 469 151 3.1 sporulation protein 
yitI 630 215 2.9 probable acetyltransferase 
 
 
 
 
 
Table 2.3. Daptomycin stimulon. 
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Table 2.3. (Continued) 
  Signal Intensity
2
   
Gene + DAP - DAP Fold Change Gene Function
3
 Regulon  
rpmB 892 1631 0.5 ribosomal protein L28 
degR 115 216 0.5 activation of degradative enzymes (AprE, NprE, SacB) 
yisY 138 264 0.5 similar to chloride peroxidase 
ydgK 39 77 0.5 similar to bicyclomycin resistance protein 
yocH 759 1513 0.5 similar to cell wall-binding protein (autolysin) YycFG (3, 51) 
yxeQ 60 119 0.5 putative MmgE/Prp family protein 
lmrB 261 534 0.5 lincomycin-resistance 
rpsT 541 1140 0.5 ribosomal protein S20 
yxeM 66 156 0.4 similar to amino acid ABC transporter (binding protein) 
ywhE 386 926 0.4 pbpG, penicillin-binding protein (sporulation)  
1 Induced genes controlled by regulator(s) known to be responsive to antibiotic-elicited stress are shown together 
with genes of predicted function or those with unknown function that are strongly induced (>5-fold). Induced and 
repressed genes were filtered to remove those with low overall expression levels (combined signal intensity <100). 
Altogether, daptomycin induced 83 genes at least 2-fold (234 genes 1.5-fold) and repressed 25 genes at least 2-
fold (181 1.5-fold) (NCBI GEO series accession GSE13900). 
2 “+DAP” and “-DAP” corresponds to average triplicates of the signal intensities of daptomycin-treated or 
untreated samples. 
3  Functions were assigned based on the SubtiList database or BSORF entry.  
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In B. subtilis, a number of genes involved in antibiotic resistance and cell wall 
metabolism are regulated by the extracytoplasmic function (ECF) σ-factors σW and 
σM. Daptomycin weakly induced 6 genes of the σW regulon (10, 12) and 19 genes of 
the σM regulon (17, 32) (Table 2.3). To monitor the transcriptional response of the liaI, 
sigW, and sigM genes to daptomycin treatment we used transcriptional (cat-lacZ) 
reporter fusions and found that all were induced by daptomycin (data not shown).  
The phage-shock protein A homologs LiaH and PspA protect against 
daptomycin. Of the liaIHGFSR genes, liaFSR are well conserved within Gram-
positive bacteria with a low G+C content. Only the bacilli also contain the phage-
shock protein A homolog LiaH. S. aureus harbors the liaFSR orthologs SA1702 and 
vraSR (35). When tested for daptomycin susceptibility, Muthaiyan et al. observed an 
increased susceptibility of a vraSR mutant strain to daptomycin (0.78 µg/mL vs. 1.0 
µg/mL for wild-type) (47). Here, we have used growth inhibition studies to examine 
whether the daptomycin induced liaI operon affects susceptibility to daptomycin. A 
deletion of the entire liaI operon significantly increased susceptibility from an MIC of 
1.0 µg/mL for wild-type to an MIC of 0.3 µg/mL (Table 2.4). A null mutant of the 
negative regulator liaF, which overexpresses LiaIH (34, 35), did not appear to increase 
resistance.  
 To test for possible functional redundancy between liaH and its paralog pspA 
(which was not strongly induced by daptomycin treatment despite being part of the σW 
regulon) we tested single and double mutants of these loci. A pspA deletion showed 
almost no change of MIC compared to wild-type, but the double mutant liaH pspA 
further decreased the MIC by 2-fold relative to the liaH single mutant. These results 
indicate that the PspA (phage-shock-protein A) homologs, LiaH and PspA, both 
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contribute to decreased daptomycin susceptibility and that the induction of LiaH by 
daptomycin is adaptive.  
 The mechanisms by which PspA proteins protect cells against membrane-
disruption are unclear, but are likely to involve direct interactions with the inner 
surface of the membrane (16). Escherichia coli PspA forms abundant, oligomeric ring-
like structures that are speculated to coat the inner surface of the membrane, and 
thereby prevent proton leakage (39). In vitro, E. coli PspA binds preferentially to 
liposomes containing anionic lipids and suppresses proton leakage (39). LiaH has also 
been observed to be an abundant oligomeric protein with a similar ultrastructure (T. 
Mascher, personal communication). Together, these findings are consistent with the 
notion that daptomycin toxicity results from disruption of the membrane integrity and 
that the two B. subtilis PspA paralogs can counteract this disruptive effect.  
ECF σ-factors also contribute to decreased daptomycin susceptibility. 
Since several σW and σM regulon members were upregulated upon daptomycin 
treatment, we tested null mutants of ECF σ-factor genes for daptomycin susceptibility. 
In the singly mutant strains, there was a slight decrease of MIC for sigM and sigW (0.8 
µg/mL for both), whereas a sigX mutant was unaffected. Multiply mutant strains 
displayed even greater susceptibility with the lowest MIC noted for the sigXM double 
(0.6 µg/mL) and the sigMWX triple mutants (0.6 µg/ml) (Table 2.4). Increased 
daptomycin susceptibility in the multiply mutant strains is consistent with the recent 
demonstration that these three ECF  factors have overlapping regulons and multiply 
mutant strains are often more susceptible to antibiotics than single mutants (42). 
In B. subtilis, several ECF σ-factors have been implicated in conferring 
resistance to cell envelope-active antibiotics. For example, σX regulates the dlt operon  
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Table 2.4. Minimum inhibitory concentration of B. subtilis mutants and strains with 
altered membrane composition, or deletion of transcriptional regulators. 
Strain/ DAP MIC Strain/ DAP MIC  
Deletion Mutant  [µg/mL]
2
 Deletion Mutant [µg/mL] 
W168  1.0 liaH pspA  0.2  
CU1065  1.0 liaIH pspA  0.2 
LiaR-regulated   liaIH mprF pspA  0.2  
liaIHGFSR
1
  0.3 sigXM liaIH  0.2 
liaH  0.4 sigMWX liaIH  0.2  
liaIH  0.4  sigW pspA  0.8  
liaR  0.5 sigMWX pspA  0.5  
liaF  1.0 Membrane alterations 
liaGFSR  0.5 W168 at 25°C  0.7  
liaIH mprF  0.2 des
1 
at 25°C  0.4 
liaH yhcYZ  0.2 des
1
  0.9  
yhcYZ  0.8 des pspA  0.9 
ECF σ-regulated   ugtP  0.9  
sigM  0.8 pssA  1.0  
sigW  0.8 ywnE  1.0  
sigX  1.0 psd  1.0 
sigXM  0.6 mprF  0.5  
sigWM  0.7 mprF ugtP  0.6 
sigXW  0.9   mprF pssA   0.9  
sigMWX  0.6 psd mprF  0.9  
pspA  1.0 mprF pspA  0.5  
LiaR/ECF σ-regulated   mprF overexpression  1.3  
liaH sigW  0.3 pgsA depletion  8.0 
liaH pspA sigW  0.2 IPTG induced pgsA   1.0 
 
1 Mutants derived from strain W168, other mutants derived from strain CU1065. 
2 MIC was determined by liquid growth inhibition experiments. Data represent the mode of the lowest daptomycin 
concentration that led to complete growth inhibition (minimum of triplicates). 
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and the pssA ybfM psd operon which reduce the net negative charge of the cell 
envelope by D-alanylation of teichoic acids and insertion of phosphatidylethanolamine 
into the membrane, respectively. As a result, mutants in sigX are more susceptible to 
cationic antimicrobial peptides (8). The W regulon includes a large number of genes 
implicated in resistance against both small molecule inhibitors such as fosfomycin and 
peptide antibiotics such as sublancin and SdpC (4). Finally, the σM regulon has 
recently been shown to include many genes known to be important for cell envelope 
synthesis and sigM mutants are susceptible to some cell wall antibiotics such as 
moenomycin and bacitracin (17, 42). The identity of the ECF  factor-dependent 
operons that confer daptomycin protection is not yet clear.  
Mutants with altered membrane composition affect daptomycin 
susceptibility. Since the decanoyl side-chain of daptomycin is predicted to insert into 
the membrane, we tested whether susceptibility is influenced in strains altered in 
membrane lipid composition. Daptomycin susceptibility was measured for B. subtilis 
strains lacking phosphatidylethanolamine (psd, pssA), lysyl-phosphatidylglycerol 
(mprF), glycolipids (ugtP), or cardiolipin (ywnE). Of the null mutants, only mprF 
showed a significant difference compared to wild-type (MIC 0.5 µg/mL vs. 1.0 
µg/mL; Table 2.4). Moreover, overexpression of mprF led to slightly decreased 
susceptibility (MIC 1.3 µg/mL). MprF catalyzes the tRNA-dependent modification of 
phosphatidylglycerol (PhG) with lysine to form the positively charged lysyl-
phosphatidylglycerol (LPhG) (57).   
 It has been shown earlier that a change in membrane charge due to mprF 
disruption affects the susceptibility to antimicrobial agents in S. aureus (49). Here, we 
speculate that the reduction of the net negative charge of the membrane upon 
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increased production of LPhG functions to reduce the affinity of a positively charged 
daptomycin-Ca
2+
 complex due to electrostatic repulsion. Indeed, previous studies of S. 
aureus strains that were selected for increased daptomycin resistance found that point 
mutations in mprF frequently occurred as an early event during selection (21). 
However, the effect of these mutations alone was quite modest and further selection 
led to additional mutations in the yycFG TCS and RNA polymerase subunit genes 
rpoBC (21). Since an mprF null mutant is more susceptible to daptomycin, we suggest 
that these mprF mutations may have been gain of function mutations. Independently, 
Jones et al. found that daptomycin resistance in S. aureus was correlated with 
increased translocation of LPhG from the inner to the outer leaflet of the membrane 
without changing the overall concentration of LPhG (33). An increase of mprF gene 
expression was not seen upon daptomycin treatment in B. subtilis, but an increase in 
positive charge through LPhG translocation to the outer leaflet, and an additional 
effect of reduction of the membrane net negative charge by σX, could together affect 
the ability of daptomycin to insert into the membrane. 
The physical properties of the membrane are determined by both the membrane 
head-group composition and the length and desaturation of the fatty acyl side chains. 
In B. subtilis, the fluidity of the membrane is regulated, in large part, by the lipid 
desaturase Des which introduces cis-double bonds at Δ5 in response to reduction in 
temperature. The desaturase is under the control of the DesRK TCS (31). Deletion of 
des resulted in increased susceptibility to daptomycin and this effect was especially 
notable during growth at low temperatures (MIC at 25°C of 0.4 µg/mL vs. 0.7 µg/mL 
for wild-type).  The underlying mechanisms of the effect of des deletion are not 
entirely clear. The increased rigidity of the membrane in a des mutant might facilitate 
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the membrane disruptive action of daptomycin, impair repair mechanisms by the cell, 
or the decrease in unsaturated fatty acyl moieties might affect interactions with the 
decanoyl side chain of daptomycin.   
Depletion of phosphatidylglycerol greatly decreases daptomycin 
susceptibility. The effect of reducing the net negative charge of the cell membrane on 
daptomycin susceptibility was especially apparent when we studied a strain in which 
PhG could be depleted from cells using a conditionally expressed allele of pgsA. PgsA 
is required for the first step in PhG synthesis from phosphatidic acid (37). Depletion of 
this essential complex lipid, by transfer of cells to medium lacking the inducer IPTG, 
results in cells that lose the characteristic helical staining pattern associated with 
anionic-lipid favoring membrane dyes (e.g. FM 4-64). This strain continues to grow 
for several hours even in the absence of IPTG as they gradually become depleted of 
PhG (58). When PhG-depleted cells were sub-cultured in medium lacking IPTG, but 
containing daptomycin, they were able to grow in the presence of significantly higher 
daptomycin concentrations than wild-type. Conversely, when expression of pgsA was 
induced by IPTG addition, wild-type levels of daptomycin susceptibility were restored 
(Table 2.4). This increased resistance was specific for daptomycin: PhG-depleted cells 
were unaffected in susceptibility to vancomycin (which targets PG synthesis) and were 
increased in susceptibility to duramycin which interacts specifically with 
phosphatidylethanolamine (2). Presumably, in this case, depletion of PhG from the 
membrane led to an increase in the concentration of phosphatidylethanolamine.  
The effects of membrane composition and charge on daptomycin insertion 
have also been studied by Jung et al. in artificial liposomes. By means of fluorescence 
spectroscopy, differential scanning calorimetry, and 
31
P NMR, they found that 
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daptomycin (with Ca
2+
) binds to acidic and neutral lipids in a different fashion and 
leads to a change of the structural organization of acidic membranes (induction of non-
lamellar lipid phases and membrane fusion) (58). This again emphasizes the influence 
of membrane lipid composition on daptomycin susceptibility.  
Daptomycin preferentially localizes to the cell septum and in a helical 
pattern along the cell wall. Fluorescent imaging with Bodipy-FL labeled daptomycin 
(daptomycin-BDP) was used to study the localization of daptomycin in the cell 
envelope in B. subtilis. Strikingly, daptomycin-BDP was not distributed evenly 
throughout the cell membrane, but rather in a complex, reproducible pattern. The 
highest concentration was found along the newly formed division septa, and in a 
helical pattern along the long axis of the cell, whereas no fluorescence was detected at 
the cell poles (Fig. 2A and 2B).  This helical pattern and localization to the septa is 
reminiscent of localization studies of both the cell wall biosynthetic machinery (50) 
and anionic phospholipids (including PhG) in B. subtilis (56). Sites of active cell wall 
biosynthesis have been visualized using Bodipy-FL labeled vancomycin (vancomycin-
BDP) (45). 
We next compared the localization of daptomycin-BDP with vancomycin-BDP 
which binds to the D-Ala-D-Ala dipeptide of uncrosslinked PG (2). In separate 
labeling experiments, the daptomycin-BDP and vancomycin-BDP labeling showed 
very similar patterns (Fig. 2C). Since both antibiotics are bound to the same 
fluorophore, we were unable to carry out direct colocalization studies. However, pre-
treatment with vancomycin did not affect labeling by daptomycin-BDP, nor did 
unlabeled daptomycin interfere with staining with vancomycin-BDP. This suggests 
that these two antibiotics may have distinct targets, as expected from prior work (2).  
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Figure 2.2. Daptomycin-BDP inserts preferentially at new division septa and in a 
spiral pattern. 
Fluorescent and DIC micrographs of B. subtilis stained with daptomycin-BDP (DAP-
BDP) and vancomycin-BDP (VAN-BDP). (A) B. subtilis W168 treated with 
daptomycin-BDP at two-fold MIC for 10 minutes (during exponential growth phase). 
(B). W168 treated with daptomycin-BDP at ten-fold MIC for 10 minutes. (C). W168 
treated with equal amounts of vancomycin and vancomycin-BDP for 20 minutes. A 
and B show a spiral localization of daptomycin-BDP and the preferential insertion at 
newly formed division septa, similar to vancomycin-BDP (C). The arrowhead 
indicates old, the arrow new division septa. Scale bars represent 2 µm. 
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Figure 2.3. Daptomycin-BDP staining of stationary phase cells. 
Fluorescent and DIC micrograph of stationary growth phase culture of B. subtilis 
W168 treated with daptomycin-BDP (DAP-BDP) at two-fold MIC for 10 minutes. 
The staining shows a similar insertion pattern compared to exponential growth phase 
cultures. Scale bars represent 2 µm. 
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Recently, Mascio et al. showed that daptomycin also exhibits bactericidal 
effects on S. aureus cells in stationary growth phases (albeit with higher MIC) (47) 
which prompted us to test  daptomycin-BDP labeling in B. subtilis stationary cells. We 
observed a similar pattern as in exponentially growing cells (Fig. 3), albeit with less 
intense labeling at the division septa. 
In light of the recently reported helical distribution of PhG in B. subtilis 
membranes (30) we next tested whether PhG depletion affects the observed staining 
pattern seen with daptomycin-BDP. Remarkably, cells depleted of PhG exhibited a 
significant loss of staining intensity and failed to exhibit the characteristic helical 
staining pattern seen in the non-depleted cells (Fig. 4C vs. 4A/B). Very similar effects 
were noted when the cells were stained instead with the membrane dye FM 4-64 (Fig. 
4D vs. 4E) which is known to stain regions enriched in PhG (36, 39). Together, these 
results suggest that the characteristic staining pattern observed with daptomycin-BDP 
is due to a preferential interaction with the membrane in regions enriched in PhG, 
consistent with the effects of PhG depletion on daptomycin susceptibility as noted 
above.  
Cluster analysis of the stimulons of daptomycin and other cell envelope 
active antibiotics. Analysis of the daptomycin stimulon and the effects of membrane 
mutations on susceptibility, combined with the preceding analysis of daptomycin-BDP 
localization, are all consistent with a primary mechanism of action involving insertion 
into the cell membrane in regions enriched in anionic lipids. However, recent studies 
of the transcriptional response of S. aureus to daptomycin led Muthaiyan et al. to 
suggest that daptomycin might interfere both with membrane integrity and PG 
biosynthesis (21).  
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Figure 2.4. Correlation between daptomycin-BDP staining and anionic phospholipid 
content and distribution. 
Fluorescent and DIC micrographs of (A) wild-type W168 and pgsA::pMutin grown in 
the (B) presence or (C) absence of 1 mM IPTG, stained with daptomycin-BDP at two-
fold MIC for 10 minutes. Daptomycin-BDP delocalizes when pgsA is not expressed 
from the IPTG-inducible promoter suggesting preferential insertion of daptomycin in 
membrane lipid domains rich in anionic phosphatidylglycerol. (D) W168 and (E) 
pgsA::pMutin stained with the membrane lipid dye FM 4-64 in the absence of IPTG. 
Scale bars represent 2 µm. 
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In this organism, daptomycin induced genes characteristic of membrane-disrupting 
agents (e.g. m-chlorophenylhydrazone) as well as genes induced by cell wall synthesis 
inhibitors (e.g. vancomycin).  
 To determine whether the daptomycin stimulon of B. subtilis most closely 
resembled the stimulons for membrane-perturbing agents or cell wall synthesis 
inhibitors, we performed a hierarchical clustering analysis using datasets representing 
the transcriptional responses to daptomycin, vancomycin,  moenomycin, and 
ramoplanin (our results), and 35 other antibiotics from a study by Hutter et al. (5). The 
daptomycin stimulon is most similar to a cluster of treatment conditions that includes 
compounds that inhibit PG synthesis (vancomycin, ristocetin, ramoplanin, and 
moenomycin) and that perturb membrane function (Triton X-114 and polymyxin B). 
All of these conditions induce the M regulon and several compounds are strong 
inducers of the LiaRS TCS (Fig. 5). These results lead us to suggest that insertion of 
daptomycin into membrane regions enriched in anionic lipids may have multiple 
effects including both disruption of membrane function and perhaps interference with 
the assembly or function of cell wall biosynthetic complexes.  
 
2.4 Conclusions   
We here report a detailed genetic analysis of factors affecting daptomycin 
susceptibility in B. subtilis. Transcriptome analyses indicate that daptomycin induces 
sets of genes previously shown to be induced by exposure to membrane-active 
compounds and cell wall synthesis inhibitors. The LiaRS TCS is strongly induced by 
daptomycin, and genetic studies indicate that both LiaH and the paralog PspA 
contribute to decreased daptomycin susceptibility. By analogy with E. coli PspA (2), 
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these proteins are likely to help stabilize the membrane and prevent depolarization. 
These results are consistent with the expectation that daptomycin acts primarily on the 
membrane.  
 Analysis of strains with altered membrane composition suggests that 
daptomycin interacts preferentially with regions of the membrane enriched in anionic 
lipids including PhG, the dominant anionic lipid in B. subtilis. For example, a strain in 
which PhG is depleted becomes less susceptible to daptomycin although it retains 
normal (or even increased) susceptibility to other cell wall and membrane-active 
antibiotics. Conversely, strains lacking MprF, which synthesizes the cationic lipid 
LPhG, are more susceptible to daptomycin. Mutations in mprF have been previously 
associated with daptomycin resistance (23) although, in light of the results here, it 
seems likely that these are gain-of-function mutations that increase MprF levels or 
activity. Indeed, overexpression of mprF in B. subtilis decreases daptomycin 
susceptibility.  
 Cells depleted of PhG not only display decreased daptomycin susceptibility; 
they lose the characteristic helical staining pattern seen in wild-type cells treated with 
daptomycin-BDP. This may result directly from the reduction in levels of negatively 
charged membrane lipids which would thereby decrease the affinity of the positively 
charged daptomycin-Ca
2+
 complex for the membrane. Alternatively, or in addition, 
PhG depletion might result in altered composition or localization of membrane 
proteins, or cell envelope biosynthetic complexes. For instance, Campo et al. reported 
that reduced PhG led to delocalization of the translocation ATPase SecA in the B. 
subtilis membrane (20); and Barák et al. observed enrichment of the cell division 
protein MinD in anionic phospholipid spirals in the membrane (25, 55). 
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Figure 2.5. Cluster analysis of B. subtilis microarray studies with 40 different 
antimicrobial agents. 
The gene expression patterns of daptomycin-treated B. subtilis are most closely related 
to those of cells treated with cell membrane and cell wall active antibiotics: 
moenomycin, triton X-114, polymyxin B, ramoplanin, ristocetin, and vancomycin. 
Cluster analysis was performed on whole genome datasets for each antibiotic (see 
Materials and Methods) and selected clusters enriched for daptomycin-induced genes 
are shown. Red indicates induction and green repression after treatment, whereas 
black corresponds to unchanged gene expression. 
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Daptomycin is used clinically as a reserve antibiotic against complicated skin 
and skin structure infections (21) as well as S. aureus-induced bacteremia and 
infective endocarditis (35). To date, reports about resistance to daptomycin in clinical 
settings have been relatively rare (41). To better understand the evolution of 
daptomycin resistance, S. aureus strains with increased daptomycin resistance (either 
selected in the laboratory or arising during clinical treatment) were chosen for DNA 
sequence analysis. These studies indicate that the evolution of resistance is a 
multigenic phenomenon. Often, mutations in mprF emerge early and other 
contributing mutations occur in the essential yycFG TCS and rpoBC genes (11). To 
date, there are no documented examples of high level daptomycin resistance emerging 
due to a single gene mutation. In light of these findings, it is interesting that cells 
depleted of PhG display such a dramatic decrease of susceptibility. However, null 
mutations that confer daptomycin resistance are unlikely to arise in pgsA since, at least 
in B. subtilis, it is an essential gene.  
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CHAPTER 3  
PGSA DEPLETION LEADS TO HIGH DAPTOMYCIN RESISTANCE IN 
BACILLUS SUBTILIS 
 
Resistance to antibiotics is of high concern in particular when considering the 
low number of new antibiotics discovered in the past 40 years. One of the newest 
antibiotics on the market, daptomycin, is a cyclic lipopeptide that disrupts the 
functional integrity of the cell membrane of Gram-positive pathogens in a Ca
2+
-
dependent manner. To date, few resistances against daptomycin have been reported 
with the highest stemming from laboratory isolates. Here, we present detailed genetic 
and phenotypic analyses of a daptomycin resistant isolate, Dap
R
1, from the Gram-
positive model bacterium Bacillus subtilis. This strain was obtained by serial passage 
with increasing daptomycin concentrations in the laboratory, and is 30-fold more 
resistant to daptomycin than the parent strain. In addition, Dap
R
1 displays cross-
resistance to cell wall active antibiotics, including vancomycin, moenomycin, and 
bacitracin. Dap
R
1 is characterized by aberrant septum placement and by a thickened 
cell wall, especially at the cell poles. However, peptidoglycan analysis did not show 
significant changes compared to the parent strain. On a transcriptomic and proteomic 
level the strain deviates significantly from the parent strain. Solexa sequencing 
revealed 44 point mutations of which 31 changed protein sequence. An intermediate 
isolate of Dap
R
1 that is 20-fold more resistant to daptomycin than wild-type, only has 
three point mutations; in the cell shape modulator gene mreB, the stringent response 
gene relA, and the phosphatidylglycerol synthase gene pgsA. We suggest that the high 
resistance of Dap
R
1 can be attributed to the mutation in pgsA, resulting in a more 
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positively charged membrane, and a repulsive effect on the positively charged Ca
2+
-
daptomycin complex. 
The majority of the studies in this chapter were performed by A. B. Hachmann, 
David Popham (Blacksburg, Virginia) contributed the quantification of muramic acids, 
and Haike Antelmann (Greifswald, Germany) carried out the proteomic analyses of 
Dap
R
1 and W168. 
 
3.1 Introduction 
Daptomycin is a cyclic lipopeptide antibiotic used to treat complicated skin 
and skin structure infections caused by Staphylococcus aureus or enterococci. In 
addition, it has been approved to treat S. aureus-induced bacteremia and infective 
endocarditis (13). The mechanism of action involves the calcium ion dependent 
insertion of daptomycin into the bacterial membrane, followed by depolarization of 
the membrane potential and extrusion of potassium ions, leading to arrest of 
macromolecular synthesis and cell death (26, 27). 
With over 500,000 patients treated since market approval, resistances to 
daptomycin developed rarely. According to the SENTRY Antimicrobial Surveillance 
Program from the United States for the years 2002-2008, 99.9% of methicillin 
resistant S. aureus treated with daptomycin had an MIC of 1.0 µg/ml or lower, with 
only a slight increase of MIC over time (http://www.gp-pathogens.com/data/ 
default.cfm) (25). Previous studies targeting mechanisms of resistance to daptomycin 
were performed on clinical isolates and in vitro (14, 18). In-vitro isolation of resistant 
bacterial strains can give clues about the effectiveness of a certain antibiotic, and 
uncover information about mechanisms of resistance.  
 67 
After serial passage with increasing daptomycin concentration, Friedman et al. 
characterized three S. aureus isolates that displayed increased daptomycin resistance 
(14). Mutations contributing to resistance were found in genes that encode for the 
membrane lipid modulator MprF, the two-component system YycFG, and 
RpoB/RpoC. MprF modifies membrane lipids by tRNA catalyzed lysinylation of 
phosphatidylglycerol, thereby increasing amounts of positively charged membrane 
lipids. This mutation is possibly a gain-of-function mutation as we found increased 
daptomycin susceptibility in an mprF deletion mutant and decreased susceptibility for 
MprF overexpression in B. subtilis (16). While the role of mutations in RpoB and 
RpoC was unknown, mutations in YycG could account for changes in cell wall 
metabolism, perhaps leading to decreased cell lysis (4). 
To further investigate possible mechanisms of resistance to daptomycin, we 
isolated a mutant (Dap
R
1) by serial passage in the Gram positive model bacterium B. 
subtilis. Here, we discuss the characterization of this daptomycin resistant strain, 
including possible mechanisms of resistance. 
 
3.2 Materials and Methods 
Bacterial strains and growth conditions. Unless otherwise noted, bacteria 
were cultured at 37°C with vigorous shaking using Müller Hinton broth supplemented 
with 50 mg/l Ca
2+
 as growth medium. The following antibiotics were used for 
selection when necessary: spectinomycin 100 g/ml, kanamycin 10 g/ml, 
chloramphenicol 10 µg/ml, tetracycline 20 µg/ml, and erythromycin 1 µg/ml with 
lincomycin 25 µg/ml (mls: macrolide-lincomycin-streptogramin B resistance). Table 
3.1 lists the strains and primers used in this study. Deletion mutants were generated by 
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replacing genes with antibiotic resistance cassettes using long-flanking-homology 
PCR (21, 31) in the wild-type W168 (trpC2) or CU1065 (W168 trpC2 attSPβ). 
Daptomycin and Bodipy-FL labeled daptomycin were provided by Cubist 
Pharmaceuticals (Lexington, MA). The minimal inhibitory concentration (MIC) was 
determined by diluting overnight cultures 1:100, growing to OD600 of 0.4, and re-
diluteding to 5 x 10
5
 CFU/mL in Müller Hinton broth supplemented with 50 mg/l 
Ca
2+
. At least 10 appropriate antibiotic concentrations close to the predicted MIC were 
added to the cultures at the beginning of the growth curve (including a control without 
antibiotics) in microtiter plates with a total inoculum of 200 µl. Growth was measured 
spectrophotometrically (OD600) using a Bioscreen incubator (Growth Curves USA, 
Piscataway, NJ) at 37°C with vigorous shaking. The absorbance was recorded every 
20 minutes for 24 hours. Inhibition was defined as a final OD600 < 0.05 (at the 24 hour 
time point). The mode of the MIC of a minimum of triplicate experiments is shown in 
Table 3.2 and Table 3.3. 
RNA preparation and microarray analyses. Total RNA was isolated from 
three biological replicas of W168 and Dap
R
1 grown to mid-log phase (OD600 of 0.4) 
using the RNeasy Mini Kit (Qiagen Sciences, Maryland). After DNase treatment with 
TURBO DNA-free
TM
 (Ambion), RNA concentrations were quantified using a 
NanoDrop spectrophotometer (NanoDrop Tech. Inc., Wilmington, DE). cDNA was 
synthesized from 20 µg total RNA and differentially labeled according to 
manufacturer’s instructions with the SuperScriptTM Plus Indirect cDNA labeling 
System (Invitrogen). Before and after indirect labeling with Alexa Fluor 555 or Alexa 
Fluor 647 (at least 3 h at room temperature) cDNA was purified using the Qiagen 
MinElute PCR Purification Kit (Qiagen, Maryland) and quantified via NanoDrop. 
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Both labeled cDNA populations were combined (approximately 100 pmoles of labeled 
cDNA per sample), denatured, and hybridized to a microarray slide overnight at 42
o
C 
for 16-18 h. After washing, hybridized microarray slides were scanned with a 
GenePix
TM
 4000B array scanner (Axon Instruments, Inc.). Our B. subtilis W168 
microarray slides were printed at the W.M. Keck Foundation Biotechnology Resource 
Laboratory (Yale University) with 4109 gene-specific antisense oligonucleotides (65-
mers; Sigma-Genosys). In addition to duplicates of each ORF-specific 
oligonucleotide, the slides have additional oligonucleotides of control genes and 50% 
DMSO blank controls (8,447 features in total). The GenePix Pro 6.0 software package 
was used for image processing and analysis. Each expression value is represented by 
six separate measurements (duplicate spots on each of three arrays). Mean values and 
standard deviations of the normalized microarray datasets were calculated with MS 
Excel. Filtering was applied to remove genes that were not expressed at levels 
significantly above background (sum of mean fluorescence intensity <20). In addition, 
the mean and standard deviation of the fluorescence intensities were computed for 
each gene and those where the standard deviation was greater than the mean value 
were ignored. The fold change was calculated by using the signal intensities of Dap
R
1 
divided by W168. 
Fluorescence microscopy. Cells were either treated with Bodipy-FL labeled 
vancomycin (vancomycin-BDP) (Invitrogen) or with Bodipy-FL labeled daptomycin 
(daptomycin-BDP) (Cubist Pharmaceuticals), an N-BodipyFL-ornithine derivative of 
daptomycin. 100 µl of W168 grown to exponential phase was incubated with 4 µl 
daptomycin-BDP 0.5 mg/mL in 50% DMSO for 10 min, or with 2 µl vancomycin-
BDP mixed 1:1 with vancomycin 0.1 mg/ml for 20 min, Dap
R
1 was incubated with 40 
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µl daptomycin-BDP, and 4µl vancomycin-BDP mix, respectively. After washing in 
Müller Hinton broth the cells were mounted in the antifade reagent Citifluor (Ted 
Pella, inc.) on poly-L-lysine (Sigma-Aldrich) treated slides. Nomarski differential 
interference contrast (DIC) or fluorescent images were taken with an Olympus BX61 
epifluorescent microscope with a 100× UPlanApo (N.A 1.35) objective. The 
microscope is equipped with fluorescence filter cubes for viewing DAPI, FITC, and 
Cy3. Images were acquired using a Cooke SensiCam with a Sony Interline chip. 
Image acquisition and post-processing were performed using SlideBook Software 
package (Intelligent Imaging). 
Transmission Electron Microscopy. Cells were prepared following a 
standard protocol of fixation in 2% glutaraldehyde followed by 2% OsO4, both in 
0.1% Na cacodylate buffer, followed by 2% aqueous uranyl acetate and dehydration in 
an ethanol/acetone series. Embedding was in Epon-araldite resin and thin sections 
taken on an LKB ultramicrotome. Grids were stained with Reynold’s lead citrate and 
uranyl acetate and photographed in an FEI EM 201. 
Peptidoglycan analysis. PG was purified from cells and digested with 
muramidase, and muropeptides were separated and quantified using HPLC as 
previously described (3, 22). For quantification of cell-associated muramic acid and 
dpm, culture samples were centrifuged, washed in cold 1 mM MgCl2, and suspended 
in 6 N HCl.  Following hydrolysis at 95°C for 4 h, muramic acid and dpm were 
determined by an amino acid/amino sugar analysis method (15, 23).  
FAME analysis. W168 and Dap
R
1 were grown to mid-exponential phase at  
37
 o
C or 25
 o
C in LB. Cultures of two biological replicas were combined and frozen 
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cell pellets were submitted for fatty acid methyl ester (FAME) analysis at Microbial 
ID, Newark, DE (http://www.microbialid.com/). 
Proteome and mass spectrometry analysis. B. subtilis strains were grown in LB-
broth and harvested 1 hour after entry into the stationary phase at OD540 of 3.0. The 
TCA-precipitated extracellular, cell wall-associated and cytoplasmic proteins were 
prepared as described previously (1, 2) and resolved in a solution containing 2 M 
thiourea and 8 M urea. Protein content was determined using Bradford assay (5). For 
two-dimensional gel electrophoresis (2D-PAGE) 200 µg of the protein extracts were 
separated using non-linear immobilized pH gradients (IPG) in the pH range 4-7 for 
cytoplasmic proteins and 3-10 for extracellular and cell wall-associated proteins 
(Amersham Biosciences) and a Multiphor
 
II apparatus (Amersham Pharmacia 
Biotech) as described previously (1). The resulting 2D gels were fixed in 40% (v/v) 
ethanol, 10% (v/v) acidic acid and stained with Colloidal Coomassie Brilliant Blue 
(Amersham Biosciences). Quantitative image analysis was performed from the 
Coomassie-stained 2D gels using the DECODON Delta 2D software 
(http://www.decodon.com). For standard identification of the proteins from 2D gels, 
spot cutting, tryptic digestion of proteins and spotting of resulting peptides onto the 
MALDI-targets (Voyager DE-STR, PerSeptive Biosystems) the Ettan Spot Handling 
Workstation was used (Amersham-Biosciences, Uppsala, Sweden) (12). The MALDI-
TOF-TOF measurement of spotted peptide solutions was carried out on a Proteome-
Analyzer 4800 (Applied Biosystems, Foster City, CA, USA) as described previously 
(12).  
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Table 3.1. Strains and oligonucleotides used in this study. 
 
strains genotype, remarks, purpose reference, construction
1
 
 
W168 trpC2 BGSC no. 1A1 
CU1065 W168 trpC2 attSPß lab stock (30) 
Dap
R
1 W168 daptomycin resistant isolate this work 
HB0106 CU1065 bcrC::pMUTIN (8) 
HB0148 CU1065 ypbG::cat (9) 
HB0152 CU1065 yqjL::tet (9) 
HB0154 CU1065 yqjL::tet bcrC::pMUTIN (9) 
HB0332 CU1065 oppA::mini-Tn10 (spc
R
) (29) 
HB5140 W168 yokD::Tn7SX (spc
R
) this work 
HB5141 W168 yrkPQ:: LFH-PCR → W168 
HB5142 W168 yrkR:: LFH-PCR → W168 
HB5143 W168 yrkO::kan LFH-PCR → W168 
HB5144 W168 yrkN::kan LFH-PCR → W168 
HB5145 W168 ykcC::spec LFH-PCR → W168 
HB6050 CU1065 sdpI::mls (6) 
PS3301 gerF::ermC (17) 
 
no. name sequence
2
  
 
4788 yrkO-Up-Fwd 5-ATGGATCCTCTCCTCTTTCCACACCTCA-3 
4786 yrkO-Up-Rev(kan) 5-CCTATCACCTCAAATGGTTCGCTGGTCCAGAAAATGAACCCGTT-3 
4787 yrkO-Do-Fwd(kan) 5-CGAGCGCCTACGAGGAATTTGTATCGAAGCTGACGTACGGCAAAGT 
4789 yrkO-Do-Rev 5-AGAAGCTTCATCTTCGCAATCACCGAAC-3 
4792 yrkN-Up-Fwd 5-TCTGTTCCTCAGGTACGGAT-3 
4793 yrkN-Up-Rev(kan) 5-CCTATCACCTCAAATGGTTCGCTGGGCAGATCAGATTCCTTTGC-3 
4794 yrkN-Do-Fwd(kan)  5-CGAGCGCCTACGAGGAATTTGTATCGCGCAATGGACGTGAAGATGA-3 
4795 yrkN-Do-Rev 5-GATAAGCTCGCTGATCGTGA-3  
  
1Long-Flanking Homology (LFH-)PCR was applied as described previously to construct some of the deletions, 
using the primers listed. 
 2 Sequences complementary to antibiotic resistance cassettes for LFH-PCR are underlined. 
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Solexa Sequencing. Chromosomal DNA was isolated from W168 and Dap
R
1, 
quantified by Nanodrop and submitted for sequencing. Sequencing was performed by 
the Cornell University Life Sciences Core Laboratories Center on an Illumina GA2 
sequencer. The sequencing data was assembled using the W168 reference sequence 
with the Genebank accession number ABQK00000000 and aligned with MAQView. 
The sequencing coverage averaged 58-fold for W168 and 79-fold for Dap
R
1. 
 
3.3 Results and Discussion 
Isolation and phenotypical characterization of the daptomycin resistant 
strain Dap
R
1. In-vitro isolation of bacterial strains selected for antibiotic resistance 
allows studying mechanisms of resistance in a controlled environment. Here, we 
cultured a B. subtilis 168 wild-type strain continuously over 55 days with increasing 
daptomycin concentrations.  Starting with sub-inhibitory concentrations of daptomycin 
(0.5 µg/ml, corresponding to half the MIC), the concentrations were increased every 
day by 0.5 µg/ml, up to 27.5 µg/ml. This ending concentration was chosen arbitrarily. 
Further passage of the strain in LB without addition of daptomycin for 10 days was 
carried out to ensure that the resistance phenotype was a stable feature and not due for 
example to adaptation. This strain, named Dap
R
1, maintained its resistance to 
daptomycin at the selected concentration.  
While having a similar growth rate like its parent strain, Dap
R
1 lost two 
hallmarks of B. subtilis 168 - the ability to sporulate and natural competence. In 
addition, Dap
R
1 displayed cross-resistance to other cell envelope antibiotics. The MIC 
of Dap
R
1 increased two-fold compared to the parent strain when treated with the cell 
wall synthesis inhibitors vancomycin and bacitracin, or the pore former gramicidin. 
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Table 3.2. Minimum inhibitory concentrations of B. subtilis wild-type and Dap
R
1 with 
different antibiotics. 
Antibiotic W168
1
 Dap
R
1
1
 
Daptomycin 1.0 27.5 
Moenomycin
2
 10 >2000 
Vancomycin 0.2 0.4 
Bacitracin 500 1000 
Gramicidin 300 >600 
Fosfomycin 200 200 
Tunicamycin 0.2 0.2 
Ampicillin 20 20 
Penicillin G 0.1 0.1 
Nisin 90 100 
1 MIC in [µg/mL] was determined by liquid growth inhibition experiments. Data represent the mode of the lowest 
antibiotic concentration that led to complete growth inhibition (minimum of triplicates).  
2endpoint determined after 10h, all others after 24h. 
 
 
Table 3.3. Minimum inhibitory concentrations of B. subtilis mutants with daptomycin. 
Strain Daptomycin
1
 
W168 1.0 
CU1065 1.0 
Dap
R
1 27.5 
bcrC 0.7 
yqjL 1.1 
bcrC yqjL 1.2 
ypbG 0.9 
yrkPQ 0.9 
yrkR 1.0 
yrkO 0.9 
yrkN 0.9 
sdpI 1.0 
ykcC 1.0 
yokD 0.8 
oppA 0.7 
gerF (lgt) 0.8 
1 MIC in [µg/mL] was determined by liquid growth inhibition experiments. Data represent the mode of the lowest 
antibiotic concentration that led to complete growth inhibition after 24h (minimum of triplicates).  
  
Resistance to the transglycosylase inhibitor moenomycin was even more pronounced; 
the MIC increased more than 200-fold (Table 3.2, Table 3.3). Decreased susceptibility 
was not a universal feature with all cell envelope active compounds; the MIC of 
penicillin G, ampicillin, fosfomycin, and tunicamycin remained the same as wild-type. 
Taken together, Dap
R
1 was found to have decreased susceptibility to cell wall and cell 
membrane antibiotics, possibly indicating common resistance mechanisms, for 
instance changes in the cell envelope.  
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Fluorescence Microscopy shows increased insertion of Bodipy FL-labeled 
daptomycin in septa and poles of Dap
R
1. Light microscopic comparisons of Dap
R
1 
and its parent strain were inconclusive. In turn, fluorescence microscopic imaging 
depicts insertion of Bodipy Fl-labeled daptomycin in the septa and the poles of Dap
R
1 
(Fig. 3.1). The latter is surprising, because these results are in contrast to the parent 
strain, which had very low daptomycin insertion at old division septa or cell poles 
(16). Overall, the fluorescence intensity is lower in Dap
R
1, even with 10-fold higher 
concentration of Bodipy FL-labeled daptomycin compared to the wild-type. This 
implies that daptomycin is still able to insert albeit with a changed pattern, likely due 
to changes in the cell envelope of Dap
R
1. 
Electron Microscopy of Dap
R
1 reveals a thickened cell wall at the poles 
and irregular septum formation. In order to visualize alterations in the cell envelope 
of Dap
R
1, we performed transmission electron microscopy (TEM). TEM of thin 
sectioned cells showed striking aberrances of the cell wall of Dap
R
1 (Fig 3.2, Fig. 3.3). 
Whereas the wild-type cell has a characteristic rod-shape and regular septum 
formation, Dap
R
1 stands out with a thickened cell wall at the poles. On average, the 
lateral cell walls were slightly thinner than in W168 (1.3-fold), but the polar walls 
were 3.2-fold thicker than that of the parent strain (Table 3.4). W168 cells were 
slightly longer and thicker than Dap
R
1, 1.8 versus 1.7 µm long, respectively, and 0.6 
versus 0.5 µm in diameter. Of further notice is the septum placement in Dap
R
1. 
Invaginations and completed septa are formed aberrantly in Dap
R
1, indicating that the 
regulation and placement of the cell division apparatus is affected. 
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Figure 3.1. Daptomycin-BDP inserts in a spotted pattern and at cell poles and division 
septa in Dap
R
1. 
Fluorescent and DIC micrographs of Dap
R
1 stained with daptomycin-BDP (DAP-
BDP) and vancomycin-BDP (VAN-BDP). (A) Dap
R
1 treated with daptomycin-BDP at 
two-fold MIC for 10 minutes (during exponential growth phase). (B). Dap
R
1 treated 
with equal amounts of vancomycin and vancomycin-BDP for 20 minutes. (A) shows a 
spotted localization of daptomycin-BDP and preferential insertion at division septa 
and cell poles, similar to vancomycin-BDP (B). The arrowhead indicates cell poles, 
the arrow division septa. Scale bars represent 2 µm. 
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Together, these results are consistent with the notion of several mutations, but 
do not necessarily explain the resistance phenotype. A thicker cell wall was seen 
before in connection with vancomycin or daptomycin resistant S. aureus (7, 10). A 
partially thicker cell wall, only at the cell poles, has not been reported to our 
knowledge. Here, the increased thickness could pose a physical barrier for the tested 
antibiotics, leading to decreased susceptibility. In fact, this is supported by our 
observation of increased resistance to cell envelope active antibiotics of high 
molecular weight. Smaller antibiotics like penicillin G and ampicillin remained 
effective on Dap
R
1.  
The partially thicker cell wall and changes in septum formation let us wonder 
if the strain has alterations in its cytoskeleton, cell division, cell wall synthesis, or 
recycling apparatus. A defect in cell wall hydrolysis upon completion of cell division 
might result in the increased amount of peptidoglycan at the cell poles. A different 
explanation might be an elevated expression of cell wall synthesis proteins during cell 
division. It remains to be answered whether these alterations in the cell envelope 
architecture influence daptomycin insertion or mode of action. 
 
Table 3.4. Comparison of cell wall thickness of W168 and Dap
R
1. 
Thickness in µm
1
 n Mean SD Median Sum Minimum Maximum 
W168 wall
2
 16 0.038 0.006 0.038 0.614 0.030 0.053 
Dap
R
1 polar wall 18 0.121 0.034 0.126 2.181 0.074 0.221 
Dap
R
1 lateral wall 18 0.029 0.003 0.028 0.523 0.024 0.037 
1
 measured from transmission electron micrographs 
2 averages of lateral cell wall and polar cell wall 
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Figure 3.2. Transmission electron micrographs (TEM) of W168. 
TEM of thin sliced W168 with regular septation and cell wall in the characteristic rod-
shaped B. subtilis wild-type strain. The arrows indicate: CW=cell wall, CM=cell 
membrane, S=septum, P=pole. Scale bars represent 0.1 µm (except for bottom left, 0.2 
µm). 
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Figure 3.3. TEM of Dap
R
1 reveal a thicker cell wall at the poles and irregular septum 
placement compared to W168 (Fig. 3.2). 
 Dap
R
1 TEM with asymmetrical, aberrant septum placement and thicker cell wall at 
the cell poles and division septa. Overall, 68% of cells (n=142) displayed aberrant 
septa and thickened cell wall. The arrows indicate: CW=cell wall, CM=cell 
membrane, S=septum, P=pole. Scale bars represent 0.1 µm (except for bottom right, 
1.0 µm). 
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Transcriptomic and proteomic comparison of W168 and Dap
R
1 reveals 
differences in expression. To determine gene expression levels in Dap
R
1 and obtain 
clues about possible changes on a genetic level that might lead to daptomycin 
resistance we conducted microarray based expression profiling of Dap
R
1 and its parent 
strain. We isolated total RNA from Dap
R
1 and W168 wild-type from exponentially 
growing cultures. The resulting microarrays revealed significant changes on gene 
expression levels between Dap
R
1 and W168. Several genes with products involved in 
cell wall and teichoic acid synthesis were expressed more strongly in Dap
R
1. In turn, 
genes encoding for metabolic proteins (e.g. maltose or ribose transporters) and 
surfactin synthases, competence and sporulation proteins were expressed at a higher 
level in the wild-type (Appendix, Table S3.1, Fig. 3.4). The latter is consistent with 
the loss of competence and sporulation deficiency in Dap
R
1. 
Most strongly expressed in Dap
R
1 are the genes encoding the YrkPQ two-
component system and its regulon members: yrkR, yrkO, yrkN, ykcB, ykcC. The 
regulation of the two-component system has been studied by Ogura et al (24). The 
YrkP response regulator autoregulates the yrkPQR operon, and induces expression of 
yrkO, yrkP, and ykcBC. YrkR is homolog to PsiE (phosphate starvation inducible 
protein E), YrkO is a conserved membrane protein with similarity to a transporter, 
YrkN has similarity to an acetyltransferase, YkcB and YkcC are conserved membrane 
proteins with similarities to glycosyl transferases. In addition, the LiaRS two-
component system regulon members are expressed to a higher level in Dap
R
1. 
Previously, they were shown to be induced upon daptomycin treatment. The PspA 
family protein LiaH protects against daptomycin, like its homolog in Escherichia coli 
which was shown to protect against membrane perturbing agents (11, 20). 
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Figure 3.4. Comparison of Dap
R
1 and W168 transcriptome. 
The scatterplot represents expression levels of untreated mid-log cultures of B. subtilis 
Dap
R
1 versus W168 of triplicate microarray analyses. The legend lists highly 
expressed genes, in part grouped by their corresponding transcriptional regulators.  
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Figure 3.5. Dap
R
1 and W168 gene expression ratios after daptomycin treatment. 
The graph represents expression ratios of mid-log cultures of B. subtilis Dap
R
1 versus 
W168 treated with daptomycin for 20 minutes at MIC levels (average of triplicate). 
Shown are only genes with a fold change >2 or <0.5. 
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Next, we were interested to see the changes on the transcriptomic level upon 
treatment with daptomycin (Appendix, Table S3.2, Fig. 3.5). Compared to the parent 
wild-type strain, Dap
R
1 showed a weaker induction of the LiaRS two-component 
system including the regulon members. This can in part be explained by the fact that 
this regulatory system is already expressed to a high level in the mutant without 
treatment. A number of genes are induced in the wild-type, but are already expressed 
at a higher basal level in Dap
R
1 without daptomycin treatment: yqjL (hydrolase; 
paraquat resistance), bcrC (bacteriocin transport permease), ypbG (marker for 
inhibition
 
of cell wall biosynthesis), maf (cell division and shape determination), murB 
(UDP-N-acetylenolpyruvoyl glucosamine reductase), murG (peptidoglycan 
biosynthesis), and sigM (ECF  factor). They are all involved in cell wall metabolism 
and could in part be responsible for the cell wall changes in Dap
R
1. When tested for 
daptomycin susceptibility, deletion mutants of the above mentioned strains did not 
have a strong effect (Table 3.3). A bcrC deletion strain was slightly more sensitive to 
daptomycin with an MIC of 0.7 µg/mL, compared to W168 MIC of 1.0 µg/mL, but the 
other strains were close to wild-type within a 0.1 to 0.2 µg/mL range. 
Proteomic analysis of Dap
R
1. Differences on a transcriptomic level might not 
necessary reflect changes of the cellular proteome, especially as potential mutations 
can affect protein levels. Therefore, we set out to compare the cytosolic proteome, the 
extracellular proteome, and the cell wall proteome of Dap
R
1 and W168 wild-type (Fig. 
3.6-3.8). Proteins that also exhibited elevated gene expression in the corresponding 
microarray experiment are marked in Tables 3.5 and 3.6. Overall a lower number of 
proteins was changed; however, the proteins with the strongest changes in the 
proteomic analysis were also amongst the ones with the strongest expression changes 
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in the transcriptional studies. One strongly expressed protein was OppA, a binding 
protein of an oligopeptide ABC transporter. A deletion mutant of oppA was slightly 
more susceptible to daptomycin with an MIC of 0.7 µg/mL. 
 Interestingly, the exoproteome of Dap
R
1 resembled that of an lgt deletion 
mutant (1). This mutant was shown earlier to cause shedding of at least 23 
(lipo)proteins into the medium. The lipoproteine diacylglyceryl transferase (Lgt) 
modifies a cysteine residue in the lipobox of secretory lipoprotein precursors. Once 
exported, this lipid-modified cysteine residue serves to anchor the proteins to the 
membrane (28). Lgt, also called GerF, was not strongly altered in the microarray or 
proteomic analysis. However, this finding let us to test an lgt deletion strain for 
daptomycin susceptibility. With an MIC of 0.8 µg/mL it was slightly more susceptible 
than the wild-type. The strong resemblance of the two proteome gels led us wonder if 
Dap
R
1 has a mutation in lgt, but this was not the case (see below). 
Solexa sequencing of Dap
R
1. Attempts to transfer the resistance phenotype of 
Dap
R
1 to wild-type or to map the mutations in Dap
R
1 by classical methods had failed. 
Therefore we mapped the mutations of this strain using Solexa/Illumina sequencing 
(http://www.illumina.com/) against the parent strain. We chose Solexa over other 
methods, because multiple B. subtilis 168 reference sequences are published, 
facilitating the assembly of sequencing reads. Even though the reads are shorter than 
with 454-based sequencing, the coverage is very high, and it is more accurate in 
detecting single nucleotide polymorphisms (SNP). Both sequences were assembled 
with MOSAIC using the published B. subtilis sequence with the Genebank accession 
number ABQK00000000 and aligned with MAQView. The sequencing coverage was 
relatively high, averaging 58-fold for W168 and 79-fold for Dap
R
1. 
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Figure 3.6. Cytoplasmic proteome. 
Dual-channel image of the cytoplasmic proteome of Dap
R
1 (red image) in comparison 
to W168 (green image). B. subtilis strains were grown in LB-broth and harvested 
1 hour after entry into the stationary phase at OD540=3.0. Cytoplasmic protein extracts 
were separated using 2D PAGE in the pH range 4-7 and the resulting 2D gels were 
stained with Coomassie Brilliant Blue. Quantification of the dual channel image was 
performed using the Decodon Delta 2D software (http://www.decodon.com). Proteins 
were identified using MALDI-TOF mass spectrometry as described previously (12). 
Proteins that display changed ratios in Dap
R
1 compared to W168 are labeled in red 
(induced in Dap
R
1) and green (repressed in Dap
R
1). The respective protein induction 
and repression ratios of these proteins are listed in Table 3.7. 
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Figure 3.7. Extracellular proteome. 
Dual-channel image of the extracellular proteome of Dap
R
1 (red image) in comparison 
to W168 (green image). B. subtilis strains were grown in LB-broth and harvested 
1 hour after entry into the stationary phase at OD540=3.0. Extracellular proteins of the 
supernatant were precipitated with TCA and separated using 2D PAGE in the pH 
range 3-10 (1) and identified using MALDI-TOF mass spectrometry 
(12).Quantification of the dual channel image was performed using the Decodon Delta 
2D software (http://www.decodon.com). Proteins with induced ratios in Dap
R
1 
compared to W168 are labeled in red. The expression ratios are listed in Table 3.8. 
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Figure 3.8. Cell wall proteome. 
Dual-channel image of the cell wall proteome of Dap
R
1 (red image) in comparison to 
W168 (green image). B. subtilis strains were grown in LB-broth and harvested 1 hour 
after entry into the stationary phase at OD540=3.0. The cell wall-associated proteins 
were obtained after LiCl extraction from whole cells, precipitated with TCA and 
separated using 2D PAGE in the pH range 3-10 (1).The major cell wall-associated 
proteins (WapA, WprA) that are decreased in the cell wall fraction of Dap
R
1are 
labeled in green. Note that cytoplasmic proteins accumulate in the acidic region (right) 
due to increased lysis in the cell wall proteome. 
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Table 3.5. Fold change of cytosolic protein expression of Dap
R
1 and W168 without 
daptomycin treatment. 
Protein Ratio 
Dap
R
1/W168 
Protein Function 
YrkN 5.97* GCN5-related N-acetyltransferase 
YrkP 2.43* TCS, response regulator 
MurB 4.56* peptidoglycan synthesis 
YurP 4.29 fructoselysine-6-P-deglycase 
Abh 3.47* transcriptional regulator of transition state genes (AbrB-like) 
AbrB 2.17* transcriptional pleiotropic regulator of transition state genes 
YceC 2.62 tellurium resistance protein 
YceH 2.16* similar to toxic anion resistance protein 
YacK 2.35 DNA integrity scanning protein DisA 
YhfJ 1.83 similar to lipoate-protein ligase 
AtpF 0.67 ATP synthase (subunit b) 
CspC 0.32 cold-shock protein 
CspD 0.63 cold-shock protein 
YugI 0.60 putative RNA degradation protein 
Spo0A 0.50 TCS response regulator central for the initiation of sporulation 
Kbl 0.50 2-amino-3-ketobutyrate CoA ligase 
PpaC 0.41 inorganic pyrophosphatase 
MelA 0.36* α -D-galactoside galactohydrolase 
RbsB 0.34 ribose ABC transporter (ribose-binding protein) 
GapB 0.23 glyceraldehyde-3-phosphate dehydrogenase 
PyrG 0.49 CTP synthetase 
PyrAB 0.28 carbamoyl-phosphate synthetase (catalytic subunit) 
PyrAA 0.20 carbamoyl-phosphate synthetase (glutaminase subunit) 
 * genes also induced/repressed in Microarray 
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Table 3.6. Fold change of extracellular protein expression of Dap
R
1 and W168 
without daptomycin treatment. 
Protein Ratio 
Dap
R
1/W168 
Protein Function 
YnfF 17.56 endo-xylanase 
OppA 14.16 oligopeptide ABC transporter (binding protein) 
YhfQ 13.52 iron(III) dicitrate-binding protein 
FeuA 11.09 iron-uptake system (binding protein) 
FhuD 8.46 ferrichrome ABC transporter (ferrichrome-binding protein) 
PenP 7.84 beta-lactamase precursor 
MntA 7.18 manganese ABC transporter (membrane protein) 
YxeB 6.29 ABC transporter (binding protein) 
PbpC 5.78 penicillin-binding protein 3 
PbpA 5.70* penicillin-binding protein 2A 
BglC 3.88 endo-1,4-beta-glucanase 
RbsB 3.68* ribose ABC transporter (ribose-binding protein) 
YfiY 3.25 iron(III) dicitrate transport permease 
YodJ 3.17 D-alanyl-D-alanine carboxypeptidase 
YusA 1.71 methionine-binding lipoprotein MetQ 
XynD 1.55 endo-1,4-beta-xylanase (xylanase D) 
AmyE 1.29 alpha-amylase 
GlpQ 1.29 glycerophosphoryl diester phosphodiesterase 
YweA 1.10 member of the processed secretome 
Pel 0.97 pectate lyase 
Csn 0.93 chitosanase 
YwtD 0.82 murein hydrolase 
WapA 0.78 cell wall-associated protein precursor 
AprE 0.75 serine alkaline protease (subtilisin E) 
AbnA 0.71* arabinan-endo 1,5-alpha-L-arabinase 
NprE 0.62 extracellular neutral metalloprotease 
XynA 0.62 endo-1,4-beta-xylanase 
YfnI 0.51* glycerol phosphate lipoteichoic acid synthetase 
YxaL 0.50 similar to serine/threonine protein kinase 
Hag 0.49 flagellin protein 
YolA 0.49 SPBc2 prophage-derived uncharacterized protein 
XkdK 0.48* phage-like element PBSX protein 
YwoF 0.46 putative pectate lyase 
YlqB 0.42* hypothetical protein 
KatA 0.32 vegetative catalase 
 * genes also induced/repressed in Microarray 
 
Overall, Dap
R
1 was found to carry 44 point mutations, of which 31 lead to a 
change of amino acid sequence (Table 3.8). As this is a high number of mutations, it is 
quite possible that many mutations occurred at random or to compensate for others, 
and are not responsible for resistance or the changed phenotype of Dap
R
1. Three of the 
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31 SNPs in protein encoding genes are in essential genes, nusA, mreB, and pgsA, 
suggesting that they are mutations that alter protein activity. From the proteins that are 
affected by mutations, the SNPs in pgsA, ywnE, or mreB, are the most interesting ones 
that could have an effect on daptomycin resistance. We previously found a significant 
increase in daptomycin resistance upon depletion of the essential phosphatidyl 
glycerol synthase PgsA. This increased resistance could be due to a decrease in 
negatively charged lipids resulting in a stronger repulsion towards a calcium-
daptomycin complex. We assume that this point mutation in Dap
R
1 decreases protein 
activity without completely abolishing its function, because the strain is still viable 
with a similar growth rate like wild-type. Similarly, a mutation in ywnE which is 
involved in the production of the negatively charged membrane lipid, cardiolipin, 
could contribute to the repulsive effect. It is also worth noting that cardiolipin is a 
major component of the spore membrane (19).  
 Another mutation is in the essential protein MreB, which is involved in cell 
shape maintenance. The electron micrographs clearly show an altered cell shape for 
Dap
R
1. Again, altered protein activity might be the case. Further interesting mutations 
are upstream of murB, and in the promoter region of yrkO, which could alter gene 
expression. Indeed, the microarrays show higher expression of both genes in Dap
R
1.  
Peptidoglycan analysis. The drastic changes of the cell wall of Dap
R
1, as 
observed with electron microscopy, inspired us to perform peptidoglycan analysis of 
this strain to study its cell wall composition. Two independent methods, HPLC and 
incorporation and turnover of 
14
C labeled N-acetylglucosamine were used to quantify 
muropeptides of the cell wall (Fig. 3.9). To our surprise, Dap
R
1 did not stand out with 
a higher amount of muropeptides, when tested at different growth stages (early 
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exponential phase to stationary phase). This was confirmed by measuring muramic 
acids and di-amino-pimelic acids, which also were not significantly different from 
wild-type (data not shown). The thicker cell wall in Dap
R
1 could thus be explained by 
several ideas. First, experimental lysis of the thicker cell wall of Dap
R
1 could have 
been not as complete as that of wild-type, resulting in artificially lower values for 
measured peptidoglycan. This seems rather unlikely, as the samples were boiled in 
SDS for 30 minutes. Second, Dap
R
1 perhaps does not contain much more 
muropeptides than the wild-type, as the increased thickness is localized only to the cell 
poles and does not surround the whole cell (the side walls were slightly thinner than in 
the wild-type). On average this might be evened out. Third, cell wall is not only 
composed of peptidoglycan; increased thickness might perhaps be due to teichoic 
acids, proteins, etc. To get a clearer image, further testing of cell wall components 
could be done. 
 
 91 
Table 3.7. Single nucleotide polymorphisms in intergenic or protein coding regions. 
# Gene Amino 
Acid 
change 
Position 
within gene 
Function of Gene Product 
1 trnSL-Glu2 - 12 of 69 transfer RNA-Glu 
2 intergenic - 116bp us 116 bp upstream of start site of ydjC (unknown) 
3 guaA P477S 1429 of 1539 GMP synthetase 
4 yfhP R175H 524 of 981 unknown, may be a negative regulator for transcription of yfhQ, 
fabL, sspE and yfhP; σK-dependent promoter, similar to metal-
dependent hydrolase  
5 intergenic - 225bp us 225 bp upstream of trnSL-Gly1 (transfer RNA-Gly) 
6 intergenic - 392bp us 392 bp upstream of yhxA (similar to adenosylmethionine-8-
amino-7-oxononanoate aminotransferase) 
7 citR V50G 150 of 924 transcriptional repressor of the citrate synthase I (citA) 
8 med V151I 451 of 951 positive regulator of comK, upstream of comZ 
9 motB A222T 664 of 783 motility protein (flagellar motor rotation) 
10 intergenic - 372bp us 372 bp upstream of rok (repressor of comK) 
11 intergenic - 370bp us 370 bp upstream of rok (repressor of comK) 
12 ylbK A111V 332 of 780 similar to serine protease or patatin-like phospholipase 
13 intergenic - 26bp us 26 bp upstream of murB (UDP-N-acetylenolpyruvoyl-
glucosamine reductase) 
14 intergenic - 137bp us 137 bp upstream of fliK (flagellar hook-length control) 
15 nusA* Q112R 335 of 1113 transcription termination 
16 pgsA* A64V 191 of 579 acidic phospholipid biosynthesis 
17 odhA S573T 1717 of 2823 2-oxoglutarate dehydrogenase (E1 subunit) 
18 kdgA P115S 343 of 588 2-keto-3-deoxygluconate-6-phosphate aldolase (σA-dependent) 
19 qcrC V210I 628 of 765 menaquinol:cytochrome c oxidoreductase 
20 qcrB H35Y 103 of 672 menaquinol:cytochrome c oxidoreductase 
21 serA R157G 469 of 1575 serine biosynthesis, phosphoglycerate dehydrogenase 
22 intergenic - 72bp us 72 bp upstream of bmrU (multidrug resistance protein)  
23 nusB N73D 217 of 393 transcription antitermination 
24 spoIIIAA R85G 253 of 921 stage III sporulation, mutants block sporulation after 
engulfment, mother-cell specific 
25 yqeG F5V 15 of 516 similar to HAD family phosphatase 
26 yqeB T95S 283 of 723 similar to ribosomal protein L29 
27 intergenic - 78bp us 78 bp upstream of yrkO (put. membrane protein), regulated by 
YrkPQ TCS 
28 intergenic - 101bp ds 101 bp downstream of yrhP, 10 bp downstream of aapA (amino 
acid permease) 
29 intergenic - 102bp ds 102 bp downstream of yrhP (homoserine/threonine efflux 
protein) 
30 yrhH A171T 511 of 540 similar to methyltransferase 
31 yrrC E795G 2384 of 2394 similar to exodeoxyribonuclease V alpha subunit 
32 yrrC M659K 1976 of 2394 similar to exodeoxyribonuclease V alpha subunit 
33 relA P305S 913 of 2202 GTP pyrophosphokinase, stringent response, mutant results in 
lowered induction of proteins involved in stress response and 
amino acid biosynthesis 
34 relA R177H 530 of 2202 GTP pyrophosphokinase, stringent response 
35 mreB* A139V 416 of 1011 cell-shape determining protein 
36 intergenic - 68bp us 68 bp upstream of araA (L-arabinose isomerase converts D-
galactose into D-tagatose) 
37 ytbE W127R 379 of 840 similar to 2,5-didehydrogluconate reductase 
38 ytbJ R354Q 1061 of 1074 similar to thiamin biosynthesis 
39 ytdP E479G 1436 of 2316 similar to transcriptional regulator (AraC/XylS family) 
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Table 3.7. (Continued) 
# Gene AminoAcid 
change 
Position 
within gene 
Function of Gene Product 
40 cssS V342A 1025 of 1353 TCS HK, phosphorylates CssR, involved in cellular responses to 
protein secretion stress 
41 rnr T550M 1649 of 2337 ribonuclease R, nonspecific degradation of rRNA, 3'-5' 
exoribonuclease activity 
42 yvjB G344E 1031 of 1440 similar to carboxy-terminal processing protease 
43 ywnE I23T 68 of 1446 cardiolipin synthase 
44 tyrZ T9A 25 of 1239 tyrosyl-tRNA synthetase, minor; expressed when TyrS 
inactivated 
* essential 
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Table 3.8. Fatty acid methyl esther analysis of B. subtilis wild-type and Dap
R
1. 
Fatty Acid 37°C 25°C 
[% content] W168 Dap
R
1 W168 Dap
R
1 
10:00 0.19 0.07 0.16 0.06 
12:00 0.23 0.11 0.26 0.16 
13:0 iso 0.13 0.15 0.13 0.11 
13:0 anteiso 0.07 0.09 0.08 0.09 
14:0 iso 1.28 0.57 0.88 0.35 
14:1 ω5c 0 0 0.08 0 
14:00 0.50 0.33 0.33 0.31 
15:0 iso 15.70 17.32 15.64 14.15 
15:0 anteiso 39.30 36.87 42.21 42.29 
16:1 ω7c alcohol 0.12 0.17 0.93 0.55 
16:0 iso 5.15 2.38 3.13 1.26 
16:1 ω11c 0.27 0.54 1.91 2.17 
16:1 ω5c 0 0 0.08 0 
16:00 5.07 3.48 3.38 2.61 
17:1 iso ω10c 0.34 1.02 2.78 3.78 
17:0 iso 12.93 16.42 8.89 8.49 
17:0 anteiso 16.51 18.01 15.08 17.89 
17:00 0.19 0 0.11 0 
17:0 2OH 0 0 0.14 0 
18:1 ω9c 0.23 0.21 0.25 0.26 
18:0 iso 0.15 0.10 0 0 
18:00 0.75 0.78 0.60 0.62 
19:0 iso 0.12 0.26 0 0.13 
19:0 anteiso 0.15 0.26 0.11 0.20 
 
Analysis of membrane fatty acids. The length and saturation status of 
phospholipids affects the physical properties of the bacterial cell membrane. The 
transcriptomic analysis has shown that the desaturase gene des is expressed to a higher 
level in Dap
R
1, and we have found earlier an involvement of Des in daptomycin 
susceptibility (16). To test whether the saturation level or fatty acid composition is 
altered in Dap
R
1, we submitted samples to Microbial ID for fatty acid methyl ester 
analysis (FAME) at 37
 o
C and 25
 o
C (Table 3.8). Overall, the composition and 
saturation of fatty acids in Dap
R
1 or W168 was quite similar. At 37
 o
C, Dap
R
1 showed 
a slight shift to longer fatty acids, with a decrease in C15 (15:0 anteiso) and increase in 
C17 (17:0 iso). At 25
 o
C, however, where an effect from the desaturase should be most 
pronounced, a slight shift to longer fatty acids can be seen again, but no increase in 
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saturation is visible when compared to W168. In contrast to the visible changes in the 
cell wall, the membrane phospholipid composition of Dap
R
1 is very similar to that of 
its parent strain. 
 
3.4 Conclusions.  
One approach to study resistance to antimicrobial compounds is the 
characterization of clinical isolates of pathogenic strains, another makes use of 
evolving resistance in vitro through serial passage experiments. The latter serves as a 
controllable tool to monitor development of resistance over time. It is limited by the 
experimental set-up which does not reflect conditions present in patients or even 
conditions in nature (where antibiotics produced by micro-organisms might actually 
function as signaling molecules rather than killing factors). 
 
 
Figure 3.9. Muramic acid quantification in Dap
R
1 and W168. 
The x-axis corresponds to five sampling time points between OD600 of 0.3 and 3.0. 
The y-axis quantifies muramic acid normalized over optical density. 
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 Also, the possibility of horizontal gene transfer is very limited under the present 
conditions. Nonetheless, we can learn a great deal from the frequency and amplitude 
of resistance. Here, we have used the Gram positive model bacterium B. subtilis to 
investigate daptomycin resistance.  
The complex phenotype of the isolate Dap
R
1 implied that more than one 
mutation is needed for daptomycin resistance. This idea was supported by our inability 
to transform the resistance phenotype from Dap
R
1 to W168 wild-type. Similarly, 
attempts in our laboratory to select for resistance to daptomycin using transposon 
mutagenesis have been unsuccessful. Earlier, several mutations were found in S. 
aureus strains which were isolated with increasing daptomycin concentrations (14). 
Surprisingly, amongst the 44 point mutations in Dap
R
1 was not a single one that was 
found previously in daptomycin resistant S. aureus, indicating the diversity between 
different bacterial species, and perhaps different mechanisms of daptomycin 
resistance. 
The ease with which this resistant strain was obtained does not necessarily 
reflect a frequent occurrence of resistance in clinical settings, in particular as this 
study was done with the non-pathogenic B. subtilis, and as the incubation was 
performed continually over 55 days (much longer than average treatment in a patient). 
However, it should not be disregarded; instead, similar studies done with pathogenic 
strains, like (14), might uncover parallel resistance mechanisms that can be taken into 
account when considering treatment options or when developing new antibiotics. 
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CHAPTER 4 
Tn7SX TRANSPOSON MUTAGENESIS: A TOOL TO STUDY ANTIBIOTIC 
RESISTANCE MECHANISMS IN BACILLUS SUBTILIS 
 
Occurrence of antibiotic resistance is an increasing concern during 
chemotherapy. Understanding mechanisms causing the resistance can be valuable to 
target antimicrobial therapy more specificly, and for the design of new antibiotics to 
circumvent, or delay the development of resistance. In an effort to learn more about 
resistance to cell envelope active antibiotics, we have used Tn7SX transposon 
mutagenesis in the Gram-positive model bacterium Bacillus subtilis. Two main 
features of Tn7SX can result in decreased susceptibility: the transposon can insert into 
a gene and thereby, for instance, disrupt an antibiotic target, or it can lead to 
overexpression of downstream genes via its xylose inducible promoter, thereby 
initiating other ways of resistance. As a proof-of-principle we show that the 
transposon inserted multiple times independently into the pssA-ybfM-psd operon when 
selecting for duramycin resistance. The pssA operon synthesizes the membrane lipid 
target of duramycin, phosphatidyl ethanolamine. In addition, we obtained transposon 
insertions in 25 different genes that each conferred resistance to the transglycosylase 
inhibitor moenomycin. Moreover, coupling Tn7SX with replica plating allowed us to 
screen for increased susceptibility to the cell wall synthesis inhibitor fosfomycin. This 
type of screen could potentially identify new antibiotic targets demonstrating the 
versatility of the Tn7SX transposon mutagenesis system. 
The majority of the studies in this chapter were performed by A. B. Hachmann, 
Christophe Bordi (Aix-Marseille Université, France) contributed to the identification 
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of duramycin-resistant transposants, and Michael Somuah (Kentucky State University) 
assisted with the fosfomycin susceptibility screening. Parts of the results of this study 
were published in C. Bordi, B. G. Butcher, Q. Shi, A. B. Hachmann, J. E. Peters, and 
J. D. Helmann. 2008. Appl Environ Microbiol 74:3419-25. 
 
4.1 Introduction 
Transposon mutagenesis serves as a valuable genetic tool for a variety of 
applications. The Tn7SX transposon mutagenesis system (Fig. 4.1) (6), adapted from 
the Tn7 transoposon and the EZ::TN transposase system by GeneHunter (50, 59), is 
characterized by high efficiency of transposition and random and stable insertions (6). 
Genes disrupted by the transposon can be identified for instance as antibiotic targets. 
Addition of xylose induces a PxylA promoter in the transposon and can result in 
overexpression of downstream genes, thereby allowing for the identification of genes 
that can confer resistance to certain stresses.  
We have used Tn7SX in Bacillus subtilis to discover resistance mechanisms to 
cell envelope active antibiotics. Here, we discuss Tn7SX insertions which we found to 
confer resistance to the cell envelope synthesis inhibitors moenomycin, penicillin G, 
cephalosporin C, and duramycin. In addition, we have used this system to screen for 
increased antibiotic susceptibility. We have found multiple ways in which cells can 
become more sensitive to the cell wall synthesis inhibitor fosfomycin, providing more 
details about mechanisms of detoxification.  
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Figure 4.1. The Tn7SX transposon.  
Insertions by Tn7SX can either disrupt gene function, or conditionally activate 
expression of downstream genes in the presence of xylose. 
 
4.2 Materials and Methods 
 Bacterial strains and growth conditions. Bacteria were cultured at 37°C with 
vigorous shaking using Luria Bertani (LB) as growth medium.The following 
antibiotics were used for selection when necessary: spectinomycin 100 g/mL, 
kanamycin 10 g/mL, chloramphenicol 10 µg/mL, tetracycline 20 µg/mL, and 
erythromycin 1 µg/mL with lincomycin 25 µg/ml (mls: macrolide-lincomycin-
streptogramin B resistance). The strains used in this study were derived from Bacillus 
subtilis wild-types W168 (trpC2) and CU1065 (W168 trpC2 attSPβ) and are listed in 
Table 4.1 and Table 4.4. Gene deletions were generated by replacing open reading 
frames with antibiotic resistance cassettes using long-flanking-homology PCR (42, 
68). Moenomycin was kindly provided by Biovet JSC (Bulgaria).  
 Minimal inhibitory concentrations (MIC) were determined by diluting 
overnight cultures 1:100, growing to OD600 of 0.4, and re-diluteding to 5 x 10
5
 
CFU/mL in microtiter plates with a total inoculum of 200 µL. Growth was measured 
spectrophotometrically (OD600) using a Bioscreen incubator (Growth Curves USA, 
Piscataway, NJ) at 37°C with vigorous shaking. The absorbance was recorded every 
20 minutes for 24 hours. Inhibition was defined as a final OD600 < 0.05 (at the 24 hour 
time point). In most cases, B. subtilis wild-type or mutants treated with moenomycin 
did not result in a clear determinable MIC, but rather in a delayed lag phase. After 24h 
W168 was able to grow even with addition of 500µ/ml or 2000µ/ml moenomycin. 
Here, to compare different mutants, we used the ability to outgrow a certain 
moenomycin concentration after a particular time as a measure of susceptibility.  
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(additionol strains are listed in Table 4.4) 
strains genotype, remarks, purpose reference, construction 
 
W168 trpC2 BGSC no. 1A1 
CU1065 W168 trpC2 attSPß lab stock (67) 
DPVB49  ΔpbpD pbpG::kan pbpF::Ermr (44) 
HB0031 CU1065 sigM::kan (12) 
  
 
Tn7SX transposon mutagenesis. The pTn7SX transposon is characterized by 
a spectinomycin resistance marker and a xylose inducible promoter PxylA, adapted 
from the EZ::TN transposase system by GeneHunter (Fig. 4.1) (59). For in-vitro 
transposon reactions proteins TnsA, TnsB, and TnsC
*
 were used (Table 4.2). TnsC
*
 
carries an A225V gain-of-function mutation, resulting in loss of target specificity. For 
further details about this system see reference (6). We obtained a random and highly 
efficient transposition with approximately 55,000 clones per reaction, on average 
corresponding to one insertion per 75 base pairs. 
Selection of duramycin-resistant mutants. The in-vitro transposition reaction 
was performed as described in (6). After gap-repair, the transformation of the 
transposition library into B. subtilis CU1065 cells was plated on solid LB containing 
spectinomycin and xylose to select for duramycin-resistant (Dur
r
) mutants. After 
incubation for 5 h at 37°C, these plates were overlaid with 5 ml of soft LB agar (0.7%) 
containing spectinomycin, xylose, and 6 μg/ml duramycin and incubated at 37°C 
overnight. Clones were checked for insertion of Tn7SX into the pssA operon by PCR 
with primers 2369 and 1916. MICs for these resistant mutants and wild-type B. 
subtilis were determined by growth (optical density at 600 nm) after incubation 
overnight at 37°C in microtiter plates with LB containing 0, 1, 1.5, 2, 5, 20, 30, 40, 50, 
75, 100, 150, and 200 μg/ml duramycin and either 2% xylose or glucose.  
Table 4.1. Strains and oligonucleotides used in this study. 
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Selecting of moenomycin resistant mutants. This selection was carried out 
on LB agar plates with different concentrations of moenomycin using an amplified 
version of the Tn7SX library. Therefore, random Tn7SX in-vitro reaction was 
performed as described previously (6), with the following modifications. Two 
reactions were transformed into W168, grown over night in 20ml LB, combined, and 
chromosomal DNA was extracted. This was repeated with cultures grown with 2% 
xylose in order to induce the PxylA promoter of the transposon. The libraries of 
chromosomal DNA were used to transform the transposon into different background 
strains (W168, CU1065, sigM, pbpDFG; Table 4.4). Most mutants were obtained by 
selecting at 0.4µg/ml moenomycin and 2% xylose, mutants M36 - M50 were selected 
at 10µg/ml , and M51-M56 at 1µg/ml. Mutants M89-M95 were obtained  directly after 
in-vitro transposition and selected at 10µg/ml moenomycin. Mutants were confirmed 
by sequencing, linkage tests, and growth inhibition studies. 
Screening of fosfomycin-sensitive mutants. Fosfomycin-sensitive (Fos
S
) 
mutants were selected by plating B. subtilis W168 transformed with the amplified 
Tn7SX transposition library on solid LB plates containing spectinomycin, with or 
without 2% xylose. Supsequent transfer of the colonies into microtiter plates and 
replica plating on plates containing 30 μg/ml fosfomycin was used as a measure to 
identify fosfomycin sensitive mutants. MICs of these mutants were determined as 
described above (for duramycin), with the following concentrations of fosfomycin: 0, 
10, 20, 30, 40, 50, 60, 70, 80, 100, 150, and 200 μg/ml. Insertions are summarized in 
Table 4.7. 
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Table 4.2. Tn7 proteins and their roles during transposition. 
Protein Function Biochemical activities Structural motifs or 
homologs 
TnsA transposase subunit cutting at the 5’ ends of Tn7 Type II restriction enzymes 
TnsB transposase subunit cutting and joining at the 3’ 
ends of Tn7 
retroviral integrases and 
transposase DDE motif 
TnsC regulator/connector ATP-dependent DNA 
binding and ATP hydrolysis 
nucleotide-binding motif 
TnsD target selection – 
recognition of attTn7 
sequence-specific DNA 
binding 
none 
TnsE target selection – conjugal 
replication/lagging-strand 
DNA synthesis 
structure-specific DNA 
binding: 3’ recessed ends 
none 
Table adapted from Peters et al. (50) 
 
4.3 Results and Discussion 
Isolation of duramycin-resistant mutants. We used the Tn7SX transposon 
system to isolate mutants with increased resistance to the lantibiotic duramycin. 
Duramycin is a 10-amino-acid tetracyclic peptide produced by Streptoverticillium 
cinnamoneum that binds exclusively to ethanolamine phospholipids (29). Duramycin-
resistant B. subtilis mutants have little or no phosphatidylethanolamine (PE) and 
cardiolipin, but the mutant loci were not determined (16). 
Our first attempts to isolate Dur
r
 mutants by plating the B. subtilis 
transformants directly on duramycin-containing LB plates failed. Since duramycin 
resistance appears to be conferred by a change in membrane composition, we 
hypothesized that our method did not allow for sufficient growth in the absence of 
selection for the effects of Tn7SX insertions to manifest themselves as changes in the 
membrane lipid composition. Therefore, we plated the transformed cells on LB agar 
containing spectinomycin (for selection of the mutants) and xylose (to allow for 
upregulation from the PxylA promoter) and incubated these plates for 5 h to allow time 
for potential alterations in membrane composition to become manifest. These plates 
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were then overlaid with 0.7% soft LB agar containing spectinomycin, xylose, and 6 
μg/ml duramycin and incubated overnight. We obtained 60 clones resistant to 
duramycin upon restreaking on plates containing 10 μg/ml duramycin. 
Since the pssA-ybfM-psd operon is required for the synthesis of PE and 
cardiolipin, we checked whether any of these mutations were at this locus and found 
that 53 of the 60 clones gave a PCR product consistent with insertion of Tn7SX within 
this region. We prepared chromosomal DNA from 10 of the 53 putative pssA-ybfM-
psd::Tn7SX clones and used this to transform B. subtilis CU1065. Transformants were 
selected on spectinomycin, and in all cases subsequent testing revealed that these 
transformants were resistant to more than 200 μg/ml duramycin. This confirmed that 
the resistance phenotype was linked to disruption of the pssA operon by Tn7SX. 
Mapping of the Tn7SX junctions indicated that each insertion was unique, and they 
were found regularly spaced throughout all three genes of the operon. Analysis of 
chromosomal DNA from the other seven isolates indicated that the Dur
r
 phenotype 
was not linked to the mTn7SX insertion, suggesting that a second mutation 
(presumably within the pssA-ybfM-psd operon) was responsible for the resistance 
phenotype. 
Phosphatidylserine (PS) synthase (encoded by pssA) catalyzes the formation of 
PS, the first step in PE synthesis (Fig. 4.2). PS is rapidly converted to PE by PS 
decarboxylase (encoded by psd). Therefore, the disruption of these genes results in a 
lack of PE in the membrane and insensitivity to duramycin (60). The function of 
YbfM is unknown; however, we have shown that nonpolar mutations within its gene 
do not result in duramycin resistance (60). Therefore, the insertions that we isolated 
within this gene are predicted to be polar on the downstream psd gene. Since we 
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obtained multiple unique insertions across the pssA-ybfM-psd operon, we suspect that 
we have saturated the screen, indicating that there are no other genes within the B. 
subtilis genome that, when disrupted or overexpressed, result in duramycin resistance. 
 
Figure 4.2. Synthesis of phosphatidylethanolamine. 
PssA catalyses synthesis of phosphatidylserine (PtdSer) from CDP-diacylglycerol 
(CDP-DAG). PtdSer is decarboxylated by Psd to phosphatidylethanolamine (PtdEtn) 
(71).   
 
Moenomycin – an antibiotic with one cellular target, but many 
mechanisms of resistance. In Bacillus subtilis, peptidoglycan is synthesized by high 
molecular weight (HMW) penicillin binding proteins (PBP) that are bifunctional, 
performing both transglycosylation and transpeptidation reactions (Table 4.3). The 
glycolipid moenomycin binds to and inhibits HMW PBPs by mimicking the 
membrane bound disaccharide substrate of the growing glycan chain (Fig. 4.3).  
Moenomycin is a strong inducer of the extracytoplasmic σ factor (ECF) σM in 
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B. subtilis (see Chapter 5, Table 5.3). This is consistent with the fact that σM is induced 
by other cell wall active agents, and that it regulates genes involved in cell envelope 
synthesis and regulation, shape determination and cell division. In turn, a sigM 
deletion strain is much more sensitive to moenomycin than wild-type W168 (Fig. 4.4).  
 
Table 4.3. High molecular weight penicillin binding proteins in B. subtilis. 
Gene Protein Function Localization 
ponA PBP1 cell division-specific 
transglycosylase/ 
transpeptidase, vegetative 
septal (shown by immuno-fluorescence, GFP-
fusion) (49, 53, 62) 
pbpD PBP4 not known, vegetative  distributed along membrane with distinct spots 
at periphery (GFP) (53, 62) 
pbpF PBP2c synthesis of spore 
peptidoglycan, vegetative, 
late stages of sporulation 
distributed along membrane, redistributed to 
prespore during sporulation (GFP) (43, 61, 62) 
pbpG PBP2d synthesis of spore 
peptidoglycan, sporulation 
distributed along membrane (GFP), redistributed 
to prespore during sporulation (43, 61, 62) 
 
 
 
Figure 4.3. Structure and target of moenomycin. 
The growing peptidoglycan chain is crosslinked by extracytoplasmic domains of 
transglycosylases. Moenomycin is a glycolipid antibiotic that mimics the sugar 
component of lipid II and therefore binds to transglycosylases (13). 
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Figure 4.4. Growth inhibition of W168 and a sigM deletion by moenomycin. 
The graph measures absorbance over time. The colors of the growth curves represent 
different moenomycin concentrations: blue 0µg/ml, red 0.4 µg/ml, green 1.0µg/ml, 
and yellow 10 µg/ml. Both strains grow equally fine without moenomycin (blue). 
Whereas wild-type W168 outgrows moenomycin after a prolonged lag-phase, sigM is 
much more susceptible at the shown concentrations. 
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Produced by Streptomyces species, the transglycosylase inhibitor moenomycin 
is highly active against a broad range of Gram-positive organisms (25). Poor 
absorption limited its effectiveness in humans; however, it is widely used as a growth 
promoter in animal feeding. Although having been used for more than 30 years in the 
animal industry (25), reports about resistance to moenomycin have been rare (10).  
A plausible mechanism of resistance would include upregulation of an 
alternative transglycosylase. Popham et al. have shown that a B. subtilis mutant 
lacking all four HMW PBPs (which are known transglycosylases) was still viable (44). 
As could be expected, this strain was resistant to moenomycin. This indicates that 
another enzyme could perform the transglycosylase function (since the strain was 
viable), but is structurally not too similar to the known transglycosylases, or else it 
would be a target for moenomycin. In fact, no homologs have been found to date. One 
option could involve a partial synthesis of peptidoglycan subunits to oligomers at the 
cytoplasmic side of the cell membrane before being flipped to the periplasm. This 
phenomenon prompted us to take a closer look at mutations that could affect resistance 
to moenomycin. In particular we wondered if the xylose inducible promoter of the 
Tn7SX transposon would be useful to direct our search towards the alternative 
transglycosylase; if overexpressed through addition of xylose, this could confer 
resistance to moenomycin.  
To increase the likelihood of finding a transposon insertion upstream of a 
transglycosylase, we used a triple mutant missing three out of the four HMW PBPs, 
pbpDFG. We were unable to use the quadruple deletion mutant, which misses all four 
HMW PBPs, because it is no longer competent, grows at a slower rate, and lyses 
earlier than wild-type (data not shown). In addition, we also used a sigM deletion as a 
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background strain, because it is much more susceptible to moenomycin (Fig. 4.4); and 
σM regulates ponA, one of the four HMW PBPs that are targeted by moenomycin. In 
an independent study we found ponA expressed at a lower level in a sigM deletion 
strain (Chapter 5, Table 5.3); this perhaps increases the chance for upregulation of an 
alternative transglycosylase. 
To our great surprise, we readily obtained moenomycin resistant mutants using 
Tn7SX transposon mutagenesis (detailed in Table 4.4, summarized in Table 4.5). We 
found 95 insertions in 25 different genes and two in intergenic regions that decreased 
susceptibility to moenomycin (Fig. 4.5). Most phenotypes are independent of xylose, 
meaning, they are caused by gene disruption with the transposon. However, in two 
mutants the resistance is clearly dependent on addition of xylose. One has a Tn7SX 
insertion in the YdfH histidine kinase gene of a two-component regulatory system 
(TCS), with the xylose inducible promoter facing towards the response regulator. We 
hypothesize that the addition of xylose drives expression of the response regulator and 
thereby upregulates expression of genes that can confer resistance. In the next 
paragraphs, we will focus on a subset of insertions in more detail.  
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Figure 4.5. Distribution of moenomycin resistant Tn7SX insertions across the B. 
subtilis chromosome. 
Ilustrated are genes on the forward (red) or reverse (blue) strand that were disrupted 
by the Tn7SX transposon. The number of different insertions obtained in separate 
transposition events in a gene is given in parenthesis (no number indicates one 
insertion in the respective gene). The chromosome map was created using BacMap 
(64). 
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Table 4.4. Moenomycin resistant Tn7SX insertions in W168, CU1065, sigM, and 
pbpDFG. 
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Strain Gene Tn7SX 
insertion 
site
1
 
Gene Function Down-
stream 
gene 
moenomycin out-
growth after X min.
3
 
without/ with xylose 
Strain 
back-
ground
4
 
M01 qoxB 970 (-) cytochrome aa3 quinol 
oxidase (subunit I) 
ywzA 
(transglycosylase 
associat. protein) 
300 320 W168 
M02 ybcD 959 (+) conserved unknown ybcF (carbonic 
anhydrase) 
360 300 W168 
M03 yerH 143 (-) putative lipoprotein yerI (kinase)   W168 
M04 ydfH 383 (+) TCS histidine kinase ydfI (TCS RR) 660 400 W168 
M05 yerH 143 (-) putative lipoprotein yerI    
M06 yerH 420 (-) putative lipoprotein yerI 260 260 CU1065 
M07 yerH 493 (-) putative lipoprotein yerI 300 260 CU1065 
M08 yerH 465 (-) putative lipoprotein yerI 300 280 CU1065 
M09 ypmB 30 (-) similar to propeptide PepSY aspB (aspartate 
aminotransferase) 
340 160 CU1065 
M10 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. CU1065 
M11 yerH 493 (-) putative lipoprotein yerI n.t. n.t. CU1065 
M12 -  sequencing gave no hits  240 240 CU1065 
M13 dinG 2102 (-) ATP dependent DNA helicase ypmAB 240 240 CU1065 
M14 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. CU1065 
M15 yclO 89 (+) ferrichrome ABC transporter yclP (permease) 260 260 CU1065 
M16 ypmB 30 (-) similar to propeptide  aspB n.t. n.t. CU1065 
M17 dinG 2258 (-) ATP dependent DNA helicase ypmAB n.t. n.t. CU1065 
M18 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. CU1065 
M19 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. CU1065 
M20 yerH 420 (-) putative lipoprotein yerI n.t. n.t. CU1065 
M21 yerH 475 (-) putative lipoprotein yerI 260 220 W168 
M22 ydfH 938 (+) histidine kinase ydfI 720 380 W168 
M23 -  no hits  240 240 W168 
M24 ypmB 30 (-) similar to propeptide PepSY  aspB 220 180 W168 
M25 yerH 1183 (-) putative lipoprotein yerI 240 240 W168 
M26 ybcD 144 (-) conserved unknown ybcF 2402 2202 W168 
M27 -  no hits  680 660 W168 
M28 -  no hits  240 240 W168 
M29 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. W168 
M30 ybcI 51 (-) conserved unknown ybcL(transporter) 520 500 W168 
M31 ydfH 938 (+) histidine kinase ydfI  240 240 W168 
M32 ypmB 30 (-) similar to propeptide PepSY  aspB n.t. n.t. W168 
M33 fhuC 744 (+) ferrichrome ABC transporter yvrP (exporter) 240 240 W168 
M34 yebC 284 (-) putative membrane protein yebD (unknown) 260 300 W168 
M35 ybcD 1690 (+) conserved unknown ybcF  180 160 W168 
M36 ytrP 1656 (+) diguanylate cyclase-related 
enzyme 
yttP (transcriptional 
regulator) 
520 280 sigM 
M37 ybcD 680 (-) conserved unknown ybcF  800 520 sigM 
M38 ybcD 680 (-) conserved unknown ybcF  520 280 sigM 
M39 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M40 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M41 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M42 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M43 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M44 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M45 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M46 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M47 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M48 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M49 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M50 ybcD 680 (-) conserved unknown ybcF  n.t. n.t. sigM 
M51 dinB 43 (+) nuclease inhibitor ydgF(amino acid 
permease) 
720 480 sigM 
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Table 4.4. (Continued) 
Strain Gene Tn7SX 
insertion 
site
1
 
Gene Function Down-
stream 
gene 
moenomycin out-
growth after X min.
3
 
without/ with xylose 
Strain 
back-
ground 
M52 dinB 43 (+) nuclease inhibitor ydgF 420 320 sigM 
M53 dinB 43 (+) nuclease inhibitor ydgF 540 300 sigM 
M54 dinB 43 (+) nuclease inhibitor ydgF n.t. n.t. sigM 
M55 yerH 144 (-) putative lipoprotein yerI 200 200 sigM 
M56 ppsD 184 (-) plipastatin synthetase ppsE 240 260 sigM 
M57 -  no hits  860 760 pbpDFG 
M58 yebC 206 (-) putative membrane protein yebD 880 980 pbpDFG 
M59 -  no hits  560 720 pbpDFG 
M60 psd 37 (-) phosphatidylserine 
decarboxylase (DC) 
ybfN (unknown) 220 260 pbpDFG 
M61 psd 278 (+) phosphatidylserine DC  1402 n.t. pbpDFG 
M62 psd 44 (-) phosphatidylserine DC ybfN (unknown) n.t.  n.t. pbpDFG 
M63 psd 54 (-) phosphatidylserine DC ybfN (unknown) n.t.  n.t. pbpDFG 
M64 ybfM 20 (-) in pssA-ybfM-psd operon  1402 n.t. pbpDFG 
M65 ypmB 30 (-) similar to propeptide PepSY  1202 n.t. pbpDFG 
M66 yebC 297 (-) putative membrane protein  5002 n.t. pbpDFG 
M67 ybcD 199 (-) conserved unknown  1802 1802 pbpDFG 
M68 yerH 103 (-) putative lipoprotein yerI 2402 n.t. CU1065 
M69 ypmB 27 (-) similar to propeptide PepSY  n.t.  n.t. CU1065 
M70 ybcC 211 (+) conserved unknown ybcD 3402 n.t. CU1065 
M71 yokA 486 (-) DNA recombinase yokB 
(lipoprotein) 
3802 3002 CU1065 
M72 yokD 599 (+) similar to aminoglycoside N3-
acetyltransferase 
 2002 n.t. CU1065 
M73 yokD 10 (+) similar to acetyltransferase  3802 3802 CU1065 
M74 yokH 
or 
481 (-) unknown 
(both have similar sequence) 
yokF (nuclease?) 2202 n.t. CU1065 
 yobM 412 (-) unknown yobN (oxidase) 2202 n.t. CU1065 
M75 rsiX 880 (-) σX anti σfactor  3402 n.t. CU1065 
M76 interg. (+) 177bp upstream of bsaA 
(peroxidase) 
ypbQ 3802 3802 CU1065 
M77 yerH 499 (-) putative lipoprotein yerI n.t.  n.t. CU1065 
M78 yerH 420 (-) putative lipoprotein yerI n.t.  n.t. CU1065 
M79 yokA 305 (-) DNA recombinase yokB n.t.  n.t. CU1065 
M80 yerH 103 (-) putative lipoprotein yerI n.t. n.t. W168 
M81 ydfH 938 (+) histidine kinase ydfI  6602 1402 W168 
M82 ybcD 136 (-) conserved unknown ybcF n.t.  n.t. W168 
M83 ybcD 1688 (+) conserved unknown ybcF n.t. n.t. W168 
M84 ybcI 51 (-) conserved hypothetical ybcL 3002 n.t. W168 
M85 ypmB 27 (-) similar to propeptide PepSY  n.t. n.t. W168 
M86 yobI 1303 (-) conserved hypothetical  1802 n.t. W168 
M87 yerH 1183 (-) putative lipoprotein yerI n.t.  n.t. W168 
M88 yerH 1019 (-) putative lipoprotein yerI n.t.  n.t. W168 
M89 hpr 3 (-) ScoC transcriptional regulator - 300 280 W168 
M90 interg. (-) 20bp downstream of yheA yheC 180 180 W168 
M91 yerH 436 (-) putative lipoprotein yerI 320 n.t. W168 
M92 ybcD 680 (-) conserved unknown ybcF 280 300 W168 
M93 -  no hits  300 300 W168 
M94 ndhF 388 (-) NADH dehydrogenase 
(subunit 5), upstream of ybcD  
ybcD 300 300 W168 
M95 qoxB 738 (-) cytochrome aa3 quinol oxidase 
(subunit I) 
ywzA 320 340 W168 
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Table 4.4. (Continued) 
Strain Gene Tn7SX 
insertion 
site
1
 
Gene Function Down-
stream 
gene 
moenomycin out-
growth after X min.
3
 
without/ with xylose 
Strain 
back-
ground 
 W168 wild-type  670 650 W168 
 CU1065 wild-type  850 860 CU1065 
 pbpDFG LFH deletion  950 800 W168 
 sigM LFH deletion  no growth no growth CU1065 
 pssA LFH deletion  3002 n.t. CU1065 
 psd LFH deletion  2002 n.t. CU1065 
1orientation of xylose inducible promoter in relation to gene (same orientation = (+), opposite orientation = (-)) 
2 tested at 1µg/ml, all others at 10µg/ml moenomycin. 
3 moenomycin treatment did not result in a clear determinable MIC, but rather in a delayed lag phase. To 
compare different mutants, we used the ability to outgrow a certain moenomycin concentration2 after a 
particular time as a measure of susceptibility. 
4 Tn7SX insertions are sorted by strain background. 
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Table 4.5. Moenomycin resistant Tn7SX insertions summary. 
Insertion 
in… 
Orientation
2
/ 
Background 
Gene Function
3
 Inducible promoter 
upstream of… 
  Xylose        
dependency 
ybcD (21/5X)1 +/- W168, sigM, 
pbpDFG 
conserved unknown (ybcC) ybcF (carbonic 
anhydrase) 
slight 
ybcC (1X) + CU1065 conserved unknown ybcF (carbonic 
anhydrase) 
no 
ybcI (2/1X) - W168 conserved hypothetical - no 
yerH (17/8X) - W168, sigM, 
CU1065 
putative lipoprotein yerD (ferredoxin-dep. 
glutamate synthase) 
slight 
ypmB (12/1X) - W168, CU1065 
pbpDFG 
similar to propeptide PepSY - slight 
dinG (2/2X) - CU1065 ATP dependent DNA helicase - no 
yebC (3/3X) - W168, pbpDFG putative membrane protein - no 
psd (4/3X) +/- pbpDFG phosphatidylserine decarboxylase  - no 
ybfM (1X) - pbpDFG in pssA-ybfM-psd operon psd (PS decarboxylase) no 
dinB(4/1X) + sigM nuclease inhibitor ydgF (amino acid permease) slight 
ydfH (4/2X) + W168 TCS histidine kinase ydfI (response regulator) yes 
yokA (2/2X) - CU1065 DNA recombinase yokB (lipoprotein) slight 
yokD (2/2X) + CU1065 similar to aminoglycoside N3-
acetyltransferase 
yokA (DNA recombinase) no 
hpr (1X) - W168 ScoC, transcriptional regulator - no 
qoxB (2/2X) - W168 cytochrome aa3 quinol oxidase 
(subunit I) 
ywzA (transglycosylase 
associated protein) 
no 
ytrP (1X) + sigM diguanylate cyclase-rel. enzyme yttP (transcr. regulator) yes 
ppsD (1X) - sigM plipastatin synthetase - no 
intergenic (1X) - W168 ds of yheA and yheC yheC (reg. by SpoIIID) no 
intergenic (1X) + CU1065 us of bsaA (peroxidase) ypgQ (metal 
phosphohydrolase) 
no 
ndhF (1X) - W168 NADH dehydrogenase  - no 
rsiX (1X) - CU1065 σX anti σ factor - no 
yobI (1X) - W168 conserved hypothetical - no 
yokH (1X) - CU1065 unknown - no 
yclO (1X) + CU1065 ferrichrome ABC transporter yclP (permease) no 
fhuC (1X) + W168 ferrichrome ABC transporter yvrP (efflux transporter) no 
1 Parentheses: (number of total insertions / number of independent insertions X) in respective gene.  
2 “+ or –“ corresponds to the orientation of the xylose inducible promoter of Tn7SX relative to the gene.  
3 Function/Similarity based on Subtilist entries.  
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The YdfHI two-component system regulon confers resistance to 
moenomycin. Four Tn7SX insertions were found in the histidine kinase gene of the 
YdfHI TCS. According to the sequencing results they are in two different insertion 
sites in W168 (Table 4.4). All four are oriented in the same way, with the xylose 
inducible promoter facing the downstream response regulator gene ydfI. Susceptibility 
assays with moenomycin in liquid cultures showed that this strain was more resistant 
than W168 upon addition of 2% xylose, which drives expression of the PxylA promoter 
of Tn7SX. Without addition of xylose, the strain was as susceptible as W168 for most 
of the time; a subset showed decreased susceptibility without xylose. This could either 
be due to a slight leakiness of the xylose driven promoter, or in case that the histidine 
kinase acts as a phosphatase, the disruption by the transposon could also lead to 
increased amounts of phosphorylated response regulator. 
The YdfHI TCS has not been studied very well. Kobayashi et al. examined 24 
out of 30 TCS pairs in B. subtilis by cloning them into an isopropyl-β-d-
galactopyranoside (IPTG)-inducible expression vector (pDG148), inducing for two 
hours, followed by microarray analysis (34). Even though induction for two hours 
starting from early logarithmic phase is a very long time frame which can lead to 
secondary effects being present in the transcriptional analysis, we took the published 
regulon members as a starting point (Table 4.6; (34)). A total of 29 genes were altered 
in their expression at least four fold, 21 genes were induced, and eight genes were 
repressed. A gene that caught our interest was ykuD (34).  
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Table 4.6. Regulon members of the YdfHI two-component regulatory system. 
Genes that were at least 4-fold induced or repressed are shown (adapted from 
Kobayashi et al. (34)) 
Gene Gene Function 
Induced:  
ydfE putative flavoprotein  
ydfH TCS, histidine kinase 
ydfI TCS, response regulator 
ydfJ putative proton metabolite efflux transporter 
ydfT cotP, spore coat protein 
ydgJ putative transcriptional regulator (MarR family) 
ydjM conserved hypothetical protein 
ykuD ldt, L,D-transpeptidase 
pyrR transcriptional attenuation of the pyrimidine operon /   
uracil phosphoribosyltransferase activity 
proJ glutamate 5-kinase (proline biosynthesis) 
proH pyrroline-5-carboxylate reductase (proline biosynthesis) 
yqjD Propanoyl-CoA carbon dioxide ligase 
ysbA murein hydrolase regulator LrgA 
rbsR transcriptional repressor of the ribose operon 
rbsK ribokinase 
rbsD ribose ABC transporter (membrane protein) 
rbsA ribose ABC transporter (ATP-binding protein) 
rbsC ribose ABC transporter (permease) 
rbsB ribose ABC transporter (ribose-binding protein) 
licC PTS lichenan-specific enzyme IIC component 
yydH putative peptide zinc metalloprotease protein 
Repressed:  
lctE L-lactate dehydrogenase 
lctP L-lactate permease 
yqxL magnesium transport protein corA 
ywcJ formate/nitrite transporter 
ywbH holin-like protein cidA 
cydC ABC transporter required for expression of cytochrome bd 
(ATP-binding protein) 
cydB cytochrome bd ubiquinol oxidase (subunit II) 
cydA cytochrome bd ubiquinol oxidase (subunit I) 
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YkuD was found to be a sporulation protein, under the regulation of σK, with a 
LysM domain, typical for peptidoglycan binding proteins (35). More recently, it was 
renamed Ldt, for L,D-transpeptidase (14, 40). Cremniter et al. report Ldt to have 
activity in Enterococcus faecium, catalyzing the transpeptidation between the third 
amino acid of lipid II during peptidoglycan (PG) synthesis (Fig. 4.6). In vitro, the 
ortholog in B. subtilis catalyzes the condensation between two meso-diaminopimelic 
acid
3
 residues (40), instead of the third and the fourth amino acid that are used during 
regular peptidoglycan synthesis. This alternative pathway leads to resistance to 
glycopeptide and β-lactam antibiotics in E. faecium, as the specific target is missing in 
both cases. Here, a potential induction of ldt through the YdfHI TCS is intriguing, 
because this could lead to upregulation of an alternative cell wall synthesis pathway, 
circumventing the need for the four known HMW PBPs. However, preliminary results 
are discouraging. Deletions of both ldt and its paralog yciB were not more susceptible 
to moenomycin or other cell wall active antibiotics (our unpublished results, and (7)); 
though this has not been tested in a mutant missing all four HMW PBPs. An 
involvement of Ldt or YciB in resistance could also be tested by ectopic 
overexpression. Focusing on the YdfHI TCS, a comprehensive analysis of the regulon 
members (for instance by microarray, but with shorter induction periods), chip, or 
transcriptional fusions, could shed light on the involvement in moenomycin resistance. 
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Figure 4.6. Regular and alternative cell wall synthesis pathways in E. faecium. 
 (A) Regular peptidoglycan synthesis. The extracellular polymerization and cross-
linking of peptidoglycan is mediated by penicillin-binding proteins (D,D-
transpeptidases). (B) An alternative peptidoglycan synthesis uses L,D-transpeptidases 
(Ldt) which circumvent the need for regular penicillin-binding proteins. Ldt requires 
the pentapeptide precursor of lipid I to be cleaved to a tetrapeptide by a D,D-
carboxypeptidase (14). 
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YbcC and YbcI, two conserved hypotheticals. The Tn7SX transposon is 
inserted 24 times in the genes ybcC (22X) and ybcI (2X), with six different insertion 
sites in ybcC (previously annotated as ybcC and ybcD). The xylose inducible promoter 
is not uniformly oriented in the same directions in these insertions. When searched 
with NCBI blast, both proteins are listed as conserved hypothetical proteins, and 
similar proteins are also not annotated. ybcI is located about 1kb further downstream 
of ybcC, separated by ybcF (similar to carbonic anhydrase), and ybcH (hypothetical 
protein) (17, 28). 
When compared to closely related Bacillus species, it is notable that ybcC is 
not present in B. pumilis. In S. aureus the ybcC and ybcI genes are direct neighbors 
(http://string.embl.de). Using the String software with a maximum of ten interactions 
and one additional node, all three genes, ybcC, ybcD (still shown as separate genes), 
and ybcI, are interconnected due to being in the same neighborhood, and due to co-
occurrence across genomes (Fig. 4.7). Connnected with the three genes is ndhF, 
encoding a NADH-quinone oxidoreductase subunit, which is directly upstream of 
ybcC. The only other interaction that stands out is with rasP, coding for a zinc-
metalloprotease that cleaves RsiW, the anti-σW ECF σ factor, though rasP is only 
connected to ybcI. Due to the fact that both genes are not yet annotated and do not 
have a particular motif (only regions of low complexity, when analysed with EMBL-
SMART), the reason for moenomycin resistance is not yet clear. However, the 
frequent occurrence of transposon insertions in these two genes leading to 
moenomycin resistance remains worthy of investigation. 
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Figure 4.7. Putative interaction network of ybcI. 
STRING analysis of protein associations based on: co-ocurrence across genomes 
(blue), genetic neighborhood (green), gene fusions (red). Displayed connections have 
a confidence score of 0.6 or higher. Adapted from http://string.embl.de/ (30) 
  
 
The sex-pheromone homolog YerH. 17 Tn7SX insertions were found in 
yerH, of which eight are independent (at different insertion sites). The insertions 
occurred in three different backgrounds, W168, CU1065, and the sigM deletion. The 
PxylA promoter faced opposite the gene orientation, towards yerD (encoding a protein 
with similarity to a ferredoxin-dependent glutamate synthase (52, 58)), though the 
resistance was independent of xylose. According to UniProtKB, YerH is anchored to 
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the membrane, has a signal peptide (1-18), and is likely to be lipidated at cysteine-19 
via N-palmitoyl or S-diacylglycerol.  
YerH is homolog to CamS (44% identity) of Staphylococcus aureus, which 
processes the sex pheromone staph-cAM373. The latter is a heptapeptide and potential 
intergeneric inducer of transfer-proficient genetic elements (20). Similar to CamS are 
Eep in E. faecalis and Lsp in Escherichia coli. Eep stands for enhanced expression of 
pheromone, a metallopeptidase that cleaves signal peptides of lipoproteins to yield 
octapeptides (3). These peptides act as aggregation pheromones, inducing conjugation 
between different E. faecalis strains. Eep is 44% identical to YluC in B. subtilis, which 
is a RIP peptidase that degrades the anti σ factor RsiW through intramembrane 
proteolysis (15). At this point, the correlation between the disruption of the lipoprotein 
YerH and decreased moenomycin susceptibility are not known.  
 
YpmB – an extracellular protease? 12 Tn7SX insertions were obtained in 
ypmB in three different background strains, W168, CU1065, and the triple deletion of 
the HMW PBPs pbpDFG. Upon addition of xylose, the strains were slightly more 
resistant to moenomycin, although no gene is directly downstream in the same 
orientation as the PxylA promoter. YpmB has a PepSY domain, which is found in the 
propeptide of members of the MEROPS peptidase family M4, containing for instance 
the thermostable thermolysins (EC 3.4.24.27), and related thermolabile neutral 
proteases (bacillolysins) (EC 3.4.24.28). Extracellular proteases are often produced as 
propeptides with dual function: an intramolecular chaperone necessary for the folding 
of the polypeptide (FTP domain) and an inhibitor preventing premature activation of 
the enzyme (PepSY domain, IPR011096) (8, 65).  
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ypmB is part of the dinG ypmA ypmB aspB operon. The transposon insertion 
could perhaps have a polar effect on aspB, encoding an aspartate aminotransferase 
(Fig. 4.8, Fig. 4.9). Effects from ypmB disruption on moenomycin resistance or 
potential polar effects remain to be tested. 
 
 
Figure 4.8. Expression of the dinG ypmA ypmB aspB operon. 
Excerpt from B. subtilis tiling array with strand specific probes, top strand shown in 
blue, bottom strand in pink. The upper panels of each strand correspond to gene 
expression in rich (LB), the lower panels in minimal medium (M9).The higher the 
graph/darker the color the higher the expression. Red triangles illustrate predicted 
terminators; green circles indicate predicted σ factor binding sites (56). 
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Figure 4.9. Putative interaction network of ypmB. 
STRING analysis of protein associations based on: co-ocurrence across genomes 
(blue), genetic neighborhood (green), text mining (yellow). Displayed connections 
have a confidence score of 0.5 or higher. Adapted from http://string.embl.de/ (30) 
 
 
Insertions in dinG – a polar effect on ypmB? Two independent Tn7SX 
insertions occurred in dinG in the wild-type CU1065. Disruption of the ATP-
dependent helicase is suspicious, because of the close proximity to the downstream 
genes ypmA and ypmB (24). A total of 12 insertions in three different backgrounds 
(W168, CU1065, and pbpDFG) were found in ypmB, leading to moenomycin 
resistance. It could be possible, that the Tn7SX insertions in dinG have a polar effect 
on the downstream genes ypmA ypmB aspB (Fig. 4.8).  
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Xylose dependent moenomycin resistance through a Tn7SX insertion in 
ytrP. One Tn7SX insertion was detected in ytrP, in the sigM deletion background. 
YtrP is a putative diguanylate cyclase-related enzyme (9). Using blast, close hits also 
report similarity to a histidine kinase, but a corresponding reponse regulator is 
missing. Since resistance to moenomycin was observed after addition of xylose, we 
assume that a downstream gene is affected. Downstream (in the same orientation as 
the PxylA promoter) is the monocistronic gene yttP. Little is known about yttP, which 
has similarity to a transcriptional regulator (TetR/AcrR family). Allenby et al., list yttP 
as a member of the PhoP regulon where it was induced in response to phosphate
 
starvation (2, 54). Fujita et al., however, found yttP to be a high-threshold member of 
the Spo0A regulon, (21, 45, 55). Rahn-Lee et al. tested effects of a yttP deletion on 
inhibition of replication, but were unable to observe a phenotype (55). Overexpression 
of yttP , in wild-type and a sigM deletion background might give clues about a relation 
to moenomycin resistance. 
 
YebC, a member of the σM regulon. Three independent insertions are located 
in yebC, in the W168 and pbpDFG backgrounds. YebC has similarity to integral inner 
membrane proteins, or permeases (not to be confused with E. coli yebC which encodes 
a different protein) (23, 27, 36, 63). Disruption of yebC by the transposon leads to high 
resistance to moenomycin, both in liquid susceptibility studies and when tested in disc 
diffusions assays with moenomycin soaked filter discs. Interestingly, yebC is a 
member of the σM regulon, and is mildly induced in microarrays upon moenomycin 
treatment (unpublished results, see chapter 5) (18). Since σM was found to confer 
resistance to moenomycin, this seems counterintuitive. To test effects of σM on this 
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mutant, we transformed a sigM::kan LFH deletion into a yebC::Tn7SX insertion 
strain. This deletion was now much more sensitive to moenomycin, indicating a 
possible connection between the resistance and σM regulon members.  
 
Psd and YbfM – alterations in the phospholipid content of the membrane 
are likely to affect moenomycin anchoring. In total, five Tn7SX insertions were 
found in the pssA-ybfM-psd operon. This operon, as already described for selection of 
duramycin resistant Tn7SX isolates, is involved in the synthesis of phosphatidylserine 
and phosphatidylethanolamine, two important members of membrane phospholipids 
(Fig. 4.2, Fig. 4.10) (71). Insertions in both ybfM and psd result in inhibition of the 
zwitter-ionic phophatidylethanolamine production, thereby increasing amounts of the 
negatively charged precursor phosphatidylserine. This could alter the overall 
phospholipid composition in the membrane. Nishi et al. showed previously that 
transposon insertions in mprF, which synthesizes the positively charged membrane 
lipid lysyl-phosphatidylglycerol, led to moenomycin resistant mutants in S. aureus 
(47). This also indicates that an increase in negatively charged membrane lipids affects 
susceptibility to moenomycin.  
Two aspects could be responsible for the decreased susceptibility to 
moenomycin. First, for full activity, moenomycin needs to anchor in the membrane 
with its moenocinol side chain, a C25 branched acyl chain. It was shown that a 
shortened side chain (C10) was able to interact with the target transglycosylase, but 
was unable to exert biological activity, inhibiting its function (1, 4). By changing 
properties of the membrane, the anchoring ability of moenomycin could be impaired.  
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Second, moenomycin also needs to interact with the trans-membrane domain 
of the transglycosylase to be active (Fig 4.11) (13). By changing the phospholipid 
content of the membrane, this interaction could be hindered or changed, for example 
through conformational changes of the transglycosylase. To fully answer the question 
which of these two options plays a role, binding and activity studies could be done 
with moenomycin, and perhaps compared to moenomycin with altered side chain 
lengths. Furthermore, titration experiments with ectopically inducible copies of psd 
could indicate whether a certain threshold is needed for this effect. This could be 
coupled with ESI-MS based quantification of membrane phospholipids.  
Lastly, why these Tn7SX insertions were only found in the pbpDFG 
background, but not in wild-type B. subtilis, remains to be answered. Perhaps, if PonA 
is the only remaining transglycosylase, membrane charge and conformation 
characteristics have a greater impact on moenomycin binding and activity. We 
conducted growth inhibition studies with psd deletions in the wild-type background, 
and found this strain to be less susceptible to moenomycin as well, although to a lesser 
extent, than in the pbpDFG background. 
 
 
Figure 4.10. Tn7SX transposon insertions in ybfM and psd. 
Five independent insertions were found in the pssA-ybfM-psd operon. 
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Figure 4.11. Affinity of moenomycin to truncated HMW PBPs. 
Binding constants of moenomycin with different domains of PBPs are listed. Presence 
of a transmembrane domain increased moenomycin binding (13).  
 
dinB insertions increase moenomycin resistance in a sigM deletion strain. 
A transposon insertion in the nuclease inhibitor dinB (33, 72) does have no apparent 
advantage regarding moenomycin resistance. Here, we only obtained Tn7SX 
insertions in the sigM deletion background, which is otherwise very susceptible to 
moenomycin. The PxylA promoter is oriented facing the downstream gene ydgF, which 
has been renamed aapA, an amino-acid permease, transporting d-serine/d-
alanine/glycine. In fact, the moenomycin resistance of this Tn7SX insertion was 
slightly dependent on xylose addition. It could be argued that induction of the 
membrane protein AapA leads to increased transport of these amino acids, 
compensating for defects in the sigM mutant or affecting the membrane potential, and 
subsequently moenomycin activity. To confirm a dependency on the sigM deletion, or 
on AapA, this transposon could be transformed into B. subtilis wild-type background, 
and could be coupled with a deletion of aapA.  
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Four insertions in close proximity, YokA and YokD. Two Tn7SX insertions 
each are located inside yokA and yokD, respectively. YokD has similarity to an 
aminoglycoside N3-acetyltransferase and YokA to a DNA site-specific recombinase. 
These insertions could be independent, the close chromosomal proximity, however, 
might suggest a connection. In all cases, the insertions are in the CU1065 wild-type 
background strain. The xylose inducible promoters in yokD face in direction of the 
2kb downstream yokA, whereas the insertions in yokA face the opposite orientation 
towards yokB, which has similarity to a lipoprotein. Addition of xylose to the 
insertions in yokD could perhaps affect expression of yokA; whereas xylose added to 
Tn7SX in yokA could affect expression of yokB. From the resistance studies, we can 
see a slight increase in resistance, when xylose is added to the insertion in yokA, the 
insertions in yokD had not yet been tested with xylose. 
Transposon insertions in the aminoglycoside N3-acetyltransferase are 
interesting in terms of antibiotic resistance. This enzymatic group (EC:2.3.1.81) 
catalyses the acetyl transfer to 2-deoxystreptamine antibiotics, leading to N3'-acetyl-2-
deoxystreptamine antibiotics, thereby inactivating for example gentamicin, 
kanamycin, neomycin and others (according to the NCBI Conserved Domain Database 
(CDD)(41)). A functional relationship to moenomycin is not apparent, as it is a 
phospho-glycolipid. Besides having the ability to inactivate aminoglycosides, an 
additional function of a YokD homolog was observed in Providencia stuartii: O-
acetylation of peptidoglycan (48). If YokD has similar functions in B. subtilis is still 
unknown. 
 
 131 
Increased expression of proteases by disruption of the transcriptional 
regulator ScoC (Hpr)? Hpr, renamed to ScoC, is a transcriptional regulator of the 
MarR family. It negatively regulates sporulation and extracellular protease genes 
(aprE, nprE, sin), as well as peptide transport genes (appABCDF and oppABCDF) 
(31). These extracellular proteases are produced in large quantities at the end of 
logarithmic growth to degrade extracellular high-molecular-weight materials to serve 
as nutrients. Their regulation is important because their production is very energy 
consuming. Next to AbrB, SinR, and Pai, ScoC is a negative regulator of AprE, 
binding directly upstream of aprE (Fig 4.12) (32).  
Even though the regulation of the degradative proteases is complex, it was 
shown that for example SenS, is able to supress transcription of ScoC, and in turn 
increase levels of AprE (32). A disruption of ScoC by Tn7SX probably leads to 
elevated expression of secreted proteases. Whether this affects moenomycin directly, 
or rather indirectly, remains to be answered. 
 
 
 
Figure 4.12. aprE regulatory network. 
The negative regulator of aprE, ScoC, can be repressed by SenS and SalA.  
Adapted from T. Tanaka, Saitama University, Japan (http://www.molbiol.saitama-
u.ac.jp/091028.gif) 
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Insertions in the cytochrome quinol oxidase gene qoxB. Two insertions are 
in qoxB, coding for subunit I of the cytochrome aa3 quinol oxidase. B. subitilis is 
known to have three different terminal oxidases that transfer electrons from reducing 
equivalents to oxygen. While cytochrome c is the minor oxidase, the major ones are 
the quinol oxidases cytochrome bd (cydABCD) and aa3 (qoxABCD), which translocate 
one to two protons per electron transferred to oxygen (69). Oxygen levels determine 
which oxidase is predominantly used. During aerobic growth conditions the 
cytochrome aa3 oxidases are predominant, at low oxygen levels the cytochrome bd 
oxidases. The quinol oxidases are synthetically lethal. Either one is sufficient, but both 
cannot be replaced by cytochrome c (69).  
Zamboni et al. have examined effects of a qox mutant in B. subtilis. They 
observed acetate overflow during carbon metabolism, which they suggest is due to 
kinetic limitation of the terminal oxidases. At the maximum growth rate the remaining 
oxidases were insufficient to oxidize all catabolically generated NADH (70). How this 
translates to the transposon insertion in qoxB and moenomycin resistance is not clear. 
The kinetic limitation could perhaps result in slower metabolism, and consequently 
reduced growth rate and cell wall synthesis, thereby presenting fewer targets to 
moenomycin. 
Of note is that the gene upstream of qoxB, ywzA, encodes a transglycosylase 
associated protein. ywzA, a member of the σB regulon, was shown to be induced by 
phenol and salicylic acid and downregulated by ComK (5, 51).  
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Insertion in the usually inactive plipastatin synthase operon. ppsD is part of 
the 38.4-kb plipastatin synthesis operon ppsABCDE. Plipastatin is a non-ribosomal 
peptide (NRP) that is usually not synthesized by B. subtilis W168 because of a frame-
shift mutation in sfp and a mutation in the promoter region of degQ (Fig 4.13). Sfp, a 
phosphopantetheinyl transferase is necessary to convert the peptidyl carrier domains 
of the plipastatin synthetase from the inactive apo-forms to active holo-forms. DegQ is 
a putative regulator for expression of the ppsABCDE operon (66).  
It is surprising that the Tn7SX insertion in ppsD showed a moenomycin 
resistance phenotype, because the background strain is supposedly a non-producer of 
plipastatin. The PxylA promoter should have no effect here, because it is facing in the 
opposite orientation of ppsD. Attempts to delete ppsD via LFH deletion have failed 
probably because of the large size of the gene (10.8 kb).  
 To further investigate the effects of ppsD on moenomycin resistance, we 
received two strains from Dr. Kenji Tsuge (Keio University): BEST8628, which 
produces plipastatin (due to reversal of the mutations in sfp
0
 and degQ
0
); and 
BEST8666, which does not produce plipastatin due to deletion of the pps operon, sfp, 
and degQ (66). When tested for moenomycin sensitivity, neither of the strains showed 
differences compared to wild-type W168. This does not confirm our transposon 
phenotype. Perhaps this strain has another mutation close to the Tn7SX insertion site 
that co-transformed during our linkage tests. 
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Figure 4.13. Structure of the NRPS produced lipopeptide plipastatin. 
R = alkyl chain, usually C14 to C16 (66). 
 
 
Tn7SX insertion downstream of yheA and yhaZ. The Tn7SX insertion 
downstream of the genes yheA and yhaZ does not have an obvious genetic effect. The 
xylose inducible promoter is oriented opposite to yheA, in direction of yheC, which is 
similar to a spore coat associated protein, a UDP-MurNAc-tripeptide-D-ala-D-ala 
ligase. yheC and yheD were found to be upregulated by SpoIIID (19). YheD forms a 
ring during spore coat formation, but is not essential for sporulation. The fact that this 
transposon insertion is not directly dependent on xylose, and the distance of about 2kb 
from the insertion site to the start of yheC, do not support a likely induction of yheC, 
unless the promoter is slightly leaky. The relation to moenomycin resistance is unclear 
at this point.  
 
Effects of transposon insertion upstream of bsaA. One insertion was located 
upstream of bsaA. BsaA is similar to glutathione peroxidases, but since B. subtilis 
lacks glutathione, this function is unlikely. Instead, it could be a peroxidase using 
other low molecular weight thiols in the cell (e.g., bacillithiol (22, 46)). The Tn7SX 
insertion is upstream of bsaA with the PxylA promoter in the same orientation as the 
gene. An effect could therefore either be caused by induction of bsaA or by the 
downstream gene ypgQ, which is a putative metal-dependent phosphohydrolase. These 
options still remain to be tested. 
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Isolation of fosfomycin sensitive mutants. We used Tn7SX to select for 
sensitivity to fosfomycin, an antibiotic produced by Streptomyces species and used in 
the treatment of lower urinary tract infections (57). Fosfomycin enters the cell via the 
GlpT ABC transporter transporter, where it inactivates MurA, a cytoplasmic enzyme 
involved in the first step of peptidoglycan biosynthesis (37). Mutations in glpT of E. 
coli result in increased fosfomycin resistance, and in B. subtilis, the glpT locus was 
originally mapped by selection for Fos
r
 mutants (39). B. subtilis was found to become 
resistant to fosfomycin by its inactivation through addition of L-cysteine (57). This 
step is catalyzed by bacillithiol and the bacillithiol-S-transferase enzyme FosB (11, 
22).  
Bacillithiol (BSH) is a recently characterized low-molecular-weight thiol, 
similar to glutathione or mycothiol, which helps the cell maintain a reduced cytosolic 
state by detoxifying electrophiles (22, 46). BSH is synthesized by the BshA 
glycosyltransferase, BshB1 or BshB2 deacetylase and a methylglyoxal synthase (Fig. 
4.14). BshC, the cysteine adding enzyme was not known, which encouraged us to 
utilize the highly random insertion power of the Tn7SX library to screen for 
candidates that would disrupt BSH production, and thereby render the cells susceptible 
to the antibiotic fosfomycin. Since BshB1 and BshB2 are partially redundant, likely 
candidates of Tn7SX insertions would be bshA, bshC, or fosB. However, if BshC is an 
essential enzyme, the transposon mutagenesis will not be successful. 
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Figure 4.14. Synthesis of the low-molecular-weight thiol bacillithiol in B. subtilis. 
Bacillithiol (BSH) synthesis is catalysed by BshA (glycosyltransferase), BshB (N-
acetylhydrolase), and BshC (cysteine-adding enzyme) (22). 
 
In order to screen for fosfomycin sensitivity, cells were plated on LB plates 
containing spectinomycin (with or without xylose) after transformation of W168 with 
the Tn7SX amplified library. Colonies were then transferred to microtiter plates, from 
which they were replica plated onto plates containing spectinomycin, and 30 µg/ml of 
fosfomycin, a concentration that wild-type W168 can tolerate. Half of the plates 
contained 2% xylose. In total, 10 microtiter plates were employed, resulting in 960 
colonies tested (with and without xylose). We found more than 18 colonies that were 
not able to grow at the selected concentration of fosfomycin.  
Results of the insertion mapping are listed in Table 4.7. The fact that we 
obtained a Tn7SX insertion in bshA, the first gene involved in BSH synthesis, 
indicates that the screen was successful for our purpose. Another insertion indirectly 
relevant to fosfomycin detoxification is in ecsB. EcsB is part of an operon with EcsA, 
an ATP binding cassette
 
(ABC) of an ABC transporter (38). Heinrich et al. report that 
mutants of ecsA inhibit
 
proteolysis of ECF anti-σW factor RsiW by the intramembrane 
cleaving protease RasP (26). In wild-type, σW is sequesterd by its anti-σW factor RsiW, 
and after stress-induced degradation by regulated intramembrane proteolysis, σW is 
released and can activate the transcription of σW-controlled genes. It is plausible, that 
the ecsB mutant from this Tn7SX sceen also fails to proteolytically degrade RsiW, 
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causing σW to be inactive. Since σW is normally necessary for fosB activation, the 
resulting low levels of FosB are likely insufficient to detoxify fosfomycin.  
When tested in liquid growth curves for sensitivity to fosfomycin, strains with 
Tn7SX insertions in bshA, yvzA, ecsB, upstream of bglA and cypC, as well as a  fosB 
deletion as positive control had an MIC of 100 µg/ml or less, whereas wild-type W168 
has an MIC of 200 µg/ml. The different Tn7SX insertion mutants can be tested for 
their effect on BSH and fosfomycin degradation. However, while these studies were 
conducted, John D. Helmann and Ahmed Gaballa discovered a candidate for BshC 
using phylogenomic methods, namely YllA. This gene was not found in the first 
rounds of sequencing mutants from the Tn7SX library screen. Nonetheless, the 
remaining mutants might give clues to other aspects of fosfomycin detoxification. 
 
Table 4.7. Fosfomycin sensitive Tn7SX insertions in W168. 
ID # Insertion 
in… 
Gene function At position Tn7SX 
orientation 
vs. gene  
6H2 us of ybxI 
and cypC 
ybxI: similar to β-lactamase 
cypC: fatty acid β -hydroxylating CYP450 
(-106) ybxI, 
(-67) cypC 
same as 
cypC 
8C1 bshA bshA, BSH synthesis 601 of 1131 opposite 
6F8 citB aconitate hydratase 502 of 2727 opposite 
4D8 murAA UDP-GlucNAc-1-carboxyvinyltransferase 46 of 1308 opposite 
4C1 us of bglA 6-phospho-beta-glucosidase (-25) same 
4G10 yvzA unknown, part of the LiaRS regulon ? 291 of 357 opposite 
4H8 yfmI similar to macrolide-efflux transporter 284 of 1218 opposite 
8H1 ecsB ABC transporter (membrane protein) 1004 of 1224 opposite 
5G11 possibly 
in cwlH 
N-acetylmuramoyl-L-alanine amidase 
(sporulation) 
373 of 750 opposite 
5C4 yetI similar to positive regulator of σB 950 of 1083 opposite 
5D3 us of cysK cysteine synthetase A (-33) opposite 
3/21 citB aconitate hydratase 504 of 2727 opposite 
12/24 yfmI similar to macrolide-efflux transporter 284 of 1218 opposite 
4G7 murAA UDP-GlucNAc-1-carboxyvinyltransferase 1261 of 1308 opposite 
10E5 yhaJ unknown 47 of 237 opposite 
10E8 ylmD unknown 571 of 834 opposite 
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4.4 Conclusions.  
Stress response to cell envelope active antibiotics by ECF σ factors and TCS 
can result in upregulation of alternative cell wall synthesis pathways and thereby 
confer resistance. Use of moenomycin serves as a valuable tool to study proteins 
involved in cell wall synthesis and its regulation. σM regulates genes that confer 
resistance to moenomycin via a still unknown mechanism. Here, we investigated 
aspects of cell wall synthesis and resistance to moenomycin with the help of Tn7SX 
transposon mutagenesis.  
Interestingly, amongst the 25 different Tn7SX insertions, only one mutant is 
part of the sigM regulon, yebC, which has similarity to a membrane permease. In 
addition, most mutants are different from the genes induced by moenomycin (see 
transcriptional analysis of moenomycin treatment, Chapter 5, Table 5.3). An insertion 
in the histidine kinase of the YdfHI TCS was found to confer resistance to 
moenomycin, perhaps by regulating Ldt expression which is part of an alternative 
peptidoglycan synthesis pathway. Additional members of this pathway including the 
transglycosylase and the D,D-carboxypeptidase that provides the tetrapeptide substrate 
for Ldt still need to be investigated.Insertions in the phosphatidylethanol synthesis 
operon pssA-ybfM-psd alter the phospholipid composition of the membrane, 
increasing the net negative charge. This might affect the ability of moenomycin to 
insert into the membrane, or to interact with the trans-membrane domain of the 
transglycosylase.  
Here, a shortcoming of using the amplified Tn7SX library is the occurrence of 
siblings amongst the insertion hits, especially as some insertions have a growth 
advantage over others and are present in higher copy numbers, resulting in lower 
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randomness as the direct transformation after transposition. However, using this 
library multiple times, we still obtained moenomycin resistant insertions in different 
genes, indicating, that the selection is close to, but not yet saturated.  
The technique used in this work also has its limitations. The transposon 
mutagenesis can be unsuccessful if a good screening method is not found, if the 
spectinomycin resistance cassette poses a problem, or if more than one mutation is 
needed for resistance. The latter was the case in an attempt to use Tn7SX to select for 
resistance to the cell membrane perturbing antibiotic daptomycin. We only obtained 
insertions with minimal decreases in susceptibility, which is likely due to the fact that 
multiple mutations are needed for resistance, or a point mutation in essential genes. 
Altogether, the high number of different insertions that conferred resistance to 
moenomycin is remarkable. The mutations opened up many new aspects related to the 
mechanism of action and resistance of moenomycin, and linked to cell wall synthesis 
that remain subjects worthy of further investigation. The findings of mutants 
potentially involved in fosfomycin detoxification by screening for drug sensitivity 
highlight the versatility of the Tn7SX transposon system. 
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CHAPTER 5 
THE TRANSGLYCOSYLATION INHIBITORS RAMOPLANIN AND 
MOENOMYCIN INDUCE DISTINCT TRANSCRIPTIONAL RESPONSES 
 
The transglycosylation step of cell wall synthesis is an important antibiotic 
target because it is essential and specific to bacteria. Moenomycin and ramoplanin are 
two antibiotics targeting this step, albeit by different mechanisms. The glycolipid 
moenomycin binds to the transglycosylase domain of penicillin binding proteins, 
while the lipoglycopeptide ramoplanin binds to lipid II, the enzyme and substrate 
during the transglycosylation reaction, respectively. In order to study how bacteria 
respond to inhibition of cell wall synthesis at the transglycosylation step, we have 
determined transcriptional profiles after treatment with moenomycin and ramoplanin 
in the Gram-positive model organism Bacillus subtilis. Contrary to our expectations, 
the antibiotics did not stimulate overlapping responses. Ramoplanin strongly induced 
the LiaRS two component system, which was previously shown to be induced by cell 
envelope active antibiotics, like vancomycin and daptomycin. LiaRS controls 
expression of the phage-shock-protein LiaH, which is assumed to protect against 
membrane perturbation. Moenomycin, however, almost exclusively induced genes that 
are part of the extracytoplasmic function σ factor σM regulon. σM regulates genes that 
are involved in cell wall synthesis, division, or cell shape determination. While a liaH 
deletion was not more susceptible to ramoplanin, a sigM deletion was much more 
sensitive to moenomycin. Overexpression of σV, which led to induction of a large 
fraction of the σM regulon, was not able to compensate for moenomycin susceptibility. 
The roles of σM and σV are discussed in the context of moenomycin resistance. 
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The majority of the studies in this chapter were performed by A. B. Hachmann. 
Thorsten Mascher (Ludwig-Maximilians-University Munich, Germany) contributed to 
the ramoplanin microarrays. Bronwyn Butcher (Cornell University) constructed the σV 
overexpression strain and did the σV microarrays. The data analysis was completed by 
A. B. Hachmann. 
 
5.1 Introduction 
Ramoplanin is a lipoglycodepsipeptide that inhibits cell wall synthesis of 
Gram-positive bacteria (Fig. 5.1). As a non-ribosomal peptide synthesis product of 
Actinoplanes ATCC 33076, it was found in at least three forms, A1, A2, and A3, 
which differ in their acyl chain substituents. With an overall positive charge, it 
comprises 17 amino acids that form a 49-member lactone ring with a di-mannose 
group and a polyprenyl tail (4, 19). It is in phase III clinical trials for the treatment of 
Clostridium difficile-associated diarrhea (CDAD) (2). In addition, it is also active 
against methicillin resistant Staphylococcus aureus and vancomycin resistant 
enterococci; though a systemic administration is not yet developed, because of 
ramoplanin’s hydrolytic instability and potential to aggregate into insoluble fibrils (15, 
16, 18). 
Initial reports in 1990 on the mechanism of action of ramoplanin suggested that 
it targets lipid I and MurG (27). Then, it was not known that MurG and lipid I are 
intracellular targets. Walker et al., however, found that ramoplanin inhibits 
transglycosylation by binding to extracellular lipid II, in a 2:1 ratio (Fig. 5.2) (18). It 
was shown to bind to the reducing end of the nascent glycan chain, at the initiation 
sites of PG synthesis and lipid II (16, 32). Figure 5.3 shows an x-ray crystal structure 
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(at 1.4 Å resolution) of a ramoplanin dimer appearing as two stacked antiparallel half-
disks (19). By sequestering lipid II, the substrate for transglycosylation and 
transpeptidation, formation of the mature, fully cross-linked peptidoglycan is 
inhibited, which leads to a mechanically weakened cell wall and bacterial death from 
osmotic lysis (19).  
 
 
Figure 5.1. Structure of the lipoglycodepsipeptide ramoplanin (19). 
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Figure 5.2. Ramoplanin inhibits transglycosylation by binding extracellular lipid II 
(16). 
 
 
 
Figure 5.3. Structure of a ramoplanin dimer at the membrane interface (dotted line). 
Monomers are colored blue and yellow. Water: red spheres, chloride ions: magenta 
spheres, detergent molecules: green. The positions of the solvents illustrate the 
hydrophobicity distribution, PDB ID 1DSR (19). 
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Another well-characterized antibiotic targeting the transglycosylation step of 
Gram-positive bacteria is moenomycin (see also Chapter 1 and 4). Moenomycin is a 
glycolipid that was shown to bind to transglycosylase by mimicking lipid IV (dimer of 
two lipid II molecules) during peptidoglycan synthesis (Fig 5.4) (23, 29). 
Here, we examined the transcriptional response to two antibiotics that both 
inhibit the transglycosylation step during cell wall synthesis in B. subtilis. The results 
prompted us to further investigate the regulons of the LiaRS two-component system 
and the extracytoplasmic function (ECF) σ factors σM and σV. 
 
 
 
Figure 5.4. Crystal structure of moenomycin. 
Sites of interaction with amino acids of the glycosyltransferase subunit of PBP2 of S. 
aureus are indicated, PDB ID 2OLV(23). 
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5.2 Materials and Methods 
 Bacterial strains and growth conditions. Bacteria were cultured at 37°C with 
vigorous shaking using Luria Bertani (LB) as growth medium. The following 
antibiotics were used for selection when necessary: spectinomycin 100 g/ml, 
kanamycin 10 g/ml, chloramphenicol 10 µg/ml, tetracycline 20 µg/ml, and 
erythromycin 1 µg/ml with lincomycin 25 µg/ml (mls: macrolide-lincomycin-
streptogramin B resistance). The strains used in this study were derived from Bacillus 
subtilis wild-types W168 (trpC2) and CU1065 (W168 trpC2 attSPβ) and are listed in 
Table 5.1. Gene deletions were generated by replacing open reading frames with 
antibiotic resistance cassettes using long-flanking-homology PCR (25, 31). 
Moenomycin was kindly provided by Biovet JSC (Bulgaria). Minimal inhibitory 
concentrations (MIC) were determined by diluting overnight cultures 1:100, growing 
to OD600 of 0.4, and re-diluteding to 5 x 10
5
 CFU/ml in microtiter plates with a total 
inoculum of 200 µl. Growth was measured spectrophotometrically (OD600) using a 
Bioscreen incubator (Growth Curves USA, Piscataway, NJ) at 37°C with vigorous 
shaking. The absorbance was recorded every 20 minutes for 24 hours. Inhibition was 
defined as a final OD600 < 0.05 (at the 24 hour time point). In most cases, B. subtilis 
wild-type or mutants treated with moenomycin did not result in a clear determinable 
MIC, but rather in a delayed lag phase. After 24h W168 was able to grow even with 
addition of 500µ/ml or 2000µ/ml moenomycin. Here, to compare different mutants, 
we used the ability to outgrow a certain moenomycin concentration after a particular 
time as a measure of susceptibility. Zone of inhibition assays were performed as 
described previously (10). 
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RNA preparation and microarray analyses. Cultures were grown to mid-log 
phase (OD600 of 0.4) and split into two flasks. For ramoplanin, one sample was treated 
with 5 µg/ml for 10 mintues, for moenomycin, one sample was treated with 1 µg/ml 
for 15 minutes, for σV overexpression, 1mM IPTG was added for 20 minutes; the other 
sample was used as non-treated control. Total RNA was isolated from three different 
biological replicas with the RNeasy Mini Kit (Qiagen Sciences, Maryland). After 
DNase treatment with TURBO DNA-free
TM
 (Ambion), RNA concentrations were 
quantified using a NanoDrop spectrophotometer (NanoDrop Tech. Inc., Wilmington, 
DE). The corresponding cDNA was synthesized from 20 µg total RNA and 
differentially labeled according to manufacturer’s instructions using the SuperScriptTM 
Plus Indirect cDNA labeling System (Invitrogen). Before and after indirect labeling 
with Alexa Fluor 555 or Alexa Fluor 647 (at least 3 h at room temperature) cDNA was 
purified using the Qiagen PCR purification kit (Qiagen, Maryland) and quantified with 
NanoDrop. Both labeled cDNA populations were combined (approximately 100 
pmoles coupled cDNA each), denatured, and hybridized to a microarray slide 
overnight at 42
o
C for 16-18 h. After washing, hybridized microarray slides were 
scanned with a GenePix
TM
 4000B array scanner (Axon Instruments, Inc.). Our B. 
subtilis W168 microarrays, consisting of 4109 gene-specific antisense 
oligonucleotides (65-mers; Sigma-Genosys), were printed at the W.M. Keck 
Foundation Biotechnology Resource Laboratory, Yale University. Each slide contains 
8,447 features corresponding to duplicates of each ORF-specific oligonucleotide, 
additional oligonucleotides of control genes, and 50% DMSO blank controls. Images 
were processed using the GenePix Pro 4.0 software package which produces (R,G) 
fluorescence intensity pairs for each gene. Each expression value is represented by at 
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least six separate measurements (duplicate spots on each of three arrays). Mean values 
and standard deviations were calculated with MS Excel. The normalized microarray 
datasets were filtered to remove those genes that were not expressed at levels 
significantly above background in either condition (sum of mean fluorescence 
intensity <20). In addition, the mean and standard deviation of the fluorescence 
intensities were computed for each gene and those where the standard deviation was 
greater than the mean value were ignored. The fold induction values were calculated 
by using the signal intensities of treated samples divided by untreated samples.  
Cluster analysis. Results of whole genome microarray analyses of B. subtilis 
with a set of antimicrobial compounds from our data and from a study by Hutter et al. 
(20) was compared by complete linkage clustering (arrangement based on treatment 
and genetic response similarity) using the Gene Cluster 3.0 software. The resulting 
cluster was visualized with Treeview 1.60 written by Michael Eisen (14). 
 
 
 
Strains Genotype, remarks Reference 
 
W168 trpC2 BGSC no. 1A1 
CU1065 W168 trpC2 attSPß lab stock (30) 
HB5121 W168 liaIHGFSR::spc (17) 
HB0933 CU1065 liaR::kan (25) 
HB0031 CU1065 sigM::kan (11) 
BSU2007 Δ7 ECF σ factor unmarked deletion (1) 
  
 
Table 5.1. Strains and oligonucleotides used in this study. 
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 5.3 Results and Discussion 
Unexpected stress responses to the transglycosylation inhibitors 
ramoplanin and moenomycin. Ramoplanin and moenomycin target the same step 
during peptidoglycan formation, with the former binding to the substrate (lipid II), and 
the latter the enzyme (HMW PBP) (Fig. 5.4) (18). In order to compare the 
transcriptional response to these two molecules that both inhibit transglycosylation, we 
performed microarrays of B. subtilis treated with the antibiotics. 
Surprisingly, the transcriptional response showed no obvious overlap between 
the two antibiotics. Moenomycin treatment strongly induced the σM regulon, which is 
known to be upregulated by cell wall active antibiotics (Table 5.3). This is in contrast 
to earlier studies with vancomycin or bacitracin, where the induction of σM genes was 
almost always accompanied by induction of other ECF σ factors and TCS (e.g., σW, or 
LiaRS TCS) (8, 13). Here, we mainly saw members of the σM regulon, which 
confirmed Eiamphungporn’s recent findings about the regulon (13). 
Ramoplanin treatment, in turn, did not strongly induce the σM regulon. Instead, 
treatment resulted in upregulation of the LiaRS TCS and potential regulon members. 
Overall, the transcriptional response resembled more that of daptomycin treatment in 
B. subtilis (detailed in Chapter 2). This indicates that both antibiotics instigate 
different stresses in the cell envelope, and correspondingly lead to different responses.  
The transcriptional response to ramoplanin. In order to learn more about the 
transcriptional response of B. subtilis to the lipid II-binding antibiotic ramoplanin, we 
conducted microarray experiments. Upon treatment with the drug we observed a 
strong induction of LiaRS TCS regulon members (Table 5.2, Fig. 5.5). LiaRS was 
originally named for Lipid II Interacting Antibiotics, because it was strongly 
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upregulated after treatment with the lipid II targeting antibiotics vancomycin or 
bacitracin (26). More recently, though, we found that liaRS is also induced by the 
membrane active antibiotic daptomycin (see Chapter 2, (17)). In fact, the response to 
daptomycin is very similar to that of ramoplanin (Fig 5.8). However, the two 
antibiotics differ with regard to mutant susceptibility; a liaIH deletion is more 
susceptible than wild-type to daptomycin, but not to ramoplanin. W168 and liaIH have 
an MIC of 0.4 µg/ml ramoplanin.  
The low expression of other regulon members in the ramoplanin microarray 
was unexpected, as e.g., σM regulated genes were known to be strongly induced by 
other cell wall active antibiotics, like vancomycin, which also binds lipid II. To test 
whether other genes would be induced more strongly in the absence of the LiaRS 
TCS, we repeated the microarray with ramoplanin in the absence of the LiaR response 
regulator (Fig 5.6, Fig. 5.7). The liaR deletion strain shows some compensation by σM 
and spx regulated genes as well as other regulon members. Nonetheless, the role of the 
LiaRS TCS is clearly important in the stress response to these antibiotics. A question 
that still remains is why the two antibiotics, that each target different parts of the cell 
envelope, induce such a similar transcriptional response.  
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Table 5.2. Ramoplanin stimulon. 
Genes induced or repressed more than two-fold are shown with their respective 
regulator. 
Gene Fold 
Change 
Regulon Gene Fold 
Change 
Regulon Gene Fold 
Change 
Regulon 
liaH 551.36 LiaRS yjbC 6.95 ECF gabD 6.02 Spx 
liaI 176.84 LiaRS yceD 2.89 ECF yhfJ 4.33 Spx 
liaF 54.30 LiaRS yceE 2.67 ECF yfjR 3.92 Spx 
liaG 53.72 LiaRS yceF 3.39 ECF ydiP 3.92 Spx 
liaR 31.51 LiaRS yceG 2.63 ECF nfrA 3.84 Spx 
liaS 26.06 LiaRS yceH 2.77 ECF yugJ 3.44 Spx 
yhcZ 3.52 LiaRS yrhI 2.95 ECF yuaE 3.20 Spx 
yvrI 63.36 yvrIHa yrhH 2.90 ECF yhfK 3.06 Spx 
yvrL 15.74 yvrIHa divIC 2.51 ECF yjbH 2.98 Spx 
yvrH 4.70 yvrIHa abh 2.43 ECF trxB 2.83 Spx 
oxdC 2.04 yvrIHa ywnJ 2.03 ECF ywnF 2.70 Spx 
sigM 2.64 σ
M
 ylaC 2.07 ECF yfiC 2.63 Spx 
yhdK 2.47 σ
M
 qoxD 0.53 ECF sodA 2.63 Spx 
yhdL 3.00 σ
M
 yxlD 3.21 σ
Y
  ymfH 2.54 Spx 
yqjL 10.44 σ
M
 σW yxlE 2.07 σ
Y
 yqjM 2.51 Spx 
mreB 4.99 σ
M
 yxlF 3.17 σ
Y
 ytzB 2.51 Spx 
mreD 2.65 σ
M
 yxlG 2.07 σ
Y
 yvgP 2.48 Spx 
ytpA 4.01 σ
M
 xpaC 2.37 σ
W
 ytcI 2.44 Spx 
divIB 3.98 σ
M
 yfhL 2.35 σ
W
 yqiG 2.42 Spx 
yebC 3.83 σ
M
 ydjP 2.11 σ
W
 yckI 2.38 Spx 
yfnI 3.55 σ
M
 yteJ 0.52 σ
W
 yraA 2.37 Spx 
ydaH 3.27 σ
M
 ywbO 2.77 σ
X
 yrzF 2.34 Spx 
hprT 3.16 σ
M
 ywjC 3.33 σ
B
 trxA 2.32 Spx 
ycgQ 3.15 σ
M
 yvyD 2.33 σ
B
 yugP 2.25 Spx 
ytpB 3.07 σ
M
 ykzA 2.27 σ
B
 yvrD 2.15 Spx 
ypbG 2.59 σ
M
 ytkL 2.18 σ
B
 yrzG 2.14 Spx 
yacC 2.05 σ
M
 ydaE 2.13 σ
B
 ywrO 2.13 Spx 
yacK 2.49 σ
M
 ydaG 2.10 σ
B
 yjbQ 2.11 Spx 
yacL 2.26 σ
M
 ytrA 2.80 YtrA ywoB 2.21  
sbp 2.48 σ
M
 ytrB 2.68 YtrA ywoC 5.05  
murB 2.32 σ
M
 ytrC 3.26 YtrA ywoD 3.73  
ypuA 2.23 σ
M
 ytrD 3.83 YtrA ypbH 2.02  
ypuD 2.07 σ
M
 ytrE 2.28 YtrA    
 
 
 ytrF 2.28 YtrA    
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Figure 5.5. Ramoplanin stimulon in B. subtilis. 
The scatterplot represents the average expression levels of treated versus untreated 
cultures of B. subtilis CU1065 (ramoplanin at 5 µg/mL, treated for 10 minutes) of 
triplicate microarray analyses. The legend lists highly expressed genes as grouped by 
their corresponding transcriptional regulators. 
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Figure 5.6. Ramoplanin stimulon in B. subtilis liaR deletion. 
The scatterplot represents the average expression levels of treated versus untreated 
cultures of B. subtilis liaR (ramoplanin at 5 µg/mL, 10 minutes) of triplicate 
microarray analyses.  
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Figure 5.7. Ramoplanin stimulon of a liaR deletion versus wild-type CU1065. 
The scatterplot represents the fold change of average expression levels of treated 
versus untreated cultures of B. subtilis liaR versus CU1065 (ramoplanin at 5 µg/mL, 
10 minutes) of triplicate microarray analyses.  
 
 
 
Figure 5.8. Cluster analysis of B. subtilis with 40 antibiotics. 
LiaRS TCS regulon members cluster together and are strongly induced by ramoplanin 
and daptomycin. Gene expression profiles from Hutter et al. (20) and our data after 
treatment with 40 different antibiotics, complete linkage clustered, i.e. by treatment 
and fold change of gene expression. Red indicates induction and green repression after 
treatment, whereas black corresponds to unchanged gene expression. 
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Role of the LiaRS TCS in response to ramoplanin. Initial experiments with 
daptomycin suggested a mechanism of action involving inhibition of lipoteichoic acid 
synthesis, because of accumulation of lipoteichoic acid precursors (6), but later studies 
could not confirm these findings (28). However, a link to teichoic acids could also be 
deduced from ramoplanin’s mechanism of action, binding to lipid II. Figure 5.9 shows 
the connection between peptidoglycan and teichoic acid synthesis (3). Upon treatment 
with ramoplanin, one could expect that the cell tries to compensate for the loss of lipid 
II (that is sequestered by ramoplanin), by producing more lipid II. However, the 
number of lipid II molecules is limited, as it usually is recycled during cell wall 
synthesis, and can only be compensated by drawing lipid II from the teichoic synthesis 
pathway. This could create an imbalance towards accumulation of toxic precursors, 
which was shown to be the likely reason for toxicity, when late teichoic acid synthesis 
enzymes were deleted (3, 12). Moreover, a decrease of teichoic acids also decreases 
the negative net charge of the cell envelope, probably causing further envelope stress. 
Whether the comparable response seen with ramoplanin and daptomycin is related to 
effects on teichoic acids, or has to do with secondary effects caused by accumulation 
of teichoic acid precursors, or effects of envelope charge alterations, can be the topic 
of future studies. Another aspect that both molecules have in common is that they are 
positively charged antimicrobial peptides (daptomycin indirectly by its complexation 
with Ca
2+
), and that both anchor into the cell membrane with an acyl side chain. 
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Figure 5.9. Teichoic acid and peptidoglycan synthesis. 
Peptidoglycan on left and teichoic acid synthesis on right, with common substrate 
undecaprenyl-phosphate (in black rectangle). Teichoic acids are polymerized 
intracellularly, and peptidoglycan extracellularly. Solid arrows: enzyme catalysed step, 
block arrows: activated substrate, question mark: unknown enzymatic reactions (3). 
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The transcriptional response to moenomycin. We wondered whether 
moenomycin and ramoplanin induce a similar stress response in B. subtilis, since both 
antibiotics inhibit the transglycosylation step during cell wall synthesis. Treatment 
with moenomycin, however, resulted in a different response; it induced a large 
fraction of the σM regulon genes (Fig. 5.10). The σM regulon comprises about 60 
genes, most of them involved in cell envelope synthesis, cell division and shape 
control, as well as DNA repair. The activation of its anti σ factor, YhdKL, is not yet 
known. σM is induced by cell wall active antibiotics, like vancomycin or bacitracin, 
and by heat stress or ethanol (11, 13, 21, 22). Table 5.3 summarizes the response of B. 
subtilis to moenomycin treatment. After 15 minutes treatment, 40 genes of the σM 
regulon were induced (20 minutes treatment caused even more σM genes to be 
induced, data not shown). Amongst them is yebC, a putative integral inner membrane 
protein, which was 3.3 fold induced, and which conferred resistance to moenomycin 
when disrupted by the Tn7SX transposon (see Chapter 4).  
The induction of the σM regulon is in line with a similar induction by 
vancomycin, which also binds lipid II. Yet, as this response almost exclusively 
consists of σM regulon members, we wondered how a sigM deletion mutant would 
react to moenomycin. The response was overall less strong, but the fact that we still 
saw a subset of σM genes induced including sigV was intriguing. To get a clearer 
picture of the σV regulon we therefore performed transcriptional profiling on a strain 
that overexpressed σV in the absence of all other ECF σ factors. 
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Figure 5.10. Moenomycin stimulon in B. subtilis. 
The scatterplot represents average expression levels of treated versus untreated 
cultures of B. subtilis CU1065 (moenomycin at 1 µg/mL, 15 minutes). The legend lists 
highly expressed genes as grouped by their corresponding transcriptional regulators (U 
stands for unknown regulated group, e.g., ytr operon). Spots are labeled up to 1.5-fold 
induction or repression. 
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 Table 5.3. Moenomycin stimulon and σV regulon. 
Genes induced or repressed >1.5-fold are shown with their respective regulator. 
Gene Fold Change Regulon Gene Fold Change Regulon 
 MOE σV   MOE σV  
yqjL 12.01 619.06 σM trxA 2.84 - Spx 
murG 6.97 4.43 σM yvrD 2.70 - Spx 
ypbG 6.21 2.25 σM yfiC 2.62 - Spx 
murB 4.05 3.14 σM ywnF 2.59 - Spx 
ywaC 3.58 56.90 σM nfrA 2.54 - Spx 
yfnI 3.48 3.07 σM trxB 2.49 - Spx 
ylxW 3.44 2.20 σM yuaE 2.47 - Spx 
ydaH 3.26 899.95 σM gabD 2.41 - Spx 
yhdK 3.25 2.08 σM yqiG 2.33 - Spx 
yebC 3.25 13.94 σM yrzF 2.17 - Spx 
yrhJ 2.98 5.08 σM yrzG 2.14 - Spx 
divIB 2.93 2.39 σM yvgP 2.10 - Spx 
ylxX 2.88 1.60 σM yckK 2.09 - Spx 
maf 2.83 10.34 σM yugP 2.02 - Spx 
ywnJ 2.62 360.14 σM yqjM 1.81 - Spx 
yhdL 2.59 1.54 σM yckI 1.80 - Spx 
dltE 2.50 12.13 σM ywrO 1.69 - Spx 
ycgR 2.50 20.92 σM yraA 1.67 - Spx 
ycgQ 2.49 52.37 σM yhfK 1.63 - Spx 
yrhI 2.29 6.83 σM ymfH 1.59 - Spx 
yacK 2.26 3.01 σM ydiP 1.57 - Spx 
sbp 2.25 1.45 σM yjbI 0.55 - Spx 
ywtF 2.21 7.66 σM yjbH 0.39 - Spx 
ypuD 1.95 352.45 σM sodA 0.31 - Spx 
sigM 1.93 - σM sigZ 2.72 - σZ 
mreC 1.92 3.45 σM yrpG 1.98 - σZ 
mreB 1.90 4.01 σM ywhE 2.67 - ECF 
yceC 1.88 4.41 σM ylaA 2.41 7.33 ECF 
yceD 1.84 3.69 σM qoxB 0.69 - ECF 
mreD 1.67 3.73 σM ylaB 0.48 12.76 ECF 
minC 1.64 2.33 σM sigV 2.56 47.21 σV 
ytpA 1.59 0.94 σM yrhK 2.13 16.29 σV 
recU 1.58 1.37 σM yrhL 3.19 13.15 σV 
pbpX 1.56 5.41 σM ydcA 2.31 - σW 
ywoA 1.55 24.11 σM yknW 0.68 473.04 σW 
abh 1.53 6.57 σM yuaI 0.68 - σW 
divIC 1.53 4.26 σM ysdB 0.57 - σW 
rodA 1.50 5.51 σM ythQ 0.53 1.66 σW 
yacA 1.56 1.49 σM yoaG 0.53 4.46 σW 
ponA 2.12 1.29 σM yozO 0.35 21.47 σW 
ywoB 1.80 - YtrA sigX 0.57 - σX 
ytrF 1.58 - YtrA oxdC 2.05 - YvrHI 
ywoC 1.51 - YtrA yvrI 1.82 - YvrHI 
ytrA 0.70 - YtrA yvrL 1.51 - YvrHI 
yycG 1.70 - YycFG csbC 1.94 - σB 
yxlF 1.61 92.77 σY ytkL 1.75 - σB 
yxlG 1.60 5.16 σY csbB 0.40 - σB 
yhcY 1.50 - LiaRS nap 0.32 - σB 
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The σV regulon. σV belongs to the group of four ECF σ factors σV, σY, σZ, and 
YlaC, that have not been studied extensively (24). Here, we wanted to elucidate the 
role of σV.  We carried out microarray analyses with overexpression of σV in wild-type 
and in the absence of all seven ECF σ factors. The latter is a strain, which we obtained 
from Kei Asai, Japan (1). It has unmarked deletions of all seven ECF σ actors, which 
makes it a great tool to study each single σ factor individually. Here, this strain is 
called Δ7. We constructed an ectopic IPTG inducible (Pspac) copy of sigV into these 
strains. Cultures were grown to mid-exponential phase and split in two. One culture 
was induced for 20 minutes, and RNA was harvested from both for transcriptional 
profiling.  
Surprisingly, overexpression of sigV in wild-type showed increased expression 
of 39 genes that are part of the σM regulon and four genes that are part of the σW 
regulon (Table 5.3) (Fig. 5.11). This opened up the question, whether σV induced 
expression of sigM and sigW, and thereby indirectly their regulon members, or 
whether σV induced those genes directly. 
In order to address this, we repeated the σV overexpression microarray, but this 
time in the Δ7 background (Fig. 5.12). Again, a similar set of σM and σW regulon 
members was induced, but now much stronger. As this strain is missing all other ECF 
σ factors, we concluded that this is due to direct regulation by σV. Why a subset of the 
σM and σW regulated genes was present and not the whole operon is likely a result of 
closer similarity to the σV promoter consensus sequence (Fig. 5.14).   
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Figure 5.11. Overexpression of sigV in B. subtilis W168. 
The scatterplot represents average expression levels of IPTG induced versus 
uninduced cultures of W168. The legend lists highly expressed genes as grouped by 
their corresponding transcriptional regulators. 
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Figure 5.12. Overexpression of sigV in B. subtilis Δ7 ECF deletion strain. 
The scatterplot represents average expression levels of IPTG induced versus 
uninduced cultures of Δ7. The legend lists highly expressed genes as grouped by their 
corresponding transcriptional regulators. 
 
 
Overlapping promoter recognition of ECF σ factors. We have found earlier 
indications of promoter overlap among ECF σ factors when we compared antibiotic 
susceptibility of single, double, and triple mutants of sigM, sigW, and sigX in zone of 
inhibition assays (Fig 5.13) (24). When treated with the MurAA inhibitor fosfomycin, 
we saw that mainly σW was responsible for conferring resistance to the drug; as was 
σM for the transglycosylase inhibitor moenomycin. However, if the cells were treated 
with D-cycloserine, each single or double mutant had no significant effect, only in the 
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triple mutant, sigMWX, were the cells much more susceptible to the drug. This could 
be explained by a very similar promoter consensus sequence (Fig 5.14) (24).  
The regulon overlap during overexpression of sigV could be due to promoter 
occlusion, where the three prominent ECF σ factors are hindering σV from binding to 
RNA polymerase, as they are expressed at much higher levels than σV. The 
overexpression allows σV to now bind to RNA polymerase in the presence of the other 
σ factors, and even stronger in their absence.  
 
 
Figure 5.13. Antibiotic sensitivity profile of ECF σ mutants. 
Each bar represents the average zone of inhibition of at least two assays performed 
with two independent clones of each deletion mutant (deleted sigma factors are shown 
on the x axis). The y axis shows the zone of inhibition (in millimeters), expressed as 
total diameter minus diameter of the filter paper disk (5.5 mm). NCIB: wild-type 
NCIB3610. 
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Figure 5.14. Promoter consensus sequence of σW, σX, and σM. 
Weblogo representation of the position weight matrices for recognition by σM, σW, and 
σX. The promoters used for determining the consensus sequences are derived from 
published data (5, 7, 9, 13, 21) (generated at http://weblogo.berkeley.edu/logo.cgi). 
 
Role of σV and σM in moenomycin resistance. Since σV regulates the 
expression of a large subset of genes from the σM regulon, we wondered whether σV 
overexpression could also confer resistance to moenomycin, like σM does (Fig 5.13, 
see also Chapter 4) (24). We tested this with liquid growth inhibition assays by 
measuring the minimal inhibitory concentration (MIC) after 10 hours of treatment 
with moenomycin. It turned out that a sigM deletion was very sensitive compared to 
the W168 wild-type, with an MIC of 0.4 µg/ml vs. 10 µg/ml, respectively. 
Overexpression of σV in the Δ7 background did not restore wild-type levels of 
susceptibility. In fact, this strain was as sensitive as the sigM deletion. This indicates 
that the resistance to moenomycin is conferred by regulon members that are 
exclusively regulated by σM and not by σV. The putative σV regulon is currently being 
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confirmed by other methods.  
Exclusive members of the σM regulon and their promoter consensus sequence 
are listed in the left column of Table 5.4 and top panel of Figure 5.15, respectively. 
This table summarizes the results from comparing the known σM regulon with the 
putative σV regulon. The genes/operons in the right column were induced by sigV 
overexpression. Note the possibility that the Δ7 strain may have defects in the cell 
envelope or synthesis, which could lead to activation of other stress responses. 
It is not yet known, which of the σM regulated genes is responsible for 
resistance to moenomycin. A likely candidate is PBP1 (ponA), because it is a target of 
moenomycin. Yet, when we tested a ponA deletion strain for moenomycin 
susceptibility, we did not see any difference compared to wild-type. This still leaves 
several genes as potential candidates. It is worth noting, that none of the moenomycin 
resistant mutations that were obtained through transposon mutagenesis (see Chapter 4) 
are among the genes that are exclusively regulated by σM. 
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Table 5.4. σV and σM specific regulon members. 
About 15 operons are exclusively regulated by σM (putative) and 23 operons are 
putatively regulated by both, σVand σM. 
operons exclusively 
regulated by σM 
operons putatively regulated 
by σM and σV 
  sigM yhdLK    yqjL    ywtF  
  ypbG    ydaH    rodA  
  ypuA    yfnI    ypuD  
  bcrC    maf    ywaC  
  yngC    mreBCDminCD    yrhHIJ  
  recUponA    yacLM    abh  
  (ydbO-ydbP(as))    divIC    dltABCDE  
  ytpAB    (murG)murB    ywnJ  
  yjbC spx    divIBylxXW sbp    yceCDEFG  
  rapD    ycgRQ    pbpX  
  secDF    ddlmurF    ywbNO  
  metA    yebC   
  yacAhprTftsH    
  yacBC    
  ytnA    
 
 
 
Figure 5.15. Promoter consensus sequence of σM and σV. 
Weblogo representation of the position weight matrices for the potential recognition 
by σM or σV exclusively. The promoters used for determining the consensus sequences 
are derived from results of our expression profiling (weblogo generated at 
http://weblogo.berkeley.edu/logo.cgi). 
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5.4 Conclusions.  
Even though the mechanism of action of an antibiotic has been studied, 
secondary effects, and stress responses are not quite apparent. Understanding these 
responses is of great importance to learn more about regulatory and structural aspects 
of the cell, as well as potential resistance mechanisms.  
Here, we investigated stress responses to the cell wall active antibiotics 
moenomycin and ramoplanin. In contrast to our expectations, B. subtilis responded 
differently to antibiotics that target the same step during cell wall synthesis. 
Moenomycin induced the ECF σ factor σM, and ramoplanin the LiaRS TCS. Members 
of the σM regulon also conferred resistance to moenomycin. In addition, we showed 
that σV has an overlapping but smaller regulon compared to σM. The σV regulon is 
currently being studied and confirmed by other methods by Veronica Guariglia. 
Further experiments with ramoplanin were not carried to completion due to compound 
limitations.  
The presented results focus on cell envelope stress response in B. subtilis, in 
particular on antibiotics that target the cell envelope, because of the rise in antibiotic 
resistance coupled with the slow rate of antibiotics discovery. New findings about 
stress responses and resistance can contribute to advance our understanding of the 
molecular nature of genetic systems involved in antibiotic resistance. 
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Table S3.1. Differential quantification of gene expression of Dap
R
1 and W168 
without daptomycin treatment. Genes induced or repressed >2.5-fold are shown. 
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 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
yrkP 1670 104 16.1 TCS response regulator (regulates yrkR, yrkO, yrkN, ykcC, ykcB) 
yrkQ  1151 135 8.6 TCS histidine kinase 
yrkR 6561 63.8 102.9 psiE,  phosphate starvation inducible protein 
yrkO 84 24.3 3.5 similarity to transporter 
yrkN 58 10.3 5.7 GCN5-related N-acetyltransferase 
ykcB 1128 3.3 347 similar to glycosyltransferase 
ykcC 2239 66.8 33.5 similar to glycosyltransferase 
bioA 1373 91 15.1 biotin biosynthesis 
bioB 1781 94.5 18.8 biotin biosynthesis 
bioD 2151 140 15.4 biotin biosynthesis 
bioI 1407 54.3 25.9 biotin biosynthesis 
yuiG 408 97.8 4.2 biotin biosynthesis 
yycA 438 118 3.7 similar to ykcB (glycosyltransferase) 
yorJ 314 1 314 putative DNA primase 
yorH 329 168 2.0 unknown 
liaI 2091 192 10.9 putative membrane protein 
liaH 1642 127 13.0 PspA homolog, cell membrane protection 
liaG 275 87.5 3.1 putative membrane anchored protein 
liaF 331 164 2.0 negative regulator of LiaR 
liaS 304 145 2.1 TCS histidine kinase 
liaR 113 69 1.6 TCS response regulator 
yvrI 76 14.8 5.2  factor YvrI 
yvrH 158 63 2.5 TCS response regulator 
yvrG 378 176 2.2 TCS histidine kinase 
oxdC 312.8 122 2.6 oxalate decarboxylase 
bcrC 277 48 5.7 bacteriocin transport/UPP phosphatase 
yqjL 504 55 9.2 hydrolase; paraquat resistance 
ypbG 385 39.8 9.7 phosphoesterase 
ypbH 412 159 2.6 similar to negative regulation of competence; MecA  
ywlC 112 52.8 2.1 sua5/yciO/yrdC/ywlC family protein 
ywlD 99.8 6.5 15.4 putative integral inner membrane protein 
ysbA 178 13.3 13.4 murein hydrolase regulator LrgA 
ysbB 167 28.5 5.9 antiholin-like protein LrgB 
yobE 68.5 31.3 2.2 similar to general secretion pathway protein 
yobJ 90.3 41.3 2.2 helix-turn-helix domain protein 
yobQ 173 65 2.7 AraC/XylS family 
yobR 230 34 6.8 GCN5-related N-acetyltransferase 
yobS 293 38.3 7.7 TetR family transcriptional regulator 
yobT 520 41 12.6 metallo-beta-lactamase family protein 
yvfR 371 41 9.0 similar to ABC transporter (ATP-binding) 
yvfS 310 30.1 10.1 similar to ABC transporter transmembrane subunit 
yvfT 237 48.8 4.9 similar to TCS histidine kinase 
yvfU 128 22 5.8 similar to TCS response regulator 
yfhD 227 88.8 2.6 hypothetical protein 
yfhE 347 141 2.5 hypothetical protein 
yfhK 2153 841 2.6 similar to cell-division inhibitor 
yfhL 651 230 2.83 hypothetical protein 
yfhM 792 315 2.5 similar to epoxide hydrolase; induced by phosphate starvation 
(sigma-B-dependent, PhoPR-independent) 
yfhO 504 214 2.4 similar to multidrug resistance protein 
yhfR 1088 337 3.2 similar to 2,3-diphosphoglycerate-dependent phosphoglycerate 
mutase 
yhfT 558 195 2.9 similar to long-chain fatty-acid-CoA ligase 
yhfU 152 18.8 8.1 similar to biotin biosynthesis 
yclF 93.3 46.8 2.0 similar to di-tripeptide ABC transporter (membrane protein) 
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 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
yclH 299 42 7.1 similar to ABC transporter (permease) 
cotC 74.5 10.8 6.9 spore coat protein, late sporulation; σK controlled 
ytbJ 807 377 2.1 thiamin biosynthesis 
ytbQ 651 98 6.7 similar to epimerase/dehydratase 
yqhA 101 15.5 6.5 similar to positive regulator of σB-activity, negative regulator 
of σB-activity in unstressed cells; acts with RsbR, YkoB, and 
YojH; similar to RsbR 
xlyA 173 86.5 2.0 N-acetylmuramoyl-L-alanine amidase, major role in defective 
prophage PBSX-mediated lysis, endolysin; similar to CwlA of 
the skin element 
xlyB 126 19.8 6.4 N-acetylmuramoyl-L-alanine amidase, major role in defective 
prophage PBSX-mediated lysis 
coxA 317 51.5 6.2 spore cortex protein,  located within the spore integument 
ycgA 158 27 5.9 putative short-chain fatty acids transport protein 
ycgQ 160 56.8 2.8 similar to ABC transporter, substrate-binding protein 
ycgR 103 52.5 2.0 similar to ABC transporter, permease protein 
yebC 184 31.5 5.9 putative permease 
yebG 259 129 2.0 hypothetical protein 
ywaC 339 65 5.2 similar to GTP-pyrophosphokinase, RelA/SpoT domain 
ypnP 135 26.3 5.1 putative drug/sodium antiporter 
des 1560 322.8 4.8 desaturase 
desR 175 40.8 4.3 TCS response regulator, regulating desaturase 
yaaH 81.3 33.5 2.4 spore protein required for L-alanine-stimulated germination; 
cell wall binding motif probably involved in assembly of the 
forespore; σE -dependent; similar to cortical fragment-lytic 
enzyme 
yaaK 1059 522 2.0 unknown 
yaaL 360 74.8 4.8 unknown 
yaaN 264 119 2.2 putative toxic anion resistance protein 
sigW 2573 602 4.3 ECF σ factor 
rsiW 518 125 4.1 ECF anti-σ factor 
sigM 109 45 2.4 ECF σ factor 
yhdL 194 72.5 2.7 ECF anti-σ factor 
sigY 206 105 2.0 ECF σ factor 
sigX 621 386 1.6 ECF σ factor 
rsiX 261 128 2.1 ECF anti-σ factor 
mlpA 958 227 4.2 regulation of aprE, mitochondrial processing peptidase-like, 
zinc protease 
yozE 84.3 21 4.0 similar to serine-type D-Ala-D-Ala carboxypeptidase 
yqiB 657 260 2.5 exodeoxyribonuclease 
yqiC 303 77.5 3.9 exodeoxyribonuclease 
truA 112 29 3.8 pseudouridylate synthase A 
truB 536 278 1.9 tRNA pseudouridine 55 synthase B 
yoqA 154 46 3.3 unknown 
yoqB 76.5 20 3.8 unknown 
yoqC 196 67.3 2.9 unknown 
yocD 290 113 2.6 similar to phage-related DNA-binding protein anti-repressor 
yoqE 101 38.8 2.6 unknown 
yoqF 127 1 127 unknown 
yoqG 198 1 198 unknown 
yoqH 79.3 30.8 2.6 unknown 
yoqJ 81.8 42.5 1.9 unknown 
yoqK 158 67.5 2.3 unknown 
yoqU 87.3 45.5 1.9 unknown 
divIB 1212 318 3.8 cell division 
ylxX 771 229 3.4 cell division 
ylxW 310 96.8 3.2 cell division 
sbp 841 327 2.6 cell division 
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 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
yxjA 742 279 2.7 nucleoside transporter 
yxjI 416 110 2.7 similar to UDP-N-acetylenolpyruvoylglucosamine reductase 
tdk 171 45 3.8 thymidine kinase 
leuD 110 30 3.7 3-isopropylmalate dehydratase (small subunit) 
abrB 1152 319 3.6 transcriptional pleiotropic regulator of transition state genes 
abh 3303 1293 2.6 transcriptional regulator of transition state genes (AbrB-like) 
radC 960 267 3.6 DNA repair protein 
yopX 265 119 2.2 Unknown 
yopY 184 51.5 3.6 Unknown 
bofA 433 122 3.6 inhibition of pro-sigma-K processing 
yhaX 126 35.8 3.5 similar to HAD superfamily hydrolase 
yosI 271 129 2.1 SPBc2 prophage-derived uncharacterized protein yosI 
yosJ 197 82.8 2.4 hypothetical protein 
yosK 452 179 2.5 hypothetical protein 
yosL 187 52.5 3.6 hypothetical protein 
yosM 127 36.8 3.5 ribonucleotide reductase stimulatory protein 
proI 93.8 27.3 3.4 pyrroline-5-carboxylate reductase 
proS 4098 1563 2.6 prolyl-tRNA synthetase 
ykkC 220 76.8 2.9 ykkCD coexpression in E. coli gives rise to a broad specificity, 
multidrug-resistant phenotype; similar to molecular chaperone; 
ykkC and ykkD are tandemly duplicated genes 
ykkD 231 84 2.8 small multidrug resistance protein 
ykkE 327 97.3 3.4 similar to formyltetrahydrofolate deformylase 
ymaA 829 335 2.5 similar to NrdI protein 
ymaB 540 163 3.3 mutt/nudix family 
spoVT 
555 170 
3.3 
transcriptional positive and negative regulator of sigma-G-
dependent genes 
spoVC 862 370 2.3 peptidyl-tRNA hydrolase 
ykuR 1292 636 2.0 N-acetyl-diaminopimelate deacetylase 
ykuS 508 241 2.1 hypothetical protein 
ykuT 143 43.8 3.3 similar to MscS, small conductance mechanosenstive ion channel 
protein 
ywrE 209 64.3 3.3 Unknown 
ydpI 474 148 3.2 similar to permease 
ywqE 139 43.5 3.2 similar to capsular polysaccharide biosynthesis 
ywqF 225 112 2.0 similar to UDP-glucose 6-dehydrogenase 
ymfE 104 52 2.0 similar to multidrug resistance protein 
ymfI 357 113 3.2 short-chain dehydrogenase 
ymfJ 360 142 2.5 Unknown 
araR 415 131 3.2 negative regulation of the L-arabinose metabolic operon 
(araABDLMNPQ-abfA) and of the araE/araR genes 
ydaB 47.8 15.3 3.1 similar to long-chain-fatty-acid--CoA ligase 
ydaD 218 85 2.6 similar to short-chain dehydrogenase/reductase 
ydaE 171 70.8 2.4 similar to ABC-type sugar transport system 
ydaG 2549 1178 2.2 similar to general stress protein (sigB dependent) 
ydaJ 47 16.8 2.8 putative glycosyl hydrolase lipoprotein 
ydaK 61.3 22.8 2.7 putative membrane protein, diguanylate cyclase domain 
ydaN 59 21.3 2.8 similar to cellulose synthase domain protein 
ykrI 119 55.8 2.1 Anti-sigma-I factor rsgI 
ykrL 398 160 2.5 heat shock protein HtpX (zinc dependent protease) 
ykrS 94.8 41 2.3 methylthioribose-1-phosphate isomerase (methionine salvage 
pathway) 
ykrX 337 109 3.1 2-OH-3-keto-5-methylthiopentenyl-1-P- phosphatase 
ykrY 354 123 2.9 methylthioribulose-1-phosphate dehydratase 
gspA 4970 1611 3.1 general stress protein (sigB dependent) 
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 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
xhlA 311 112 2.8 involved in cell lysis upon induction of defective prophage PBSX 
xhlB 671 218 3.1 involved in cell lysis upon induction of defective prophage PBSX 
ykgA 905 295 3.1 similar to N-Dimethylarginine dimethylaminohydrolase 
murB 1345 454 3.0 peptidoglycan synthesis 
murG 812 265 3.1 peptidoglycan synthesis 
pbpA 2233 989 2.3 cell wall elongation in spore outgrowth 
pbpX 421 169 2.5 penicillin-binding protein, beta lactamase 
ponA 1270 594 2.1 penicillin-binding proteins 1A/1B; required for vegetative growth 
or spore outgrowth under divalent cation limitation conditions; 
localized to and has an important function in the division septum 
in vegetative cells; mutant cells display a significant septation 
defect and FtsZ rings with aberrant structure or improper 
localization 
mreB 1123 564 2.0 cell-shape determining protein 
pbpB 1421 736 1.9 formation of the cell-division septum (late stage), required for 
both the initiation of division and continued septal ingrowth; 
recruited to the division site, continually during septal ingrowth; 
present transiently in the asymmetrical septum of sporulating 
cells; closely related to pbpB of E. coli 
yvrD 841 276 3.1 similar to ketoacyl-carrier protein reductase 
yvgW 176 57.8 3.0 similar to heavy metal-transporting ATPase 
yvgY 175 87.3 2.0 copZ, copper insertion chaperone and transporter component 
yvaD 70.3 23.3 3.0 putative integral inner membrane protein 
yvaE 87.8 37.3 2.4 similar to multidrug-efflux transporter 
ywkE 399 133 3.0 Protein hemK 
ywkF 152 62.8 2.4 hypothetical protein 
yfjS 55 18.5 3.0 exported N-acetylmuramic acid deacetylase 
yptA 344 117 2.9 hypothetical protein 
maf 677 235 2.9 septum formation 
yuzF 232 81.3 2.9 hypothetical protein 
yeaA 731 260 2.8 hypothetical protein 
glpD 483 172 2.8 glycerol-3-phosphate dehydrogenase 
ymzA 708 253 2.8 unknown 
ymzC 71.3 30.3 2.4 hypothetical protein 
ytzG 133 47.8 2.8 similar to 16S pseudouridylate synthase 
xkdF 538 255 2.8 PBSX prophage, similar to YqbD of the skin element 
xkdG 300 110 2.8 PBSX prophage, similar to YqbE of the skin element 
xkdH 298 134 2.2 PBSX prophage, similar to YqbH of the skin element 
xkdI 497 245 2.0 PBSX prophage, similar to YqbI of the skin element 
xkdJ 312 139 2.3 PBSX prophage, similar to YqbJ of the skin element 
xkdK 149 96.8 2.6 PBSX prophage, similar to sheath tail protein 
xkdM 166 59.5 2.8 PBSX prophage, similar to YqbM of the skin element 
xkdO 178 74.5 2.4 PBSX prophage, putative lytic transglycosylase 
xkdQ 186 102 1.8 PBSX prophage, putative phage cell wall hydrolase 
xkdU 130 47.3 2.8 PBSX prophage, similar to YqcA of the skin element 
xkdV 128 56.3 2.3 PBSX prophage, similar to YqcC of the skin element 
xkdW 140 60.8 2.3 PBSX prophage, similar to YqcD of the skin element 
xkdX 135 46.8 2.9 PBSX prophage, similar to YqcE of the skin element 
ybaE 1296 470 2.8 similar to ABC/cobalt transporter 
ybaF 411 167 2.5 similar to ABC/cobalt transporter 
yybS 630 231 2.7 hypothetical protein 
yybT 869 412 2.1 similar to diguanylate cyclase and phosphoesterase 
dltA 4819 1825 2.6 LTA/WTA synthesis 
dltB 5417 1995 2.7 LTA/WTA synthesis 
dltC 2199 827 2.7 LTA/WTA synthesis 
dltD 4698 1785 2.6 LTA/WTA synthesis 
dltE 1487 489 3.0 LTA/WTA synthesis 
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R
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tlp 324 120 2.7 small acid-soluble spore protein (thioredoxin-like protein) 
yitL 56.8 21 2.7 hypothetical protein 
ykoX 309 115 2.7 hypothetical protein 
ydjN 229 99.5 2.3 unknown 
ydjP 482 179 2.7 unknown 
yvkC 605 226 2.7 phosphoenolpyruvate synthase 
ytxD 323 122 2.7 similar to flagellar motor protein 
ytxE 133 52.5 2.5 similar to motility protein 
ytxJ 3491 1527 2.3 general stress regulon controlled by σB; induced by salt addition 
during logarithmical growth 
mtlA 441 191 2.3 phosphotransferase system (PTS) mannitol-specific enzyme 
IICBA component 
mtlD 1659 627 2.7 mannitol-1-phosphate dehydrogenase 
ypuD 265 100 2.6 hypothetical membrane lipoprotein 
thyB 478 181 2.6 thymidylate synthase 
yodS 77.8 29.5 2.6 similar to putative aminoacyloate CoA-transferase 
clpE 44.8 17 2.6 ATP-dependent Clp protease-like (class III stress gene) 
uvrB 292 111 2.6 excinuclease ABC (subunit B) 
uvrC 177 73.8 2.4 excinuclease ABC (subunit C) 
yabD 457 220 2.1 metal-dependent DNase 
yabK 1067 407 2.6 hypothetical protein 
xepA 126 48 2.6 lytic exoenzyme associated with defective prophage PBSX, 
unlikely to be involved in host cell lysis; similar to YqxG of the 
skin element 
yceG 4872 1903 2.6 tellurium resistance protein 
yceH 2037 931 2.2 similar to toxic anion resistance protein 
safA 3710 1458 2.5 morphogenetic protein associated with SpoVID during the early 
stage of coat assembly; localized in the cortex, near the interface 
with the coat in mature spores; mutant spores have defective coats 
which are missing several proteins (CotG); cell wall binding motif 
probably involved in assembly on the forespore; sigma-E-
dependent 
yxiT 305 120 2.5 hypothetical protein 
dxr 1547 611 2.5 1-deoxy-D-xylulose-5-phosphate reductoisomerase 
yndN 277 110 2.5 Metallothiol transferase fosB 
yoaF 564 251 2.2 similar to sortase family protein 
yoaG 86 34 2.5 similar to bacitracin resistance protein? 
ybxA 401 161 2.5 similar to cobalt transporter ATP-binding subunit 
sspA 510 206 2.5 small acid-soluble spore protein (alpha-type SASP), major; 
localized on the nucleoid in developing forespores; localized to 
the ring-shaped nucleoid of the germinating spore 
ahrC 787 321 2.5 negative regulation of arginine biosynthesis 
gid 1112 468 2.4 glucose-inhibited division protein 
uppS 2078 910 2.3 undecaprenyl pyrophosphate synthetase 
ywiE 845 374 2.3 similar to cardiolipin synthetase 
yfnI 2659 1267 2.1 exported glycerol phosphate lipoteichoic acid synthetase and 
anion-binding protein 
     
     
     
idh 547 1983 0.28 myo-inositol 2-dehydrogenase 
malL 5265 19093 0.28 maltose-inducible alpha-glucosidase 
yuxI 41.3 151 0.27 hypothetical protein 
lacR 23.3 85.5 0.27 negative regulation of beta-galactosidase (lacA) 
ybbC 33.3 124 0.27 similar to beta-lactamase 
mmsA 277 1044 0.26 methylmalonate-semialdehyde dehydrogenase 
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yqaR 21.8 83.8 0.26 hypothetical protein 
yoaP 88.8 346 0.26 uncharacterized N-acetyltransferase 
opuCA 80.3 203 0.40 glycine betaine/carnitine/choline ABC transporter (ATP-binding 
protein) 
opuCB 89.3 313 0.28 glycine betaine/carnitine/choline ABC transporter (membrane protein) 
opuCC 108 443 0.24 glycine betaine/carnitine/choline ABC transporter (osmoprotectant-
binding) 
opuCD 144 459 0.31 glycine betaine/carnitine/choline ABC transporter (membrane protein) 
yczF 58.3 239 0.24 hypothetical protein 
iolB 783 2874 0.27 myo-inositol catabolism 
iolC 373 1247 0.30 myo-inositol catabolism 
iolD 244 1004 0.24 myo-inositol catabolism 
iolE 163 640 0.26 myo-inositol catabolism 
iolF 528 1597 0.33 myo-inositol catabolism 
iolH 225 630 0.36 myo-inositol catabolism 
iolI 99.5 285 0.35 myo-inositol catabolism 
yvbI 64.8 194 0.33 putative permease 
yvbJ 197 820 0.24 hypothetical protein 
htrA 450 1889 0.24 serine protease Do (heat-shock protein), probably involved in 
processing, maturation, or secretion of extracellular enzymes 
yurI 18.5 82.8 0.22 extracellular ribonuclease 
yxeL 44.0 200 0.22 similar to GCN5-related N-acetyltransferase 
yxeM 45.0 163 0.28 putative ABC transporter, extracellular solute binding protein, polar 
amino acid transporter 
yxeN 39.8 119 0.33 putative ABC transporter, permease 
yxeO 83.5 194.5 0.43 putative ABC transporter, ATP-binding protein 
yxeP 29.3 70.5 0.41 putative carboxypeptidase, aminohydrolase 
yxeQ 45.5 102 0.45 MmgE/PrpD family protein, propionate catabolism 
ytiB 2889 13333 0.22 carbonic anhydrase 
ytmA 36.3 182 0.20 putative hydrolase 
ytmI 41.0 109 0.38 putative N-acetyltransferase 
araB 26.8 82.3 0.33 L-ribulokinase 
araD 69.0 231 0.30 L-ribulose-5-phosphate 4-epimerase 
araL 48.8 132 0.37 L-arabinose operon, putative phosphatase 
araM 3187 16405 0.19 Glycerol-1-phosphate dehydrogenase 
araP 56.3 148 0.38 L-arabinose transport 
yvdA 64.3 138 0.47 similar to carbonic anhydrase 
yvdF 2090 5557 0.38 glucan 1,4-alpha-maltohydrolase 
yvdG 8787 29262 0.30 maltose/maltodextrin-binding lipoprotein 
yvdH 3556 24806 0.24 maltodextrin ABC transport system (permease) 
yvdI 5467 24465 0.22 maltodextrin ABC transporter (permease) 
yvdJ 4340 22404 0.19 putative component of transporter 
yvdK 5594 22591 0.25 maltose phosphorylase 
yvdO 50.5 195 0.26 spore coat protein assembly factor CotR 
yqbR 45.5 250 0.18 conserved hypothetical protein; skin element 
ctaC 534 2805 0.19 cytochrome caa3 oxidase 
ctaD 699 3878 0.18 cytochrome caa3 oxidase 
ctaE 895 5266 0.17 cytochrome caa3 oxidase 
ctaF 401 2228 0.18 cytochrome caa3 oxidase 
ctaG 2166 4506 0.48 cytochrome aa(3) assembly factor 
ctaO 19 99.8 0.19 protoheme IX farnesyltransferase (heme O synthase) 
qcrA 908 6094 0.15 menaquinol:cytochrome c oxidoreductase 
qcrB 1385 9258 0.15 menaquinol:cytochrome c oxidoreductase 
qcrC 656 3739 0.18 menaquinol:cytochrome c oxidoreductase 
yveA 20 135 0.15 L-aspartate/L-glutamate permease 
yveF 139 295 0.47 hypothetical protein 
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Table S3.1. (Continued) 
 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
 
yveK 35.5 92 0.39 modulator of protein tyrosine kinase EpsB, epsA 
yveM 10.8 57 0.19 Probable polysaccharide biosynthesis protein epsC 
yveO 26.8 70.8 0.38 similar to glycosyltransferase, epsE 
yveP 47 95.5 0.49 similar to glycosyltransferase, epsF 
yveQ 46.8 120 0.39 biofilm extracellular matrix formation enzyme, epsG 
yydC 94 276 0.34 hypothetical protein 
yydI 55.0 195 0.28 ABC transporter 
yydJ 10.8 73.5 0.15 putative permease for export of a regulatory peptide 
arfM 117 802 0.15 regulation of anaerobic genes 
lctP 1937 13382 0.14 L-lactate permease 
yisN 49.5 358 0.14 hypothetical protein 
rbsA 658 4537 0.15 ribose ABC 
rbsB 1323 8676 0.15 ribose ABC 
rbsC 690 5069 0.14 ribose ABC 
rbsD 653 3203 0.20 ribose ABC 
rbsK 717 2030 0.35 ribokinase 
rbsR 538 1635 0.33 negative regulation of the ribose operon (rbsRKDACB) 
appA 179 1349 0.13 oligopeptide ABC transporter 
appB 95.0 692.8 0.14 oligopeptide ABC transporter 
appC 72.3 387 0.19 oligopeptide ABC transporter 
appF 189 1060 0.18 oligopeptide ABC transporter 
narG 299 1744 0.17 nitrite extrusion protein, nitrate reductase 
narH 2201 17613 0.12 nitrite extrusion protein, nitrate reductase 
narI 542 3755 0.14 nitrite extrusion protein, nitrate reductase 
narJ 902 6895 0.13 nitrite extrusion protein, nitrate reductase 
narK 177 1361 0.13 nitrite extrusion protein, nitrate reductase 
wprA 80.8 654 0.12 cell wall-associated protein precursor 
tnrA 283 2385 0.12 global nitrogen regulation (positive regulation of nrgAB, nasBCDEF, 
gabP, ureABC, guaD; negative regulation of glnRA, gltAB) 
abnA 19.0 165 0.11 arabinan-endo 1,5-alpha-L-arabinase 
glpT 192 1962 0.10 glycerol-3-phosphate permease 
citB 49.5 192 0.26 aconitate hydratase 
acoA 114 385 0.30 acetoin dehydrogenase 
acoB 29.0 347 0.08 acetoin dehydrogenase 
acoC 71.3 452 0.16 acetoin dehydrogenase 
acoL 59.0 371 0.16 acetoin dehydrogenase 
ptsG 142 1720 0.08 glucose transport and phosphorylation 
ptsH 4952 8698 0.57 histidine-containing phosphocarrier protein of the phosphotransferase 
system (PTS) (HPr protein) 
msmE 50.5 614 0.08 multiple sugar-binding protein 
msmR 53.5 137 0.39 transcriptional regulator (LacI family) 
msmX 289 1434 0.20 ATP-binding protein 
melA 79.8 981 0.08 α -D-galactoside galactohydrolase 
yesL 105 216 0.48 putative permease, similar to membrane enzyme for 
rhamnogalaturonan degradation 
yesY 41 535 0.08 similar to rhamnogalacturonan acetylesterase 
comP 269 807 0.33 two-component sensor histidine kinase, involved in early competence, 
phosphorylation of ComA 
comQ 342 822 0.42 transcriptional regulator, required for the processing, modification, 
and release of active competence pheromone ComX, regulation of 
late competence operon (comG) and surfactin expression (srfA) 
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Table S3.1. (Continued) 
 Signal 
Intensity 
  
Gene Dap
R
1 W168 Fold Change Function of Gene Product 
comX 65.8 235 0.28 competence pheromone precursor, required for the development of 
genetic competence possibly by activating ComA through 
extracellular signaling of Spo0K 
comGG 19.8 78.8 0.25 required for exogenous DNA-binding 
comS 354 5287 0.07 competence regulation 
ylqB 130 2498 0.05 unknown 
amyC 44.8 1003 0.04 maltose transport 
yvaW 14.3 151 0.09 Sporulation-delaying protein sdpA, export of killing factor 
yvaX 5.8 135 0.04 Sporulation-delaying protein sdpB, exporter of killing factor 
yvaY 39 332 0.12 killing factor SdpC 
yvfA 39 176 0.37 possible polysaccharide biosynthesis protein, epsK 
yvfB 149 309 0.48 possible polysaccharide biosynthesis protein, epsK, similar to O-
antigen and teichoic acid export protein 
yvfC 44.0 101 0.44 putative undecaprenyl-phosphate galactose phosphotransferase, epsL 
yvfD 77.8 141 0.55 putative acetyltransferase epsM 
yvfH 241 907 0.27 L-lactate permease 
yvfK 270 4204 0.06 maltose/maltodextrin-binding protein 
yvfL 357 7324 0.05 maltodextrin transport system permease 
yvfM 175 4479 0.04 maltodextrin transport system permease 
yvfO 83.5 1581 0.05 arabinogalactan endo-1,4- β -galactosidase 
yvfV 2260 4334 0.52 putative iron-sulfur heterodisulfide reductase, similar to Glycolate 
oxidase 
yvfW 9646 15342 0.63 iron-sulfur oxidoreductase 
srfAA 115 2481 0.05 surfactin synthetase/competence 
srfAD 2.5 87.3 0.03 surfactin production and competence 
srfAB 2.0 76.0 0.03 surfactin production and competence 
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Table S3. 2. Differential quantification of gene expression of Dap
R
1 and W168 with 
daptomycin treatment. Genes with fold changes >2 are shown. 
 
Gene 
Signal 
Intensity 
Fold 
Change 
W1682 
  +/- 
Signal  
Intensity 
Fold  
Change  
DapR1 
  +/- 
 
Function of Gene Product
3
 
W168  
   +  
W1681 
   -  
DapR1 
   + 
DapR1 
   - 
liaI 58519 44.5 1315 3397 1279 2.7 putative membrane protein 
liaH 58516 43.5 1345 5096 1438 3.5 PspA homolog 
liaG 28172 95.8 294 686 230 3.0 putative membrane anchored protein 
liaF 39778 248 160 944 518 1.8 negative regulator of LiaR 
liaS 11803 89.7 132 643 304 2.1 TCS histidine kinase 
liaR 2549 35.5 71.8 163 116 1.4 TCS response regulator 
yvrI 1826 3.5 522 68.8 25.3 2.7  factor YvrI 
yvrL 933 1.8 509 34.3 21.9 1.6 negative regulator of yvrI 
yvzA 277 32.2 8.6 36.9 27.8 1.3 hypothetical protein 
yvzC 170 5.5 31.0 33.8 16.8 2.0 hypothetical protein 
yvcB 836 33.8 24.7 83.3 72.0 1.2 hypothetical protein 
yhcY 115 34.5 3.3 122 104 1.2 TCS histidine kinase 
yhcZ 466 209 2.2 380 388 1.0 TCS response regulator 
yvkN 202 8.7 23.3 33.6 28.0 1.2 hypothetical protein 
yvpB 167 14.0 12.0 33.8 35.0 1.0 hypothetical protein 
yknU 2912 296 9.8 121 140 0.9 ABC transporter (ATP-binding protein) 
sdpI 1566 181 8.7 195 185 1.1 immunity protein for SdpC 
ywdD 125 24.0 5.2 52.4 53.5 1.0 hypothetical protein 
ywdE 340 39.2 8.7 40.3 32.9 1.2 hypothetical protein 
ywdI 1075 548 2.0 763 785 1.0 similar to uracil-DNA glycosylase 
yqjL 237 28.5 8.3 1547 1441 1.1 hydrolase; paraquat resistance 
bcrC 293 85.7 3.4 2409 2593 0.9 bacteriocin transport permease 
ypbG 172 43.7 3.9 1029 1002 1.0 marker for inhibition of cell wall 
biosynthesis 
ydaH 268 38.0 7.0 682 752 0.9 uncharacterized membrane protein 
ywfB 194 28.7 6.8 44.3 37.9 1.2 similar to Bacilysin biosynthesis protein 
yuaF 535 107 5.0 1267 135 0.9 hypothetical protein 
yuaG 238 123 1.9 278 237 1.2 flotillin-like protein 
yfiC 11470 2555 4.5 2180 2180 1.0 ABC transporter (ATP-binding protein) 
yitI 563 151 3.7 207 236 0.9 probable acetyltransferase 
yebC 119 32.5 3.7 627 589 1.1 putative permease 
ywaC 96.3 26.5 3.6 665 626 1.1 ppGpp synthase 
fabHA 972 381 2.5 667 533 1.3 fatty acid biosynthesis 
fabHB 58.8 19.2 3.1 34.1 22.9 1.5 fatty acid biosynthesis 
fabF 1526 759 2.0 1375 1212 1.1 beta-ketoacyl-acyl carrier protein 
synthase II 
sigM 160 69.7 2.3 588 606 1.0 ECF  factor 
yhdK 77.3 37.8 2.0 280 305 0.9 ECF anti- factor 
yhdL 169 61.7 2.7 405 432 0.9 ECF anti- factor 
rodA 118 42.5 2.8 386 370 1.0 cell-division membrane protein 
radC 450 168 2.7 1213 1259 1.0 DNA repair protein 
maf 469 177 2.6 2744 2556 1.1 cell division and shape determination 
ypeB 237 96.8 2.4 15.8 11.6 1.0 sporulation protein 
murB 548 262 2.1 4252 5161 0.8 UDP-N-acetylenolpyruvoylglucosamine 
 reductase 
murG 284 118 2.4 2662 2712 1.0 peptidoglycan biosynthesis 
yoeB 2165 938 2.3 406 507 0.8 protection against autolysins 
yumB 121 51.2 2.4 103 74.5 1.4 NADH dehydrogenase 
yheJ 151 63.8 2.4 30.0 27.0 1.1 unknown 
ytfI 518 223 2.3 273 329 0.8 hypothetical protein 
ywrE 121 54.2 2.2 175 189 0.9 unknown 
yxjI 106 49.8 2.1 378 342 1.1 unknown 
ylbQ 145 68.2 2.1 277 303 0.9 2-dehydropantoate 2-reductase 
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Table S3.2. (Continued) 
 
Gene 
Signal 
Intensity 
Fold 
Change 
W1682 
  +/- 
Signal  
Intensity 
Fold  
Change  
DapR1 
  +/- 
 
Function of Gene Product
3
 
W168  
   +  
W1681 
   -  
DapR1 
   + 
DapR1 
   - 
yhdA 144 69.8 2.1 94.4 114 0.8 NAD(P)H-FMN and ferric iron 
reductase 
glpD 156 76.7 2.0 415 411 1.0 glycerol-3-phosphate dehydrogenase 
liaI 58519 44.5 1315 3397 1279 2.7 putative membrane protein 
glpF 214 112 1.9 1707 1698 1.0 glycerol uptake facilitator 
yojI 141 69.5 2.0 55.4 59.9 0.9 multidrug efflux protein 
trpF 195 97.5 2.0 206 175 1.2 phosphoribosyl anthranilate isomerase 
cdsA 109 55.8 2.0 599 625 1.0 phosphatidate cytidylyltransferase 
ygxB 253 131 1.9 94.9 50.6 1.9 putative membrane protein 
ywtF 264 142 1.9 1051 1113 0.9 similar to transcriptional regulator LytR 
yvaV 515 278 1.9 333 310 1.1 putative HTH-type transcriptional 
regulator 
licA 113 78.5 1.4 724 1165 0.6 PTS, lichenan degradation 
nadA 2467 2285 1.1 1809 3050 0.6 quinolinate synthetase 
ywiC 341 445 0.8 64.4 114 0.6 putative membrane protein 
ytrP 61.8 41.8 1.5 343 613 0.6 TCS histidine kinase 
yolB 1662 2578 0.6 1646 1477 1.1 SPBc2 prophage-derived 
uncharacterized protein 
yckI 156 243 0.6 806 730 1.1 L-cystine import ATP-binding protein 
yscB 165 257 0.6 282 210 1.3 hypothetical protein 
yqzC 253 397 0.6 664 724 0.9 hypothetical protein 
rplI 354 563 0.6 1372 1301 1.1 ribosomal protein L9 
mcpB 435 692 0.6 1928 1648 1.2 methyl-accepting chemotaxis protein 
yheA 536 857 0.6 1508 1480 1.0 hypothetical protein 
hbs 3435 5532 0.6 6845 7406 0.9 non-specific DNA-binding protein 
yrvJ 309 511 0.6 451 438 1.0 similar to N-acetylmuramoyl-L-alanine 
amidase 
yhdN 164 273 0.6 7667 537 1.4 aldo/keto reductase specific for NADPH  
lmrB 255 426 0.6 106 127 0.8 lincomycin-resistance 
rpmB 671 1155 0.6 2384 2096 1.1 ribosomal protein L28 
degR 83.0 153 0.5 101 97.1 1.0 activation of degradative enzymes (AprE,  
NprE, SacB) 
ydaL 208 384 0.5 22.0 19.9 1.1 hypothetical protein 
rpsT 408 802 0.5 996 1070 0.9 ribosomal protein S20 
ywhB 213 364 0.6 687 695 1.0 4-oxalocrotonate tautomerase 
ywhE 371 737 0.5 78.6 93.3 0.8 pbpG, penicillin-binding protein 
(sporulation) 
yocH 531 1074 0.5 5743 6754 0.9 similar to cell wall-binding protein 
(autolysin) 
ywjC 79.7 168 0.5 137 122 1.1 unknown 
yxeL 31.8 69.2 0.5 33.6 52.3 0.6 similar to GCN5-related N-
acetyltransferase 
yxeM 55.8 120 0.5 67.6 78.4 0.9 putative ABC transporter 
yxeN 34.3 60.7 0.6 33.1 27.6 1.2 putative ABC transporter, permease 
yxeO 64.2 118 0.5 84.0 89.8 0.9 putative ABC transporter, ATP-binding  
protein 
yxeP 27.3 53.3 0.5 46.9 37.3 1.3 putative carboxypeptidase, 
aminohydrolase 
yxeQ 51.2 92.7 0.6 62.9 65.3 1.0 MmgE/PrpD family protein, propionate 
catabolism 
arfM 515 726 0.7 93.3 241 0.4 regulation of anaerobic genes 
1
 “+” or “-“ correspond to average triplicates of signal intensities of daptomycin-treated or untreated 
samples, respectively. 
2 “+/-” corresponds to the fold change between daptomycin-treated and untreated samples. 
3 
 Functions were assigned based on the SubtiList database or BSORF entries. 
 
